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Preface And Declaration
This thesis presents results from investigations conducted in broadly defined areas:
(1) The examination of the functions of endothelin receptors in cerebral arteries 
and arterioles. The investigations were conducted using in vitro and in situ 
techniques in the rabbit and cat.
(2) The pharmacologic evaluation and validation of doses of endothelin receptor 
antagonists in the cerebrovasculature
(3) The assessment of the pathophysiologic role of the endothelins in experimental 
animal models of focal cerebral ischaemia, subdural haematoma and global 
cerebral ischaemia.
This thesis comprises my own original work and has not been presented 
previously as a thesis in any form. Some of the experiments reported in this thesis were 
carried out in collaboration with other investigators: Mr. S. Galbraith (focal cerebral 
ischaemia in the cat); Dr. C. Wilson and Dr. C.F.C. Smith at Zeneca Pharmaceuticals (in 
vitro investigations).
Summary
This thesis examined the pathophysiologic role of the endothelins in the 
cerebral circulation. Endothelin receptors were characterised in the rabbit basilar 
artery in vitro and in feline cerebral resistance arterioles in situ. Investigations in the 
feline cerebral resistance arterioles were designed to examine the cerebrovascular 
effects and blood-brain barrier penetration of non-peptide and peptide endothelin 
receptor antagonists. The pathophysiologic role of the endothelins were examined, 
using validated doses of endothelin receptor antagonists (primarily Bosentan), in 
experimental models of focal cerebral ischaemia in the cat, transient global cerebral 
ischaemia in the rat and subdural haematoma in the rat.
In the rabbit basilar artery in vitro, pre-incubation with either the combined 
ETa/ETb endothelin receptor antagonist Bosentan (4-tert- Butyl- N- [6 -(2 -hydroxy- 
ethoxy)-5-(2-methoxy-phenoxy)-2, 2'- bipyrimidin- 4-yl]- benzene sulphonamide) or 
the endothelin ETa receptor antagonist BQ-123 (cyclo D-Aspartate-D-Tryptophan-L- 
Leucine-D-Valine-L-Proline) had minimal effect on the resting tone o f arterial 
segments. The ETb receptor agonist BQ-3020 (N-Acetyl t11 Ala^ 15 Alal ET-1 (6-21)) 
elicited a small constriction of the arterial segments. Bosentan (10 p,M) elicited a 
rightward shift of the ET-1 concentration response curve (pA2 = 5.1). BQ-123 (0.1 - 
10 jiM) elicited a concentration dependent rightward shift o f the ET-1 concentration 
response curve (pA2 = 5.3). BQ-123 (1 (iM) elicited a substantial rightward shift of 
the ET-3 concentration response curve (pA2 = 7.2). The observations suggested the 
presence of an 'atypical' endothelin ETa receptor mediating vasoconstriction in the 
rabbit basilar artery.
The receptors mediating the cerebrovascular actions of endothelins were 
exam ined in feline cerebral resistance arterioles in vivo. The adventitial 
microapplication of the endothelin ETa receptor antagonist BQ-123 (0.1 -1 0  jiM) per  
se had minimal effect on cerebral resistance arterioles examined. The adventitial 
microapplication of endothelin-1 (10 nM) elicited a marked vasoconstriction of 
cerebral resistance arterioles (-29.1 ± 1.9 % from pre-injection baseline). The 
endothelin- 1 induced vasoconstriction was attenuated, in a dose dependent manner, by
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the adventitial co-application of BQ-123 and endothelin-1 (estimated IC50 0.7 |iM). 
The adventitial microapplication of the endothelin ETB receptor agonist BQ-3020 
(0.001 - 1 |iM) effected a dose dependent vasodilatation (EC50 30 nM, maximum 
response 25 ± 5 % from pre-injection baseline). The magnitude of the vasodilatation 
elicited by BQ-3020 (100 nM and 1 fiM) was dependent on the pre-injection calibre of 
the arterioles examined. The intracarotid infusion (via the lingual artery) o f BQ- 
3020 (0.5-500 pmol/min) had no significant effect on the calibre of cerebral resistance 
arterioles. These results suggest that the peptide endothelin ETg receptor agonist fails 
to gain access to the cerebrovascular endothelin ETg receptors following its 
intraluminal administration. These investigations indicate that endothelin ET a 
receptors mediate vasoconstriction and endothelin ETg receptors m ediate 
vasodilatation in feline cerebral resistance arterioles in vivo.
The cerebrovascular actions of Bosentan, a novel endothelin antagonist with 
effects at ETa and ETg receptors, have been examined in individual pial arterioles on 
the cortical surface of chloralose-anaesthetised cats. Subarachnoid perivascular 
microapplication of Bosentan (0.3 - 300 |iM) had minimal effect on pial arteriolar 
calibre. Subarachnoid perivascular microapplication of endothelin-1 (10 nM) effected 
a marked reduction in pial arteriolar calibre (reduced by 39.2 ± 2.7% from baseline). 
This vasomotor effect of topical endothelin could be attenuated either by co­
administration of Bosentan (IC50 approximately 1 pM) or by the intravenous 
administration of Bosentan (17 |imol/kg). These investigations suggest that bioactive 
amounts of Bosentan (applied topically or systemically) gain access to the adventitial 
surface of cerebral arterioles and may be a valuable tool in the elucidation of the 
functional significance of endothelins in the cerebral circulation in vivo.
The cerebrovascular effects of the non-peptide endothelin receptor antagonist 
PD 155080 (2-benzo (1,3) dioxol-5-yl-3-benzyl-4-(4-methoxyphenyl)-4-oxobut-2- 
enoate) and the hexapeptide endothelin receptor antagonist PD 145065 (Acetyl-((R)- 
2(10,1 l-dihydro-5H-dibenzo [a,d] cyclohepten-5-yl) Glycine -L-Leucine-L-Aspartate- 
L-Isoleucine-L-Isoleucine-L-Tryptophan) in feline cerebral resistance arterioles in vivo 
were contrasted with the effects of Bosentan. PD 145065 (0.03 - 3 pM) and PD 155080
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(0.3 - 30 |iM) per se had minimal effect on pial arteriolar calibre. The perivascular 
microapplication of ET-1 (10 nM) elicited a marked reduction in pial arteriolar calibre 
(-32 ± 2 % from pre-injection baseline). The perivascular co-application of PD145065 
and ET-1 (10 nM) effected a dose dependent attenuation of the ET-1 vasoconstriction 
(IC50 0.1 p.M). The perivascular co-application of PD155080 and ET-1 (10 nM) 
effected a dose dependent attenuation of the ET-1 vasoconstriction (IC50 1 pM). The 
intravenous administration of PD 145065 (30 jimol/kg) had minimal effect on 
perivascular exogenous ET-1 induced vasoconstriction (pre-i.v. - 32 ± 2%; post i.v -28 
± 4%). However, intravenous administration of PD155080 (19.2 |imol/kg) markedly 
attenuated the ET-1 induced vasoconstriction (pre-i.v. - 32 ± 2%; post i.v 3 ± 4%). 
The dose of PD 145065 (30 jimol/kg) used in the present investigations attenuated the 
pressor and depressor blood pressure responses elicited by an intravenous 
administration of endothelin-1 (1 nmol/kg). The comparison w ith Bosentan 
demonstrated the blood-brain barrier penetration of the small molecule non-peptide 
endothelin receptor antagonists and the poor blood-brain barrier penetration of the 
peptide endothelin receptor antagonist.
The role o f endogenous endothelins in m ediating post-ischaem ic 
hypoperfusion following transient global ischaemia was investigated in halothane- 
anaesthetised rats. Pre-treatment with the broad spectrum (ET^ and ETg) endothelin 
antagonist, Bosentan (17 jimol/kg) had minimal effect on post-ischaem ic 
hypoperfusion, measured by hydrogen clearance, in the caudate nucleus and the 
parietal cortex in the 3 hours following bilateral common carotid artery occlusion with 
concomitant haemorrhagic hypotension (transient global ischaemia). In a separate 
series of rats with cerebral blood flow (CBF) measured by [14C]- Iodoantipyrine 
autoradiography at 90 min. after carotid occlusion with concomitant haemorrhagic 
hypotension, Bosentan treatment failed to significantly alter CBF in any o f the 35 
brain regions examined. No significant alterations in CBF, measured by hydrogen 
clearance, were observed following transient bilateral common carotid artery 
occlusion. [ l4C]-Iodoantipyrine autoradiography at 90 min. post-occlusion failed to 
demonstrate any significant increases in cerebral blood flow following transient
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bilateral common carotid artery occlusion in any of the 35 brain regions examined in 
anaesthetised rats. The failure of the broad spectrum endothelin antagonist Bosentan, 
at concentrations known to inhibit the cerebrovascular effects of exogenous ET-1, 
provide no support for the view that endothelins have a major role in mediating acute 
post -ischaemic hypoperfusion.
The efficacy of Bosentan (17 |imol/kg) in altering cerebral blood flow was 
assessed following subdural haematoma in the rat. Cerebral blood flow was measured 
using [14C]-Iodoantipyrine autoradiography 2.5 hours following the induction of the 
subdural haematoma. Marked reductions in cerebral blood flow were observed in 
cortex underlying the haematoma. Frequency distribution analysis of cerebral blood 
flow at 8 pre-selected coronal planes failed to demonstrate any significant effect by 
Bosentan. The volume of tissue perfused by cerebral blood flow >20 ml/lOOg/min was 
not altered by the pre-treatment with Bosentan (Vehicle 157 ± 42 mm3; Bosentan 120 
± 24 mm3). A marked swelling of the ipsilateral hemisphere was observed at 2.5 hours 
following the induction of the subdural haematoma and Bosentan did not alter the 
swelling (Vehicle 16 ± 5% of contralateral hemisphere; Bosentan 10 ± 2% of 
contralateral hemisphere). These results provide no support for a major role for the 
endothelins in the regulation of cerebral blood flow following subdural haematoma in 
the rat.
The actions of Bosentan and PD 155080, non-peptide endothelin receptor 
antagonists, were examined in feline pial arterioles in situ following middle cerebral 
artery occlusion to gain insight into the cerebrovascular influence o f endogenous 
endothelins in focal cerebral ischaemia. Immediately following permanent middle 
cerebral artery occlusion, all pial arterioles overlying the suprasylvian and ectosylvian 
gyri displayed marked dilatations which were maintained in a population of vessels 
but differentiated into sustained constrictions in others. Perivascular subarachnoid 
microinjections of Bosentan (30 |iM), PD 155080 (30 p.M) and artificial cerebrospinal 
fluid, CSF (pH 7.2) were performed between 30 and 210 minutes following middle 
cerebral artery occlusion. The perivascular microapplication of Bosentan (30 }iM) and 
PD 155080 (30 jiM) around pial vessels overlying the suprasylvian and ectosylvian
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gyri, which are within the territory of the occluded middle cerebral artery, elicited an 
increase in the calibre of post-occlusion dilated and constricted pial arterioles. The 
perivascular microapplication of PD155080 (30 |iM) around post-occlusion dilated 
pial arterioles overlying the ectosylvian and suprasylvian gyri elicited an increase in 
the calibre of arterioles (11 ± 2% from pre-injection baseline; n=36). The perivascular 
microapplication of Bosentan (30 jiM) around post-occlusion dilated arterioles elicited 
an increase in the calibre of arterioles (16 ± 9% from pre-injection baseline; n=38). In 
contrast, the microapplication of CSF (pH 7.2) elicited small reductions in pial 
arteriolar calibre of post-occlusion dilated arterioles (-9 ± 1% from baseline; n=44). 
Perivascular microapplication of Bosentan or PD 155080 had minimal effect upon the 
calibre of pial arterioles on the parasagittal gyrus (anterior cerebral artery territory) 
although these arterioles had also displayed sustained dilatation following middle 
cerebral artery occlusion. These investigations indicate that contractile factors (whose 
effects can be reversed with endothelin receptor antagonists) constrict or impair 
dilatation of cortical resistance arterioles in an acute cerebral ischaemic episode.
These investigations have provided a basis for further investigations of a role 
for the endothelins in cerebrovascular pathology and the therapeutic potential o f 
endothelin receptor antagonists in the treatment of cerebrovascular diseases.
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CHAPTER 1 
INTRODUCTION
1.1 Anatomy of the cerebral circulation
1.1.1 Cerebral circulation in man
The survival of cerebral tissue is dependent upon the continuous delivery of 
substrates by the blood. The brain receives 20% of the total cardiac output and the 
absence of any stores of glucose/glycogen makes it imperative that blood supply to the 
brain is maintained especially under conditions of cerebral ischaemia .
The blood supply to the brain is derived from four main arteries, 2 common 
carotid arteries arising from the aortic arch and 2  vertebral arteries arising from the 
subclavian arteries. The internal carotid artery gives rise to three main branches: the 
anterior cerebral artery (ACA), middle cerebral artery (MCA) and anterior choroidal 
artery. The vertebral arteries fuse at the level of the medulla oblongata to form the 
basilar artery. The basilar artery bifurcates to form the posterior cerebral artery. On the 
ventral surface of the brain these inflow vessels are linked by communicating arteries 
to form the circle of Willis. Anastomotic links between the posterior cerebral arteries 
and the internal carotid arteries via the posterior communicating arteries complete the 
circle of Willis. The circle of Willis ensures that there is the equal distribution of 
blood to all regions of the brain via the anterior, middle and posterior cerebral arteries.
The anterior cerebral arteries are linked by the anterior communicating artery 
and pass in between the sagittal fissure and supply the frontal and medial aspects of 
the frontal and parietal lobes and the corpus callosum. The medial and striate branches 
of the anterior cerebral arteries supply deep subcortical structures such as the basal 
ganglia. The middle cerebral artery branches off the internal carotid artery. The MCA 
supplies most o f the lateral aspect of the brain and branches of the MCA, e.g. the 
lenticulostriate branches are responsible for supplying the deep brain areas (caudate 
nucleus, globus pallidus and internal capsule). The anterior choroidal artery supplies 
the choroid plexus, hippocampal structures and posterior regions o f the internal 
capsule.
The vertebro-basilar arterial system is responsible for supplying blood to the 
posterior regions of the cerebrum and parts of the cerebellum. The basilar artery in 
turn bifurcates to form two posterior cerebral arteries. The vertebral and basilar
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arteries give rise to a number of branches, e.g., anterior spinal artery, posterior spinal 
artery, posterior inferior cerebellar artery, anterior inferior cerebellar artery and the 
superior cerebellar artery. These branches supply the medulla oblongata, ventral 
portions of the spinal cord, dorsal and ventral aspects of the cerebellum and the 
choroid plexus.
The posterior cerebral artery is responsible for the blood supply to the caudal 
regions of the cerebrum. Blood flow through the posterior cerebral artery (PCA) may 
be derived from the vertebro-basilar system or the internal carotid arteries via the 
posterior communicating arteries. The medial and lateral aspects of the temporal and 
occipital lobes are the main brain regions supplied by the posterior cerebral arteries. 
Branches of the posterior cerebral artery also supply the hippocampus and other 
subcortical structures. The posterior choroidal branch of the posterior cerebral artery 
supplies the choroid plexus.
1.1.2 The blood-brain barrier
The blood-brain barrier consists of epithelial/endothelial cells that have tight 
junctions which prevent the passive movement of substances across the endothelium 
[Reese & Kamovsky, 1967]. There are specific transcellular transport mechanisms 
which facilitate the movement of solutes and substrates between the plasma and the 
interstitial fluid. There is an increased number of mitochondria for the energy 
dependent transporters that transport Na+ and K+ [Bradbury, 1979]. The absence of 
fenestrations and high electrical resistance of the cerebrovascular endothelium 
prevents access of substances to the brain tissue [Begley, 1992; Ermisch et al., 1993]. 
The cerebral capillaries consist of a continuous layer of endothelial cells connected by 
tight junctions [Brightman, 1992, Ermisch et al., 1993]. There is an absence of 
channels in the capillary wall that open to the interstitial fluid and the plasma. 
Endothelial cell membranes lack vesicular transport for the movement of substances 
from the plasma to the brain and vice versa. Damage to the blood-brain barrier may 
facilitate the entry of substances through the gaps that may be created between the 
endothelial cells (Figure 1).
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F ig u re  1 Schematic representation of the cerebral circulation. The vascular 
endothelium constitutes the blood-brain barrier. The figure illustrates the gap junctions 
between endothelial cells at the level of the major cerebral arteries and the transition to 
tight junctions at the level of pial and intracerebral arterioles.
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Apart from the "physical" blood-brain barrier, there is increasing evidence for 
the existence of an enzymatic component to the blood-brain barrier [Hardebo & 
Owman, 1990]. The failure of some amine precursors such as L-DOPA and 5- 
Hydroxytryptophan to penetrate into the brain parenchyma is thought to be due to the 
degradation of these substances. Degradative enzymes such as L-Amino acid 
decarboxylase, monoamine oxidase (A & B), catechol-o-methyl transferase, butyryl 
cholinesterase and 4-Aminobutyrate aminotransferase have been identified in capillary 
and endothelial cells. Peptide transmitters and modulators in the peripheral circulation 
can be hydrolysed by peptidases in the plasma or those present on the surface of the 
cerebrovascular endothelium.
The cerebral endothelial cells are characterised by the tight junctions between 
them and the high electrical resistance which can prevent access of charged molecules 
to the brain. In recent years there has been an increasing shift to the development of in 
vitro models of the blood-brain barrier using endothelial cell cultures or co-cultures of 
cerebral endothelial cells and astrocytes [Laterra & Goldstein, 1992]. The examination 
of these in vitro models has indicated that the resistance of these cells is much lower 
than in vivo and may also affect the penetration of some substances that would 
normally be excluded.
1.1.3 Regulation of cerebrovascular tone
The pharmacological control of the cerebral circulation has been the area of 
much research. The "classical" view that the blood vessels of cerebral circulation were 
innervated by sympathetic and parasympathetic nerves similar to the peripheral 
vessels has recently undergone considerable modification. The role of the "classical' 
transmitters acetylcholine and noradrenaline in the control of CBF have been 
docum ented. However, more recent advances in m olecular b io logy and 
immunocytochemical techniques has seen the identification of a variety o f other 
transmitters in cerebral blood vessels. At the forefront of these discoveries have been 
the peptide molecules such as neuropeptide Y and substance P. Other important 
developments have seen the identification of the role of the vascular endothelium
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derived factors such as nitric oxide and prostacyclin in the regulation of 
cerebrovascular tone and CBF. The following sections will try to highlight importance 
of the myriad of neurotransmitters and neuropeptides and their role in the regulation of 
cerebrovascular tone (Table 1).
Acetylcholine
Acetylcholine is perhaps the most studied of all the neurotransmitters. Its 
responses in vivo and in vitro have been well documented, low doses of acetylcholine 
induce vasodilatation while increasing the dose elicits a vasoconstriction [Edvinsson et 
al., 1977]. The responses are blocked in a reversible and competitive manner by 
atropine [Edvinsson et al., 1977]. The pre-constriction of cerebral vessels and the 
application of acetylcholine demonstrates an endothelium dependent vasodilatation, 
known to be mediated via EDRF/NO [Furchgott & Zawadski, 1980; Edvinsson et al., 
1985c]. Transmural nerve stimulation of cerebral vessels also elicits a vasodilatation 
that is not attenuated by atropine or acetylcholinesterase inhibitors [Bevan et al., 1982; 
Duckies & Kennedy, 1982]. In the absence of the vascular endothelium acetylcholine 
elicits a vasoconstrictor response [Furchgott & Zawadski, 1980].
Muscarinic binding sites have been described in major cerebral arteries, pial 
arterioles and cerebral microvessels [Krause & Edvinsson, 1984; Tsukahara et al., 
1986; Dauphin & MacKenzie, 1995 for review]. The microapplication or superfusion 
of acetylcholine or carbachol increases the calibre of feline pial arterioles in situ not 
dependent on the size of vessel examined [Kuschinsky et al., 1974; Haller, 1987]. The 
acetylcholine induced increases in pial arteriolar calibre were attenuated by atropine. 
The application of atropine per se to pial arterioles has minimal effect on the calibre of 
arterioles demonstrating minimal acetylcholine mediated vascular tone under resting 
conditions. Damage or removal of the vascular endothelium results in a loss o f the 
dilator response in vivo and in vitro [Rosenblum et al., 1987; Haller et al., 1987]. 
Nitric oxide has been accepted as the mediator of this vasodilatation since the NOS 
inhibitors constrict the cerebral vessels in vitro and in situ and reduce CBF [Tanaka et 
al., 1991]. In some species, such as the pig the vasodilator substance is prostacyclin.
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Table 1
Transmitters and Peptides regulating cerebrovascular tone
Transmitters
Acetylcholine
Noradrenaline
5 -Hydroxy tryptamine 
Dopamine 
Histamine
Adenosine
Neuropeptides
VIP
NPY
CGRP
Substance P
Bradykinin 
Angiotensin II
Response
Dilatation
Constriction
Constriction
Constriction/Dilatation
Dilatation
Dilatation
Dilatation
Constriction
Dilatation
Dilatation
Constriction
Constriction
Endothelium derived factors
EDRF/Nitric Oxide Dilatation
p g i2
Thromboxane A2 
Endothelins
Dilatation
Constriction
Constriction
Major Source
Nerve fibres from 
Sphenopalatine Ganglion
Nerve fibres from Superior 
Cervical Ganglion
Nerve fibres from Raphe nuclei
Nerve fibres
Mast cells in perivascular 
spaces
Metabolism of nucleotide
Nerve fibres from 
Sphenopalatine Ganglion
Nerve fibres from Superior 
Cervical Ganglion
Nerve fibres from Trigeminal 
Ganglion
Nerve fibres from Trigeminal 
Ganglion
Neuronal
Cholinergic innervation to the cerebral vessels predominantly arises from the 
sphenopalatine ganglion. Acetylcholinesterase containing neurones have been 
identified in the sphenopalatine ganglion and these may innervate the major cerebral 
arteries and the pial vessels [Dauphin & MacKenzie, 1995], An intracerebral source of 
innervation has been suggested but, unlike noradrenaline or 5-Hydroxytryptamine, 
there is a diffuse distribution of cholinergic cell bodies suggesting that acetylcholine 
from this source may have a role in the local control of CBF [Dauphin & MacKenzie, 
1995]. Nerves originating in the brainstem innervate the internal carotid artery and 
vessels of the circle of Willis (via the facial nerve and geniculate ganglion) [Dauphin 
& MacKenzie, 1995].
The stimulation of the sphenopalatine ganglion elicits an increase in CBF 
while ganglionectomy reduces the reactivity of the major cerebral arteries although the 
responses of the arterioles to hypoxia and hypercapnia are unaffected suggesting that 
although acetylcholine maybe present in neurones in the sphenopalatine ganglion, the 
increases in CBF elicited by nerve stimulation may not be directly related to the 
cholinergic innervation [Seylaz et al., 1988; Dauphin & MacKenzie et al., 1995]. The 
actions of acetylcholine may be mediated via an indirect mechanism where 
acetylcholine inhibits the release of vasoconstrictor agents [Edvinsson et al., 1977].
The intracarotid infusion of acetylcholine increases CBF in a variety of species 
including canine, feline, rat and rabbit [Alborch, 1981; De Ley et al., 1984; Dauphin 
& MacKenzie 1995], Atropine attenuates the reduction in CBF while inhibition of 
acetylcholinesterase by physostigmine increases CBF and this latter response is also 
sensitive to atropine [Trigeuro et al., 1988; Dauphin et al., 1991].
Noradrenaline
Plexuses of noradrenaline containing nerve fibres, arising from the superior 
cervical ganglion, can be found around cerebral arteries, arterioles and veins 
[MacKenzie & Scatton, 1987]. There is a sparse contribution from the stellate 
ganglion but caudal portions of the circle of Willis are supplied from this source. The 
presence of noradrenaline has been identified in cortical pial vessels and cerebral
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microvessels and higher levels of noradrenaline have been found in the larger cerebral 
arteries than the smaller pial arterioles [Duverger et al., 1987]. There is an increased 
uptake of noradrenaline in the cerebral arteries where there is greater noradrenergic 
innervation (e.g. ACA, MCA, PCA and the superior cerebellar artery) [MacKenzie & 
Scatton, 1987]. The available evidence indicates that there is an increased release from 
nerves in cerebral arteries than in peripheral arteries.
The transmural stimulation of the noradrenergic innervation elicits a species 
dependent response in cerebral arteries [MacKenzie & Scatton, 1987]. In the cat, 
transmural nerve stimulation elicited a dilatation of the cerebral arteries but the 
response is not cholinergic in origin and persisted after the administration of 
adrenergic antagonists, reserpine and chronic sympathectomy [Lee et al., 1978]. 
Further investigations have indicated that the response of feline arteries may be due to 
the release o f vasodilator agents that may be co-localised with noradrenaline 
[MacKenzie & Scatton, 1987]. In other species, the constrictor response is the 
predominant response [MacKenzie & Scatton, 1987]. The constriction/dilatation of the 
cerebral arteries, is thus dependent on the species used and the localisation o f the 
artery/arterioles examined. The effects of nerve stimulation are further complicated by 
the localisation of nerve fibres of different transmitters in the perivascular space. The 
differences in these responses are probably due to the co-transmitters such as NPY 
that are also released by nerve stimulation.
In vitro studies have suggested that a-adrenoceptors mediate constrictions in 
feline/canine vessels [Skarby et al., 1983]. The contractile responses to noradrenaline 
can be potentiated by the removal of the endothelium. The contractile responses to 
noradrenaline are calcium dependent [MacKenzie & Scatton, 1987]. Existence of 13- 
adrenoceptor mediated vasodilatation has been demonstrated in pre-contracted 
cerebral arteries in vitro [Edvinsson & Owman, 1974; W inquist et al., 1982]. 
Presynaptic localisation of 012 adrenoceptors have been identified in cerebral arteries 
and these may inhibit the release of noradrenaline [Duckies, 1982]. Co-localisation of 
noradrenaline with neuropeptide Y has been identified in some vessels (see section on 
NPY).
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In vivo stimulation of the superior cervical ganglion in the feline resulted in the 
constriction of pial arterioles (only those > 1 0 0  |im) while there was no effect on the 
smaller arterioles <100 jim [Kuschinsky & Wahl, 1975; Auer et al., 1981 & 1983], 
The effects were attenuated by a-adrenoceptor antagonists such as phentolamine [Auer 
et al., 1983]. The perivascular microapplication of noradrenaline constricts pial 
arterioles in situ, although in contrast to the stimulation of the superior cervical 
ganglion there was no dependence of the response on the calibre o f arterioles 
[Kuschinsky & Wahl, 1975; Edvinsson, 1982].
The catecholamines elicit a minor reduction in CBF but these reductions have 
been observed in species where there is a contribution from extracranial circulation 
e.g. in the dog and the goat [MacKenzie & Scatton, 1987]. Other authors have 
reported a minimal alteration probably due to the inaccessibility of the amine to the 
cerebrovasculature [See section on the Blood-Brain Barrier]. The use of intravascular 
noradrenaline resulted in an increase in mean arterial blood pressure and if the 
increase was greater than the upper limit of the autoregulation, there would be an 
increase in CBF. The intraventricular administration of noradrenaline resulted in an 
increase in the glucose use, oxygen consumption and CBF. The noradrenaline induced 
increases in CBF may be related to the increased metabolic demand.
Some reports have suggested that noradrenaline may alter blood-brain barrier 
permeability. The stimulation of extrinsic sympathetic nerves can increase the 
permeability of capillaries. Monoamine oxidase has been identified in the endothelial 
cells and MAO inhibitors may facilitate the access of the monoamine oxidase to the 
cerebrovasculature.
5-Hydroxytryptamine (5-HT)
5-HT is a potent constrictor of the vasculature but the presence o f the blood- 
brain barrier and the systemic effects of 5-HT complicate the interpretation of the 
effects of 5-HT on the cerebral circulation [See section on Blood-Brain barrier]. 5-HT 
innervation in the cerebral circulation originates from the Raphe nuclei in the brain 
stem [MacKenzie & Scatton, 1987]. In animals with an intact blood-brain barrier, 5-
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HT has minimal effect on CBF [Harper & MacKenzie, 1977; Mendelow et al., 1977]. 
In situations where the blood-brain barrier is compromised, 5-HT decreased CBF and 
the reductions were confined to these areas. The absence of an effect of 5-HT when 
the blood-brain barrier is intact either due to the failure of the amine to directly 
permeate the blood-brain barrier or the inactivation of 5-HT (see section on the Blood- 
Brain Barrier).
5-HT induces marked constriction of cerebral arteries in vitro [MacKenzie & 
Scatton, 1987]. The cerebral arteries appear to be more sensitive to 5-HT than 
peripheral arteries. The 5-HT induced contractions are calcium sensitive. 5-HT has 
been demonstrated to dilate pre-constricted cerebral arteries and the responses were 
attenuated by I3-adrenoceptor antagonists [Edvinsson & Owman, 1974]. The 
microapplication of 5-HT on cortical pial arterioles in situ elicited a vasodilatation 
which was greater in arterioles <70 |im and a constriction in arterioles >150 jim 
[Harper & MacKenzie, 1977]. The administration of 5-HT into the brain reduces the 
EEG activity and reduces oxygen consumption and the reductions in CBF may be 
consequent to the metabolic depression [Harper & MacKenzie, 1977; Grome & 
Harper, 1983]. Administration of 5-HT directly into the brain or lesioning of 5-HT 
pathways results in a reduction in metabolism and a moderate reduction in CBF. 
Stimulation of the dorsal or medial Raphe nuclei increases glucose use and CBF but 
the increases in CBF are not related to alterations in glucose use. In contrast, in 
anaesthetised animals the stimulation of the Raphe nuclei reduces CBF and these 
effects may be related to the anaesthetic mediated metabolic depression [Bonvento et 
al., 1989].
Monoamine oxidase present in the cerebral endothelial cells will prevent 
access of 5-HT to the cerebrovasculature. However, high concentrations of 5-HT have 
been found in endothelial cells and a role for 5-HT in the regulation of blood-brain 
barrier permeability has been postulated [Mackenzie & Scatton, 1987].
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Dopamine
Dopamine is a potent contractile agent of cerebral arteries in vitro and the 
maximum contractions elicited by dopamine are greater than those elicited by 
noradrenaline [Hamel et aL, 1988]. The contractile actions may be mediated via a- 
adrenoceptors or 5-HT receptors as well as dopamine receptors [Edvinsson et al.,
1993]. Dopamine agonists such as apomorphine have some contractile effects on 
cerebral arteries but the effects are less pronounced than those of dopamine.
Dopamine and dopamine agonists have been reported to induce dilatation of 
major cerebral arteries in vitro in many species (man, cat, dog, rabbit, rat) [Edvinsson 
et al., 1993]. The demonstration of the relaxant effects of dopamine often requires the 
pre-contraction of the vessels, although in some species the relaxant effects can be 
elicited in the absence of pre-constriction. The signal transduction mechanisms 
associated with dopamine receptors is unclear but indication are that the dilator 
responses are mediated by the activation of adenylate cyclase and release of cAMP 
[Amenta et al., 1984],
The intracarotid infusion of dopamine constricts cerebral arteries (basilar 
artery) and cortical surface arterioles in situ [Edvinsson et al., 1985b]. Dopamine 
receptor antagonists have minor contractile effects when compared to dopamine. 
Dopamine Di agonists such as apomorphine, SKF38393 and LY 141865 have 
vasodilator actions on pial arterioles in situ [Edvinsson et al., 1985b]. These responses 
are attenuated by the Di antagonists SCH23390 [Edvinsson et al, 1985b]. Despite the 
dem onstration of vasodilatation by dopamine agonists the perivascular 
microapplication o f dopamine fails to demonstrate any vasodilator response 
[Edvinsson et al., 1985b]. However, the superfusion of dopamine on the cortical 
surface arterioles but the increases may be the result of an increase in oxidative 
metabolism in the underlying cerebral cortex [Altura et al., 1980].
Dopamine is a transmitter in the CNS and activation of dopamine receptors can 
alter cerebral function. Dopamine agonists such as apomorphine and amphetamines 
increase the cerebral metabolic rate of oxygen consumption (CMRO2) and the cerebral 
metabolic rate of glucose use (CMRgic) [McCulloch et al., 1982b]. In contrast, the
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dopamine antagonists per se have minimal effect on cerebral metabolism [McCulloch 
et al., 1982b]. Direct or indirect releasers of dopamine such as the amphetamines or 
phenylethylamine increase CBF [Edvinsson et al., 1993]. The increases in CBF are 
accompanied by increases in oxidative metabolism and the responses are attenuated by 
dopamine receptor antagonists [McCulloch et al., 1982b]. The mechanism of increases 
in CBF elicited by dopamine agonists such as apomorphine and bromocriptine is 
unclear but increases in CBF may be the result of an increase in the oxidative 
metabolism elicited by these agents [Bes et al., 1982; Leenders et al., 1985], The 
absence of any effect of dopamine antagonists on CBF suggests that dopamine may 
play a minor role in the regulation of basal CBF.
Histamine
Histamine is associated with the cerebrovasculature and brain tissue. Mast 
cells are thought to be the major source of histamine in the cerebrovasculature and 
have been localised in the perivascular spaces of the dura, pial vessels, choroid plexus 
and in the cerebral microvessels [Edvinsson & MacKenzie, 1977]. The responses of 
cerebral vessels to histamine is species dependent. In some species, such as the feline 
and guinea pig, histamine constricts cerebral vessels while in other species (canine, 
rat) histamine elicits a vasodilator response [Ottosson et al., 1988; Toda et al., 1990]. 
The general consensus is that histamine H2 receptors mediate the vasodilator 
responses while the constrictor responses are mediated by H 1 receptors [Edvinsson & 
Owman, 1975; Ottosson et al., 1990]. Although there is emerging evidence that the 
responses of cerebral vessels to histamine may be dependent on species and the 
segment of the vessel examined [Edvinsson et al., 1993]. Vasodilatation elicited by 
histamine is associated with a depolarisation of the vascular smooth muscle while the 
removal of the vascular endothelium attenuates the histamine mediated vasodilatation 
[Chang et al., 1988; Toda et al., 1990].
The perivascular administration of histamine in feline cerebral arterioles in situ 
elicits a vasodilatation mediated via H2 receptors [Wahl & Kuschinsky, 1979; Gross et 
al., 1981a]. Superfusion on the cortical surface in the feline elicits a vasodilatation
while in the mouse and rabbit there is a vasoconstriction [Raper et al., 1972; Kamitani 
et al., 1985]. There are suggestions that in the latter species histamine may be acting to 
release an endothelium derived contracting factor. There is a greater abundance of H2 
receptors on arterioles and evidence suggests that H2 receptors may be more sensitive 
to histamine and only small circulating concentrations may be required to elicit the 
vasodilator response.
The intravascular administration of histamine does not affect CBF due to its 
poor blood-brain barrier permeability [Oldendorf et al., 1971]. Some authors have 
reported that histamine can reduce CBF. The application of histam ine by 
circumventing the blood-brain barrier elicits increases in CBF but the concentrations 
required are almost 100  fold greater than the concentrations required in the 
microapplication studies [Gross et al., 1981a].
In the peripheral circulation, histamine increases vascular permeability and 
causes oedema [Gross et al., 1981b]. Histamine may have a similar effect on the 
cerebral circulation. In cerebral capillaries, a histamine sensitive adenylate cyclase 
mechanism that may affect blood-brain barrier transport has been described 
[Kamushina et al., 1980]. High concentrations of histamine (100 jiM) can cause an 
increased permeability of the blood-brain barrier to sucrose and a-aminoisobutyric 
acid [Dux & Joo, 1982; Gross et al., 1981b]. Superfusion with histamine increases the 
permeability of fluorescein dye into the brain parenchyma [Wahl et al., 1988]. 
Additionally, histamine has been demonstrated to stimulate pinocytosis in 
cerebrovascular endothelial cells [Kamushina et al., 1980; Sercombe et al., 1986]. The 
significance of these mechanisms to the regulation o f CBF and in cerebrovascular 
pathology is unknown.
Adenosine
Adenosine dilates pial arterioles in a dose dependent manner and the responses 
are attenuated by theophylline. There are some suggestions that adenosine increases 
the calibre of arterioles under normocapnic conditions more than under hypoxic or 
hypercapnic conditions [Gregory et al., 1980]. The adenosine responses are mediated
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by A 2 receptors with the cerebral veins being less reactive than arteries or arterioles 
[Ibayashi et al., 1991]. There is no correlation between the vessel size and the 
response to adenosine [Kuschinsky & Wahl, 1976]. There are species differences in 
the responses of cerebral arteries and arterioles to adenosine.
Inhibition of the uptake of adenosine by agents such as dipyridamole, reduces 
the vasoconstriction (including response to hypocapnia). The response is probably due 
to an increase in the endogenous levels of adenosine as a result of the inhibition of 
uptake [Ibayashi et al., 1988]. Adenosine may be involved in the coupling of CBF to 
neuronal activity and glucose use [Ibayashi et al., 1991]. However, the adenosine 
antagonists such as theophylline and uptake inhibitor dipyridamole have minimal 
effect on feline cerebral arteriolar calibre suggesting a minimal role for adenosine in 
the regulation of vascular tone [Kuschinsky & Wahl, 1976].
Elevations in endogenous adenosine levels have been measured following 
ischaemia, hypotension, hypoxia and seizures [Morii et al., 1984; Winn et al., 1985]. 
The alterations in adenosine levels, measured by microdialysis parallel the increases in 
CBF observed in seizures [Park et al., 1987; Phillis et al., 1987]. The increases in 
endogenous adenosine levels suggests that these conditions may cause a sufficient 
elevation in adenosine levels to increase CBF.
The effects of exogenous adenosine on CBF are more varied. Some authors 
have reported no alterations following the intravascular administration while others 
have reported increases in CBF in rabbits, primates and man [Edvinsson et al., 1993]. 
Adenosine may not penetrate the blood-brain barrier but a nucleoside transporter may 
facilitate the entry into the brain [Ermisch et al., 1993]. The alterations elicited by 
adenosine are rapid and one cannot discount an endothelium dependent mechanism. 
The uptake inhibitor dipyridamole increases CBF and this may be due to increased 
endogenous levels of adenosine [Phillis et al., 1990].
Vasoactive Intestinal Polypeptide (VIP)
VIP is a vasodilator of cerebral vessels in vitro and in situ . The direct 
administration of VIP into the brain, circumventing the blood-brain barrier, induces an
increase in CBF [Rorstad et al., 1993; Dauphin & MacKenzie, 1995]. A related 
peptide Peptide Histidine Isoleucine (PHI) also elicits a concentration dependent 
dilatation of cerebral blood vessels [Edvinsson & McCulloch, 1985] and is 
approximately 25-60 fold less potent than VIP in eliciting vasodilatation [McCulloch 
& Edvinsson, 1980; Edvinsson & McCulloch, 1985]. The investigations have 
demonstrated that VIP is less active in producing vasodilatation in cerebral veins than 
in cerebral arterioles [McCulloch & Edvinsson, 1980; Edvinsson & McCulloch,
1985]. The magnitude of the response of VIP on cerebral arterioles is dependent on 
the calibre of arterioles examined with cerebral arterioles <70|im demonstrating an 
increased reactivity to VIP [McCulloch & Edvinsson, 1980]. The vasodilatation 
induced by VIP is not endothelium dependent and VIP/PHI activate adenylate cyclase 
and increase levels of cAMP in vascular smooth muscle [Edvinsson et al., 1985a]. 
There is evidence for the co-localisation of VIP in cholinergic neurones but the role of 
acetylcholine/VIP interactions in the cerebrovasculature is unclear [Dauphin & 
MacKenzie, 1995].
VIP/PHI have been implicated as neurotransmitters in the peripheral and 
central nervous systems [Rorstad et al., 1993; Rostene, 1984]. PHI like peptide has 
been identified in the rat brain and the release of PHI is calcium dependent indicating 
release from a transmitter pool [Korchak et al., 1985; Dauphin & MacKenzie, 1995]. 
VIP/PHI have been localised in neurones in the neocortex, amygdala and 
hippocampus [Benfield et al., 1984]. The intrastriatal administration of VIP resulted in 
heterogeneous alterations in glucose use in the caudate nucleus and increased CBF 
[McCulloch et al., 1983].
Neuropeptide Y (NPY)
NPY is found in cerebrovascular sympathetic nerves and is a potent constrictor 
o f cerebral arteries, arterioles and veins in all species examined [Edvinsson et al., 
1983; Edvinsson et al., 1985b; Edvinsson et al., 1987; Meija et al., 1988]. NPY elicits 
vasoconstrictor action of longer duration than that elicited by noradrenaline in 
cerebral vessels (ti/2 = 5 min) [Edvinsson et al., 1984]. There is evidence that NPY
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may be co-localised with noradrenaline in cerebrovascular sympathetic nerves and 
NPY may serve to potentiate the actions of noradrenaline [Abel & Han, 1989]. The 
vasoconstrictor actions of NPY are calcium dependent and can be attenuated by the 
calcium channel antagonists. Despite the co-localisation of NPY with noradrenaline, 
adrenoceptor blockade does not attenuate the vasoconstrictor action of NPY 
[Edvinsson et al., 1983]. The vasoconstrictor actions of NPY are mediated via Y1 
receptors present on the cerebrovascular smooth muscle. The actions of NPY are 
modulated by receptor subtypes Yi and Y2 [Wahlestedt et al., 1985], The Y 1 receptors 
are located on cerebrovascular smooth muscle. In the periphery, NPY can act directly 
on postsynaptic receptors to induce vasoconstriction, can act postsynaptically to 
am plify vascular constriction elicited by other transm itters or can induce 
vasodilatation by the presynaptic modulation of noradrenaline release [Wahlestedt et 
al., 1985; Westfall et al., 1987]. The effects of NPY are not dependent on an intact 
vascular endothelium, however, an attenuation of the actions of NPY following the 
removal o f the endothelium have been reported [Daly & Hieble, 1987]. At the 
intracellular level, NPY induces a reduction in cAMP accumulation in feline cerebral 
vessels while in the guinea pig basilar artery the vasoconstriction elicited by NPY is 
accompanied by a slow depolarisation of vascular smooth muscle [Fallgren et al.,
1990].
The actions of NPY may involve the modulation of vasodilatation elicited by 
acetylcholine, adenosine, noradrenaline or substance P [Han & Abel, 1987; Fallgren et 
al., 1989]. NPY does not have any effect on the vasodilatation elicited by VIP or 
calcitonin gene related peptide (CGRP) [Fallgren et al., 1989]. In the periphery, NPY 
has been shown to inhibit the release of noradrenaline from sympathetic nerve fibres 
[Westfall et al., 1987; Linton-Dahlof & Dahlof, 1993]. In peripheral tissues NPY 
reduces the contractile responses induced by transmural nerve stimulation. Presynaptic 
modulation of adrenergic mechanisms can effect NPY release but the mechanism is 
unclear.
There have been reports on the effects of NPY administration on CBF and 
glucose use [Tuor et al., 1990]. The in vitro and in situ investigations have suggested
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that NPY should reduce CBF. Allen and colleagues (1985) reported that the 
intracarotid injection of NPY reduced CBF in the rat cortex for up to 2 hours and other 
investigations have demonstrated a dose dependent reduction in striatal CBF [Tuor et 
al., 1985]. NPY has minimal effect on mean arterial blood pressure.
Calcitonin Gene Related Peptide (CGRP)
CGRP is a 37 amino acid peptide that is released from the trigeminal nerves. 
CGRP immunoreactivity and binding sites have been identified in the CNS, mainly in 
the hypothalamus, amygdala and brainstem [Amara et al., 1982; Rosenfeld et al., 
1983; Skofitsch & Jacobowitz, 1985]. CGRP in often co-localised with SP in the 
trigeminal ganglion but there are a greater number CGRP containing cell bodies in the 
ganglion [Uddmann et al., 1985; McCulloch et al., 1986; Gulbenkian & Wharton,
1993]. CGRP containing neurones arise from various sub-divisions of the trigeminal 
system and in turn innervate blood vessels of the circle of Willis, extracranial and 
intracranial portions of the internal carotid arteries and the vertebro-basilar system 
[Edvinsson et al., 1989; Saito & Moskowitz, 1989]. CGRP containing varicosities 
have been observed in the adventitia and medial/adventitial border of the MCA, ACA, 
PCA , vertebral arteries and pial arterioles [McCulloch et al., 1986].
CGRP elicits vasodilatation of cerebral arterioles in all species examined 
[McCulloch & Edvinsson, 1987; McCulloch et al., 1986; Jansen et al., 1993]. CGRP is 
a more potent dilator than SP and elicits vasodilatations of a greater magnitude. The 
vasodilatation is not endothelium dependent suggesting an absence for a role for nitric 
oxide [Edvinsson et al., 1985]. The vasodilator response elicited by CGRP is 
maintained for minutes and suggests a role for CGRP in the restoration o f vascular 
diameter following vasoconstriction in an attempt to maintain CBF [McCulloch et al.,
1986], Lesioning of the trigeminal system has no effect on the vasodilator capacity of 
cerebral arterioles but it prolongs the vasoconstriction induced by noradrenaline and 
PGF2a  [McCulloch et al., 1986; McCulloch & Edvinsson, 1987].
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Substance P (SP)
SP has been identified in nerve fibres arising from the trigeminal ganglion and 
innervating cerebral arteries, pial arterioles and veins in the choroid plexus and the 
dura [Edvinsson et al., 1981; Suzuki et al., 1989]. SP neurones arising from the brain 
stem may innervate arterioles and capillaries in the brain stem [Kapadia & Lanerolle, 
1984], SP neurones arising from the dorsal root ganglia innervate the caudal portions 
of cerebral vessels [Edvinsson et al., 1981; Saito & Moskowitz, 1989].
Increases in SP release has been demonstrated with electrical field stimulation 
and capsaicin or K+ evoked depolarisation [Moskowitz et al., 1983]. The release of SP 
from neurones is a calcium dependent process [Moskowitz et al., 1983]. SP induces a 
dose dependent dilatation of cerebrovascular smooth muscle in a variety of species, 
although, there is evidence that the responses are highly variable with some authors 
reporting no alterations with SP [Edvinsson et al., 1981; Jansen et al., 1991].
The vasodilatation of SP is endothelium dependent and the mediator o f this 
vasodilatation is unclear but SP has been reported to increase levels o f cGMP 
[Rapoport & Murad, 1983; Edvinsson & Jansen, 1987]. The microapplication of SP on 
cerebral arterioles in situ elicited a concentration dependent dilatation [Edvinsson et 
al., 1982]. The indications were that the arterioles were more sensitive than veins to 
SP application but there was no correlation between the arteriolar calibre and the 
magnitude of the dilatation elicited [Edvinsson et al., 1981 & 1982]. The intracerebral 
administration of SP increased blood flow in the hypothalamus, however, these 
elevations were attenuated by cholinergic antagonists, sym pathectom y and 
adrenoceptor antagonism [Klugman et al., 1980]. Another important aspect o f the 
pharmacology of SP is its ability to increase vascular permeability of blood vessels in 
the periphery [Lembeck & Gamse, 1982; Regoli et al., 1993]. There is limited 
evidence in the cerebral circulation that SP could elicit similar effects on the integrity 
of the blood-brain barrier.
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Brady kinin
Bradykinin has been localised in nerve fibres and cell bodies of neurones in the 
hypothalamus and cerebral cortex [Wahl et al., 1986]. Bradykinin is vasoactive and 
has the ability to alter the permeability of blood vessels (in the periphery and the CNS) 
[Regoli & Barabe, 1980; Unterberg et al., 1984; Wahl et al., 1986]. The actions of 
bradykinin are mediated by one of two receptors- Bi which are contractile or B 2 
which are dilator [Regoli & Barabe, 1980; Regoli, 1984]. The receptors are localised 
on smooth muscle and endothelial cells [Edvinsson et al., 1993]. There are some 
species differences in the responses of cerebral blood vessels to bradykinin. In the 
canine, bradykinin causes a constriction of the major arteries while in man, feline, 
rabbit, elicits a vasodilator response [Edvinsson et al., 1993].
In the cat, bradykinin elicits a dose dependent dilatation following the 
microapplication or superfusion on cortical arterioles [Unterberg et al., 1983; Wahl et 
al., 1986]. In contrast, the cerebral veins demonstrate a constriction following 
prolonged superfusion [Unterberg et al, 1984]. Hypotheses explored to explain the 
above responses include suggestions that bradykinin may induce the swelling of the 
cerebrovascular endothelial cells [Unterberg et al, 1984]. The vasodilatation by 
bradykinin is prevented by superoxide dismutase and catalase indicating a role for 
oxygen radicals in the development of the responses [Kontos et al, 1984]. 
Intracerebroventricular administration of bradykinin increases CBF and glucose 
metabolism but has no effect on oxygen consumption [Unterberg et al., 1983].
Angiotensin
Angiotensin converting enzyme has been isolated in cerebral capillaries 
[Gimbrone et al., 1979]. Angiotensin binding sites have been identified in cortical and 
cerebellar microvessels [Changaris et al., 1978; Speth & Harik, 1985]. Angiotensin 
may be involved in the regulation of blood-brain barrier permeability to water. 
Angiotensin II is a constrictor of cerebral vessels in man, feline and rabbit (in the 
nanomolar range) [Edvinsson et al., 1979]. Microapplication or superfusion of
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angiotensin II on cerebral arterioles reduces the calibre of cortical surface arterioles 
[Acar & Pickard, 1978; Wei et al., 1978]. However, vasodilatation induced by 
angiotensin II has been described in some species [Toda & Miyazaki et al., 1981]. The 
vasoconstrictor and vasodilatation induced by angiotensin II is endothelium mediated 
and are inhibited by cyclo-oxygenase inhibitors [Toda & Miyazaki, 1981]. Intracarotid 
infusion of angiotensin II reduces CBF and pial arteriolar calibre but these effects are 
not observed if the hypertensive response is attenuated suggesting an autoregulatory 
response [Edvinsson et al., 1993].
Concluding Remarks
The application of exogenous noradrenaline or neuropeptide Y on to cerebral 
vessels results in a vasoconstriction. The sympathetic system does not have any 
significant role in the regulation of basal cerebral blood flow. The physiologic 
significance of the sympathetic system in the cerebrovasculature is probably to 
facilitate the attenuation or prevention of excessive cerebral vasodilatation as may be 
experienced in conditions of systemic hypertension rather than a role in the 
physiologic control of cerebral blood flow.
The cholinergic innervation is present in the cerebrovascular bed and can 
modulate local cerebral blood flow directly (smooth muscle) or indirectly 
(endothelium). However, the role of the cholinergic system in cerebrovascular 
pathology is unclear at present and further investigations are necessary for evaluating 
its role.
There are a number of issues that arise from the description of peptides in the 
cerebrovasculature. It is known that most peptides would not be expected to cross the 
blood brain barrier, however, there is evidence that some of these peptides may 
regulate blood-brain barrier function. Additionally, the release of the peptides may be 
highly localised and thus play a role in regulating haemodynamics in the vicinity of 
their release. The release of vasodilator neuropeptides from the perivascular 
innervation may be significant in preventing excessive vasoconstriction of the cerebral 
vessels as may be experienced in subarachnoid haemorrhage. The trigeminal
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innervation plays a role in the transmission of pain. The release of vasodilator peptides 
from this system may play a role in the aetiology of migraine. Certainly there is 
increasing interest in the developments of therapeutic agents that can antagonise or 
minimise the actions of the peptides since many of the peptides have been implicated 
to play a role in a variety o f cerebrovascular disease including subarachnoid 
haemorrhage, ischaemia and migraine.
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Endothelium Derived Factors
Endothelium derived relaxing factor (EDRF)
The importance of endothelium derived factors in the regulation of vascular 
tone has concentrated on endothelium derived relaxing factor (EDRF) [Furchgott & 
Zawadski, 1980; Moncada et al., 1991]. It has been suggested that EDRF may be nitric 
oxide (NO) or a nitric oxide containing moiety, e.g., Nitrosothiols [Faraci & Brian, 
1994]. Nitric oxide is a freely diffusible and highly reactive mediator of vascular and 
non-vascular function and has a short half-life (~ 6  sec). Nitric oxide is synthesised 
from L-Arginine to form L- Citrulline and nitric oxide and the synthesis is catalysed 
by a family of enzymes called the nitric oxide synthases (NOS) [Faraci & Brian, 1994; 
Iadecola et al., 1994].
Three isoforms of NOS have been identified, 2 constitutive isoforms (neuronal 
NOS and endothelial NOS) and an inducible isoform (inducible NOS) [Nathan, 1992; 
Marietta, 1993]. Neuronal NOS (nNOS) and endothelial NOS (eNOS) are involved in 
the basal synthesis of nitric oxide. These enzymes are activated by elevations in 
intracellular calcium and facilitate the phasic production of nitric oxide [Moncada et 
al., 1991]. Neuronal NOS is primarily found in the cytosolic fraction while the 
endothelial NOS is a membrane associated enzyme [Nathan, 1992; Faraci & Brian,
1994]. Nitric oxide released from the endothelium produces vasodilatation by the 
activation of soluble guanylate cyclase within the vascular smooth muscle cells to 
increase cGMP [Moncada et al., 1991]. Soluble guanylate cyclase can be activated 
directly by the nitric oxide donors, e.g. sodium nitroprusside and glyceryl trinitrite to 
produce vasodilatation [Moncada et al., 1991; Archer, 1992].
The constitutive form of NOS has been localised in the cerebrovascular 
endothelium [Bredt et al., 1990; Nozaki et al., 1993]. The basal production of nitric 
oxide has an important role in the regulation of vascular tone in cerebral arteries and 
arterioles in vivo and in vitro [Marshall et al., 1988; Faraci & Brian, 1994], A number 
o f neurotransmitters (5-Hydroxytryptamine, Acetylcholine, Bradykinin, Endothelin, 
SP, ATP, Arginine Vasopressin, Histamine, Oxytocin) produce vasodilatation of 
cerebral arteries and arterioles [Faraci & Brian, 1994]. The inhibition of constitutive
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nitric oxide synthase by L- Nitro Arginine (L-NOARG), L- Nitroarginine Methyl 
Ester (L-NAME) or L- Mono Methyl Nitroarginine (L-NMMA) produces increases in 
MABP and decreases in CBF [Faraci & Brian, 1994; Iadecola et al., 1994].
Nitric oxide is involved in the regulation of resting CBF and vasodilator 
responses in arteries and arterioles [Faraci & Brian, 1994]. The removal of the 
vascular endothelium results in a loss of vasodilator responses. NOS containing 
neuronal fibres have been identified in the sphenopalatine ganglion and activation of 
these nerves elicits a vasodilator response [Iadecola et al., 1994]. Nitric oxidergic 
perivascular nerves innervating cerebral arteries and arterioles have been described.
NO independent vasodilatation of cerebral arteries and arterioles can be 
myogenic in origin and is observed during cerebral autoregulation [Iadecola et al.,
1994]. The role of NO in preventing platelet aggregation or leucocyte activation in the 
vascular endothelium has been well documented [Nishimura et al., 1991; Rosenblum 
et al., 1992]. This property of nitric oxide is important for the maintenance of 
microvascular flow in the brain.
The enzyme has been localised to dendrites and axons of nerves associated 
with cerebral microvessels [Faraci & Brian, 1994], Stimulation of nuclei such as the 
cerebellar fastigial nucleus has demonstrated NO mediated increases in CBF 
[Iadecola, 1992; Iadecola et al., 1994]. The activation of NMDA and non-NMDA 
receptors may stimulate NO production and its release into the extracellular space 
[Faraci & Breese, 1993; Faraci & Brian, 1994]. The presence of NOS has also been 
demonstrated in perivascular nerves innervating cerebral arteries and arterioles.
Constitutive NOS activation by receptor mediated mechanisms have been 
observed in astrocytes [Aoki et al., 1991; Murphy et al., 1993]. Calcium ionophore 
A23187, bradykinin, glutamate (via NMDA and non-NMDA receptors) and 
noradrenaline have all triggered the synthesis of NO [Faraci & Brian, 1994]. Induction 
of iNOS in astrocytes and microglia by lipopolysaccharide and cytokines indicates a 
role for NO in the progression of neuronal damage following cerebrovascular injury 
[Faraci & Brian, 1994].
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Prostacyclin & Thromboxane A2
Prostacyclin (PGI2) is produced from the conversion of prostaglandin H2 by 
prostacyclin synthetase. Prostacyclin is a vasodilator that acts on peripheral and 
cerebral arteries and arterioles. Low concentrations of prostacyclin dilate arteries and 
arterioles while high concentrations (JiM) can constrict some blood vessels [Toda,
1980], Prostacyclin can reverse the vasoconstrictor effects of 5-HT, Noradrenaline, 
Angiotensin II, PGF201 and Thromboxane A2 [Paul et al., 1982]. The mechanism of 
action in cerebral arteries is unclear but in peripheral arteries prostacyclin stimulates 
the production of cAMP. The relaxant effects of prostacyclin are not abolished by the 
removal of the vascular endothelium (unlike nitric oxide) [Toda et al., 1988]. There is 
evidence that the synthesis of prostacyclin may not be endothelium dependent and 
PGH2 can be converted to PGI2 in the vascular smooth muscle.
Thromboxane A 2 is a potent constrictor of cerebral arteries. Thromboxane A2 
is produced from the metabolism of arachidonic acid by PLA2 . The thromboxane A2 
mediated constrictions are mediated via calcium channels (constrictions inhibited by 
the calcium channel antagonists verapamil, nifedipine and nimodipine). Thromboxane 
A 2 can increase intracellular calcium by increased influx through receptor operated 
calcium channels and the release calcium from intracellular stores [Wendling & 
Harakal, 1991].
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1.2 Cerebrovascular disease
1.2.1 Cerebrovascular disease in man
Stroke is the third leading cause of mortality, following heart disease 
and cancer, in the western world. Stroke, as defined by the W orld Health 
Organisation, is :
"rapidly developed clinical signs of focal disturbance of cerebral function of 
presumed vascular origin and of more than 24 hours duration".
This definition incudes most forms of intracerebral haemorrhage, subarachnoid 
haemorrhage and cerebral infarction (with or without demonstrable arterial occlusion) 
but does not include transient ischaemic attacks (TIA's) which by definition last less 
than 24 hours.
There are two general types of strokes, infarction (70%) and haemorrhagic 
(30%), and can be classified into further subtypes [Sacco, 1993]. Approximately 44% 
of infarcted strokes are thrombo-embolic in origin and two thirds of these involve the 
occlusion of the large cerebral (ACA, MCA) arteries leading to cerebral infarction 
[Sacco, 1993]. Lacunar infarcts which result from the obstruction of the small 
penetrating arteries and arterioles and the infarction of the associated deep brain areas. 
There are multiple sources for thrombo-emboli and include cardiac disease, carotid 
artery or vertebro-basilar artery disease. Haemorrhagic strokes result from 
intracerebral or subarachnoid haemorrhage. The aetiology of these haemorrhagic 
stroke include chronic hypertension and ruptured aneurysms.
Subtypes of ischaemic stroke
Thrombotic stroke
The aetiology of this form of stroke is thought to be the presence of 
artherosclerotic lesions found at the bifurcations and curves of the larger extracranial 
vessels [Mohr & Sacco, 1992]. The location of the artherosclerotic plaque is thought 
to be at proximal sites within the vessel (e.g. division of the common carotid artery
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into the internal carotid arteries and external carotid arteries). The increase in the size 
of the artherosclerotic lesions lead to a progressive stenosis of the arterial lumen and 
eventually occlusion occurs due the formation of a thrombus within the vascular 
lumen.
The mechanism for the development of stroke following this lesion is thought 
to be the inadequacy of perfusion at sites distal to primary occlusion or stenosis 
[Bogousslavsky & Regli, 1986]. The main reason for this is the response of the 
collateral vessels to undergo dilatation to compensate for the reductions in CBF. If the 
resistance arterioles are maximally dilated and there is complete occlusion of the 
carotid artery, the arterial territory is at risk of cerebral ischaemia and eventually 
leading to infarction [Mohr & Sacco, 1992]. The main brain regions at risk from the 
carotid artery stenosis are the suprasylvian, frontal, central and parietal portions of the 
cerebral hemisphere [Torvick, 1984; Mohr & Sacco, 1992]. Stenosis in the vertebro­
basilar system puts the occipital pole at risk.
Embolic Stroke
Embolic stroke constitutes approximately 15-30% of all stroke cases [Sacco, 
1993]. The common origin of this type of stroke is the formation of emboli from the 
site of the carotid artery stenosis [Mohr & Sacco, 1992]. The embolism affects the 
territory of the occluded artery (commonly middle cerebral artery) [Mohr & Sacco, 
1992], The sites of thrombi formation in the heart include the heart valves, atrial 
fibrillation or ventricular fibrillation [Mohr & Sacco, 1992; Koudstaal, 1993]. The 
emboli are formed of fragments of thrombi or platelet aggregates. The friability of the 
thrombi and platelets, the size of embolus and the decreasing size of the arteriolar 
lumen and bifurcation of the vascular tree will determine the site of arrest [Mohr & 
Sacco, 1992; Sacco, 1993]. The common sites for the lodging of the emboli are in 
arterioles, however, larger emboli composed of fibrin - platelet complexes may 
obstruct the larger cerebral arteries such as the middle cerebral artery.
The morphology of the occluded vessels indicate that although vascular 
distension is observed there is minimal damage to the vascular wall. The vascular
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endothelium in these cases does not seem to be injured and may not be the primary 
mediator of the pathogenesis of embolic stroke.
Lacunar strokes
Lacunar infarcts account for approximately 20% of stroke cases [Sacco, 1993], 
A lacunar infarct is defined by a "small, deep infarct attributable to a primary arterial 
disease that involves a penetrating branch of a large cerebral artery" [Mohr & Sacco,
1992], The size of lacunar infarcts is usually small and is largely dependent on the 
distribution territory of the occluded vessel [Mohr & Sacco, 1992]. The vessels that 
are normally affected are 100-400pm in diameter and are located in the deep brain 
regions that are supplied by the penetrating arterioles e.g. Basal ganglia (caudate , 
putamen), thalamus, internal capsule, pons and white matter tracts of cerebral gyri 
[Mohr & Sacco, 1992, Bogousslavsky, 1993], Lacunar infarcts have rarely been 
observed in cortical gray matter, corpus callosum, medulla or spinal cord [Mohr & 
Sacco, 1992]. Most lacunar infarcts are observed in the territory of the lenticulostriate 
branches of the MCA, and the ACA and paramedian branches of the basilar artery 
(supplying the pons) [Bogousslavsky, 1993]. The absence of collateral vessels in the 
deep areas of the brain, unlike the cerebral cortex, make these areas more susceptible 
to ischaemic damage. Occlusion of the penetrating arterioles may be caused by 
microartheromas, lipohyalinosis, microemboli or the result o f haemodynamic 
disorders such as polycythaemia and arteritis [Mohr & Sacco, 1992]. The risk factors 
for the development of lacunar infarcts are broadly similar for the development of 
stroke in general (see section on Risk Factors).
Haemorrhagic strokes
Intracerebral haemorrhage
An intracerebral haemorrhage occurs as a result o f bleeding from arteries or 
arterioles directly into the brain parenchyma. Intracerebral haemorrhage contributes 5- 
15% of all strokes and the incidence increases with age [Sacco, 1993; Boysen, 1993].
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Spontaneous intracerebral haemorrhage occurs predominantly in the deep 
portions of the cerebral hemispheres (putamen, subcortical white matter, thalamus, 
cerebellum and pons) [Kase et al., 1992]. The intracerebral haemorrhage is usually the 
result o f bleeding from the arterioles of 100-400p,m diameter (similar to the vessels 
affected in lacunar infarcts) and occur predominantly in the vascular distribution 
territories of the small perforating cerebral arterioles (lenticulostriate, thalamo, basilar 
artery branches) [Kase et al., 1992]. The rupture of these vessels in conditions such as 
chronic hypertension can result in the development of intracerebral haemorrhage.
Mechanisms of vascular rupture are unclear but alterations in the arteriolar 
morphology (lipohyalinosis) have been implicated in the pathogenesis of intracerebral 
haemorrhages, e.g. lesions of the intimal layer in cerebral vessels can lead to bleeding 
into medial /adventitial layer thus weakening the vascular wall [Kase et al., 1992]. 
Secondary bleeding as result of damage to the smaller vessels could be responsible for 
enlarging the size of the haematoma [Kase et al., 1992]. Rupture of microaneurysms 
or vascular weakness as a result artherosclerosis are mechanisms that may be involved 
in the production of an intracerebral haemorrhage.
General consensus is that the bleeding associated with an intracerebral 
haemorrhage is a monophasic event, however, the use of anticoagulants or vascular 
malformations may facilitate an increase in the volume of the haematoma [Boysen et 
al., 1993; Kase et al., 1992]. The increase in bleeding and size of the haematoma can 
lead to the herniation of the brain across the midline or the distribution of blood 
through the ventricular system thus increasing the pressure on the brain stem.
Although hypertension has been cited as the major risk factor for the 
development of intracranial haematoma, intracerebral haemorrhage in patients in the 
absence of hypertension have been reported [Boysen, 1993]. Vascular malformations 
(angiomas) that maybe arterio-venous, venous or cavernous, may rupture and lead to 
bleeding in the brain parenchyma [Kase et al., 1992; Boysen, 1993]. The use of 
sympathomimetic drugs, anticoagulants agents, fibrinolytic agents may be some of the 
other conditions that may result in the development of an intracerebral haemorrhage. 
Risk factors for the development of intracerebral haemorrhage include hypertension,
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which is the leading risk factor, blood dyscracies, vascular malformations and 
tumours.
Subarachnoid haemorrhage
Subarachnoid haemorrhage contributes approximately 13% of total stroke 
cases [Brown & Wiebers, 1993]. The common causes for the development of 
subarachnoid haemorrhage are traumatic (head injury), aneurysm rupture, vascular 
malformations and bleeding disorders [Brown & Wiebers, 1993]. Other causes include 
vasculitis, drug abuse, cerebral bacterial infections, cerebral sinus thrombosis and 
secondary bleeding as result of an intracerebral haemorrhage [Mohr et al., 1992], The 
blood leaks into the subarachnoid space and is in direct contact with CSF. The 
diagnosis of subarachnoid haemorrhage normally displays evidence of clotted blood 
over the ventral surface of the brain [Brown & Wiebers, 1993; Mohr et al., 1992]. The 
arachnoid membrane is very resistant to the pressure of CSF and hence a large amount 
of blood is required to rupture the subarachnoid membrane, hence, the blood is 
confined in the subarachnoid space.
Cerebral vasospasm is a major complication and leading cause o f cerebral 
ischaemia or infarction following a subarachnoid haemorrhage [Brown & Wiebers, 
1993; Mohr et al., 1992]. The aetiology for the development of cerebral vasospasm is 
unclear but the vessels affected display reduced calibre and thrombosis, although, 
these may be symptomatic and not causal of subarachnoid haemorrhage. Cerebral 
vasospasm following subarachnoid haemorrhage is typically observed 3-7 days 
following the initial insult, but, some investigators have reported vasospasm 7-14 
weeks following the event [Brown & Wiebers, 1993; Mohr et al., 1992]. The vessels 
normally affected are those comprising the circle of Willis (basilar artery may also be 
affected) and the vasospasm spreads along the vessel.
Risk factors for stroke
The strongest determinant of stroke is age with the incidence o f stroke 
increasing exponentially with age [Bamford et al., 1990; Sacco, 1993]. The majority
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of strokes occur in patients over the age of 65. Other risk factors for increasing stroke 
incidence include gender, ethnic background and heredity. The incidence of stroke is 
between 16% and 70% higher in men than in women [Sacco et al., 1991; Sacco,
1993]. Evidence from epidemiological studies in United States, Taiwan and U.K. have 
indicated that stroke incidence may be related to ethnicity [Sacco, 1993]. The genetic 
contribution to the risk of stroke is an area of some controversy since the link between 
modifiable environmental factors and genetics factors has not been isolated.
There are a number of modifiable risk factors for stroke including 
hypertension, diabetes, cardiac disease, hypercholesterolaemia, smoking and alcohol 
use [Shaper et al., 1991; Wolf et al., 1992; Higa & Davanipour, 1991]. The association 
of these risk factors varies with the subtypes of stroke examined. Hypertension is the 
second most common risk factor for the development of stroke[Shaper et al., 1991]. 
The risk of stroke increases proportionately with increases in systemic blood pressure 
[Shaper et al., 1991, W olf et al., 1992], Systolic blood pressure between 160-180 
mmHg produced a four fold increase in stroke risk while systolic blood pressures 
above 180 increases the risk six fold. Hypertension has a strong association with 
cerebral infarction, intracerebral haemorrhage and subarachnoid haemorrhage.
Cardiac diseases, such as atrial fibrillation, valvular heart disease, myocardial 
infarction, coronary artery disease, congestive heart failure and ventricular 
hypertrophy, have been associated with an increase in the risk of stroke [Wolf et al.,
1991]. Atrial fibrillation increases the stroke risk five fold. Coronary artery disease 
doubles the stroke risk while cardiac failure increases the risk four fold. Cardiac 
disease is primarily associated with cerebral infarction and not associated with 
haemorrhagic stroke [Sacco, 1993].
Diabetes mellitus increases the risk of stroke , although, if  hypertension 
cardiac disease and hypercholesterolaemia were treated then the stroke risk due to 
diabetes was reduced [Shaper et al., 1991]. Elevations in serum lipids (triglycerides, 
cholesterol, LDL, HDL) are recognised risk factors for artherosclerosis and cardiac 
disease [Qizilbash et al., 1992], The role of serum lipids in the development of stroke 
is unclear. The formation of artherosclerotic plaques is also associated with carotid
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artery diseases. Carotid artery disease can lead to the stenosis of the vessel, although, 
non-stenosing plaques do occur. The adequacy of the collateral circulation, the degree 
of carotid artery stenosis and the propensity to form thrombi at the site of stenosis can 
affect the incidence of stroke.
Cigarette smoking has been established as a risk factor for cardiac diseases 
[Higa & Davanipour, 1991], More recent investigations have suggested that cigarette 
smoking may be a risk factor for stroke [Higa & Davanipour, 1991]. The incidence of 
stroke increases in heavy smokers and with an even higher risk when combined with 
hypertension. This risk is greater than the incidence rate for cerebral infarction. The 
association of alcohol and stroke risk is controversial. The investigations carried out 
have demonstrated strong associations and others have demonstrated the absence of 
any link [Sacco, 1993]. The association in haemorrhagic stroke (intracerebral 
haemorrhage and subarachnoid haemorrhage) is more established. Other risk factors 
for the development of stroke under investigations include the use o f migraine and 
oral contraceptive fonnulations. Haematological disorders such as sickle cell anaemia, 
altered haematocrit, polycythaemia and fibrinogen levels may be potential risk factors 
for the development of stroke [Sacco, 1993].
1.2.2 Pathophysiology o f cerebral ischaemia
Alterations in ion flaxes and energy metabolism
In cerebral ischaemia, cerebral autoregulation is impaired and as a result CBF 
varies passively with increasing MABP [Symon et al., 1976]. In humans and larger 
animals, spontaneous electrical activity ceases at a flow threshold of approximately 
<20 ml/lOOg/min [Heiss , 1992; Branston et al., 1974]. At a flow threshold o f <10-12 
ml/lOOg/min there is a loss of ion homeostasis within neurones and glial cells [Astrup 
et al., 1977; Branston et al., 1977] (Figure 2). The ionic changes that ensue at these 
levels of flow are preceded by an increase in the extracellular K+ concentration. Under 
anoxic conditions there is an efflux of K+ and an intake of Ca2+, the reasons for these 
changes include the collapse in membrane function especially the cessation of ionic
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Figure 2 Schematic diagram illustrating the thresholds for reductions 
in CBF following cerebral ischaemia resulting in neuronal dysfunction 
and death (Figure adapted from Astrup etal., 1977)
pump activity [Harris et al., 1981; Nicholson et al., 1977], The mechanism of 
cessation of membrane function is discussed later.
The gross alterations in neuronal functions is the result of the loss of the 
physiologic gradients of the ions [Naritomi et al., 1988], An important distinction 
between thresholds for functional impairment and the development of infarction is that 
cerebral infarction varies and increases with the duration of ischaemia [Jones et al., 
1981; Heiss et al., 1983] (Figure 3). In transient cerebral ischaemia, a flow level of 
<10-12 ml/lOOg/min for 1-3 hours leads to cerebral infarction [Jones et al., 1981]. 
Under conditions of permanent cerebral ischaemia, a level of <17-20 ml/lOOg/min is 
required for the development of cerebral infarction [Jones et al., 1981]. In small 
animals such as rodents the flow threshold for ischaemic neuronal damage occurs at 
higher levels. The probable reasons for the higher levels are increased neuronal 
packing density and higher cerebral metabolic rate which leads to a higher basal CBF 
[Kaplan et al., 1991; Naritomi et al., 1988; Tyson et al., 1984]. The flow thresholds for 
the impairment of cell function would occur at a similar percentage reduction in CBF 
in the primate and rodent.
Although perturbations in cellular metabolism occur at the very low levels in 
CBF, alterations in other cerebral function occur at higher flow thresholds. 
Intracellular and extracellular acidosis as result of lactate accumulation occurs at 
higher flow thresholds and p0 2  levels [Siesjo, 1992a], Cerebral oedema can develop 
at high levels of CBF primarily as a result of increased MABP [Ito et al., 1989; Siesjo, 
1992a]. Protein synthesis is the cerebral function most sensitive to alterations in CBF 
[Mies et al., 1991; Heiss, 1992].
Energy metabolism and ion homeostasis are an integral part of the functions of 
neurones. The maintenance of ionic gradients across neural membranes is primarily 
carried out by active transport. ATP produced during aerobic respiration is used to 
drive Na+/K+ exchanger and Ca2+/H+ exchanger [Siesjo, 1992a]. The active transport 
of these ions leads to a 10 fold higher level of Na+ and a 10000 fold higher Ca2+ level 
in the extracellular space and a 40 fold higher K+ concentration in the intracellular 
space. During neuronal depolarisation, the increase in intracellular Na+ occurs as
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Figure 3 Schematic diagram illustrating the relationship between the 
severity of reduction in CBF and duration of cerebral ischaemia and the 
development of irreversible neuronal damage(Figure from Jones et al.,
1981)
result o f entry through conductance channels or in exchange for Ca2+ /H+ . The 
calcium gradient is maintained by a Na+/Ca2+ ion exchanger which facilitates the 
extrusion of calcium while the extrusion of H+ is carried out by an Na+/H+ pump 
[Siesjo, 1992a]. The membrane potential is the main determinant o f Na+/Ca2+ 
exchange and under normoxic conditions the active and passive ion fluxes are 
maintained [Siesjo, 1992b].
Under conditions of ischaemia where there is ionic pump failure, membrane 
depolarisation is followed by the flow of ions down their concentrations gradients, i.e., 
influx of Na+ and Ca2+ into the neurones and an efflux of K+ and Cl- [Hansen, 1985]. 
In the initial phase of ischaemia, there is a slow efflux of K+ from neurones and a 
reduction in extracellular pH (the reduction in pH is probably due to the formation of 
lactic acid) [Siesjo et al., 1992b]. The second phase of ionic changes sees the efflux of 
K+ and influx Na+/Ca2+ and osmotically obligated water leading to swelling of the 
neurones [Hansen, 1985].
The synthesis of ATP is downregulated during ischaemia/hypoxia but the 
utilisation o f ATP is unaffected [Siesjo, 1988]. The hydrolysis of ATP results in 
elevations of ADP levels. The ADP produced can be used in conversion of 
phosphocreatine to creatine and the production o f ATP. This pathway of ATP 
production is maintained until phosphocreatine levels are depleted. The transition 
from aerobic to anaerobic respiration sees the production of ATP and lactate but the 
ensuing energy failure cannot be prevented. The reductions in ATP levels in ischaemia 
are the attempts of neurones to maintain their ionic gradients.
A number of authors have described alterations in brain pH associated with 
cerebral ischaemia [Siesjo, 1992a], In general, there is a drop of approximately 0.6-1 
pH unit during cerebral ischaemia [Behar et al., 1989]. In transient cerebral ischaemia 
with reperfusion, the magnitude of pH reduction is decreased during the reperfusion 
phase. The reductions in pH may be due to increased lactate production or a decrease 
in the CMRgic. At pH levels below 6.1 there is an arrest of oxidative phosphorylation 
[Paschen et al., 1987].
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In focal cerebral ischaemia there is a greater decrease in pH in the core of the 
lesion than in the ischaemic penumbra [Paschen et al., 1987]. Reductions in 
extracellular/intracellular pH is due to a mismatch between glycolysis and oxidative 
phosphorylation [Siesjo, 1992a]. During hypoxia/ischaemia, the mitochondria lose 
their ability to sequester Ca2+ ions (energy dependent process) and this results in an 
increase in intracellular calcium levels [Siesjo & Bengtsson, 1989]. Hyperglycaemia 
exacerbates acidosis due to increased substrate availability but respiration is anaerobic 
[Chopp et al., 1988].
During complete or near complete ischaemia (global ischaemia) there is a 
cessation in the delivery of substrate (glucose) to the brain and rapidly leads to energy 
failure [von Hanwehr et al., 1986; Chopp et al., 1987]. Pre-ischaemic hyperglycaemia 
exacerbates ischaemic damage in global or forebrain ischaemia [Chopp et al., 1988]. 
The neuronal damage is associated with oedema, post-ischaemic seizures and rapidly 
maturing brain lesions [Siesjo et al., 1992b]. In transient focal ischaem ia, 
hyperglycaemia increases infarct size [Siesjo et al., 1992b]. In permanent ischaemia 
the effects of hyperglycaemia are more ambiguous, some authors have reported an 
increase in the lesion size while others have reported either no change or a reduction 
in lesion size [Ginsberg et al., 1987; Nedergaard & Diemer, 1987; de Courten-Myers 
et al., 1989]. The mechanism by which hyperglycaemia exerts its effects in ischaemia 
are unclear but the destruction of cerebral microvessels due to acidosis has been 
suggested (absence of proliferating vessels in the border between infarct and non- 
infarcted tissue) [Nedergaard & Diemer, 1987].
Mechanisms o f Ischaemic Neuronal damage
Calcium
Increases in intracellular calcium has implicated this ion as an initiator o f the 
ischaemic cascade eventually leading to neuronal death [Siesjo, 1988; Siesjo, 1992a; 
Siesjo, 1992b]. Under resting conditions there is a 10000 fold excess of calcium in the 
extracellular space and the concentration gradient is maintained by the means of
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electrogenic pumps (Ca2+/Na+ exchanger). Intracellular calcium is sequestered by the 
endoplasmic reticulum and mitochondria.
Increases in intracellular calcium can arise from a number of sources, 
increased influx of calcium or reduced efflux is one aspect of calcium homeostasis 
[Sharma & Hakim, 1993]. Increased release of calcium from intracellular stores as a 
result of reduced sequestration or reduced binding also contribute to the increase in 
intracellular calcium [Siesjo & Bengtsson, 1989]. The depolarisation of neurones leads 
to the influx of calcium and increases in intracellular calcium lead to the activation of 
transcription factors and induce the expression of immediate early genes or stress 
proteins [Hisanaga & Hirokawa, 1990; Siesjo, 1992b]. The marked increases in 
intracellular calcium during cerebral ischaemia may be detrimental due to increased 
energy failure and the inability of the electrogenic pumps to maintain the ionic 
gradient [Siesjo & Bengtsson, 1989; Stys et al., 1991].
Calcium entry from the extracellular space can occur via voltage sensitive 
calcium channels or receptor operated calcium channels [Siesjo & Bengtsson, 1989]. 
The release of calcium from intracellular stores occurs primarily via G-protein coupled 
receptors which stimulate phospholipase C and the production of diacylglycerol 
(DAG) and inositol triphosphate (IP3) [Siesjo, 1992b]. IP3 initiates the release of 
calcium from the endoplasmic reticulum [Siesjo & Bengtsson, 1989]. Glutamate 
acting through the metabotropic receptor may initiate the increase in intracellular 
calcium [Nicoletti et al., 1986; Sladeczek et al., 1988]. Intracellular calcium is 
inactivated by its binding to specific proteins such as calmodulin and calcibindin or 
sequestration into the endoplasmic reticulum or mitochondria [McBumey & Neering,
1987].
An increase in intracellular Ca2+, through voltage sensitive channels or 
receptor operated channels, following hypoxia/ischaemia is thought to trigger neuronal 
necrosis [Choi, 1988]. Increases in intracellular calcium lead to the activation of 
lipases, proteases, endonucleases and protein kinases and results in the alterations in 
membrane function [Siesjo et al., 1992b]. Calcium mediated protease activation can 
result in the breakdown of the cytoskeleton. An important aspect on increased
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intracellular calcium levels is the activation of phospholipases [Siesjo et al., 1992b]. 
Phospholipid hydrolysis by phospholipase A2 results in the formation of free fatty 
acids, lysolipids and arachidonic acid [Siesjo et al., 1992b]. The lysophospholipid and 
free fatty acids may cause membrane damage. The activation of phospholipase C 
results in the formation of IP3 and DAG and DAG undergoes metabolism to form 
arachidonic acid [Siesjo et al., 1992b]. Metabolism of arachidonic acid by cyclo- 
oxygenase and lipoxygenase results in the formation of metabolites that can cause 
vasomotor disturbances, blood-brain barrier breakdown, free radical release and the 
activation of protein kinases.
Excitatory Amino Acids
The excitatory amino acid glutamate is one of the major neurotransmitters in 
the brain. Ischaemic neuronal damage is characterised by the damage to neuronal cell 
bodies but the sparing of axons [Olney, 1978; Choi, 1988]. Axonal sparing allows the 
release o f neuro transmitters from the terminals and thus exacerbating the neuronal 
damage. The physiologic role of these transmitters and receptors is varied. Amongst 
the possible roles are long term poteniation (LTP), burst firing of CNS neurones and 
some aspects of learning and memory [Collingridge & Bliss, 1987; Herrling et al.,
1983]. The main amino acids are glutamate and aspartate and the actions of these 
substances are mediated via excitatory amino acid receptors. There are five types of 
receptors classified on the basis of selective agonists and these are the NMDA 
receptors, AMPA receptors, kainate receptors, metabotropic receptors and the L-AP4 
receptor [Choi, 1990]. The NMDA, AMPA and Kainate receptors are linked to ion 
channels-Na+, K+ and Ca2+ permeable [Siesjo, 1981; Gill, 1994]. The metabotropic 
receptor is linked via a G-protein to phospholipase C while the transduction 
mechanism for the L-AP4 receptor is suggested to be via cGMP [Choi, 1990]. The 
excitotoxic hypothesis has implicated glutamate as a mediator of neuronal damage 
following cerebral ischaemia [Benveniste, 1991].
The NMDA receptor is the most widely studied of the excitatory amino acid 
receptors. Under normal physiologic conditions, the NMDA receptor ionophore is
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blocked by Mg2+ ions [Foster & Fagg, 1987]. This blockade is voltage dependent and 
the depolarisation of the cell membrane relieves the Mg2+ blockade and allows the 
influx of calcium and sodium ions [Foster & Fagg, 1987; Choi, 1988], The NMDA 
receptor complex comprises a number of distinct sites that allow the modulation of 
receptor activity [Foster & Fagg, 1987]. Activation of the NMDA receptor can be 
attenuated by the competitive inhibition of the neurotransmitter recognition site by 
antagonists (CGS19755, D-CPP-ene) [McCulloch et al., 1991]. Non-competitive 
antagonism of sites within the ionophore is usually use dependent by agents (MK801, 
PCP) and decrease the activity of this receptor [McCulloch et al., 1991]. Allosteric 
modulatory sites also exist on the receptor complex and these are the strychnine 
insensitive glycine site (positive modulation site), which is antagonised by L-687414, 
ACEA-1021 and a polyamine site antagonised by ifenprodil and eliprodil. Antagonism 
of the allosteric sites reduces the activity of the NMDA receptor [Muir & Lees, 1995].
The non-NMDA receptors (AMPA and Kainate) are mediators of fast synaptic 
transmission and activation of these receptors facilitates membrane depolarisation and 
alleviation of the Mg2+ block in the NMDA channel. The ion channels associated with 
these receptors are permeable to Na+ and K+ although there is some evidence that 
calcium may also enter through the ion channels [Choi, 1988; Hollman et al., 1991].
The role of glutamate in the genesis of ischaemic cell injury has been 
demonstrated in vitro and in vivo [Choi, 1990; Benveniste, 1991], Lucas and 
Newhouse (1957) demonstrated the neurotoxicity of excitatory amino acids to retinal 
neurones. Subsequent studies demonstrated that increasing concentrations of 
glutamate were neurotoxic to neuronal cell cultures and the cell necrosis was 
associated with a lethal influx of Ca2+ as a result of overactivation o f glutamate 
receptors [Choi, 1990; Benveniste, 1991]. Increases in the extracellular concentrations 
of glutamate have been observed in global and focal cerebral ischaemia and the extent 
o f glutamate increases have been correlated with the degree of neuronal damage 
[Benveniste et al., 1984]. Further evidence was provided by the neuroprotective 
efficacy of NMDA and non-NMDA receptor antagonists in experimental models of 
ischaemia [McCulloch et al., 1991; Gill, 1994; Muir & Lees, 1995].
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Free Radicals
Apart from glutamate, other mediators of ischaemic neuronal damage include 
the free radicals [Phillis, 1994]. The source of free radicals has been speculated upon 
but arachidonic acid metabolism is thought to be a major source of free radicals 
[Siesjo, 1992b, Phillis, 1994], Other sources include hyperoxia, impaired metabolism 
within the mitochondria and unchelated iron [Phillis, 1994]. The release o f free 
radicals activates lipid peroxidation and can lead to membrane damage [Phillis, 1994]. 
Most cells possess endogenous free radical scavengers such as vitamins (A and C), 
glutathione peroxidase and superoxide dismutase (SOD). In experimental forebrain 
ischaemia there is increased lipid peroxidation and SOD production and the 
production of free radicals is dependent on oxygen tension [Siesjo, 1992b; Phillis, 
1994]. During reactive hyperaemia following transient ischaemia, there is an increase 
in the production of free radicals due to an increase in the oxygenation o f the 
ischaemic territory.
The Ischaemic Penumbra
The lesion following focal cerebral ischaemia comprises a central core region 
with dense ischaemia and a peri-focal region with less dense ischaemia, also termed 
the ischaemic penumbra [Astrup et al., 1981; Hakim et al., 1992]. The central core of 
the lesion normally comprises the caudate nucleus and some neocortical areas that are 
normally supplied by perforating arteries from the MCA and its lenticulostriate 
branches while the peri-focal areas are supplied by collateral anastomoses between the 
arterioles of the anterior cerebral artery (ACA), posterior cerebral artery (PCA) and 
the MCA [Strong et al., 1983a & 1983b].
The differences in the flow thresholds for reductions in spontaneous electrical 
activity and dysfunctions in ion homeostasis has led to the description o f the 
ischaemic penumbra as an area where neurones are inexcitable but viable [Astrup et 
al., 1981; Strong et al., 1983a & 1983b]. The development of the ischaemic lesion is 
dependent on duration of the ischaemic period and the level of CBF maintained during
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the ischaemic period [Jones et al., 1981]. The peri-focal areas may be viable for longer 
periods of time provided adequate blood flow is maintained from the collateral blood 
vessels [Heiss, 1992; Siesjo, 1992a]. Failing this the peri-focal areas are recruited into 
the ischaemic territory. Peri-focal areas can be salvaged by reperfusion or 
pharmacologic interventions that either increase CBF or prevent neuronal death 
[McCulloch et al., 1991; Gill, 1994].
Delineation of the penumbral areas is difficult. The peri-focal areas have blood 
flow, decreased electrical activity, efflux of K+ and scattered neuronal necrosis, i.e., at 
early time points it is difficult to differentiate penumbral tissue from the ischaemic 
core [Strong et al., 1983a & 1983b; Heiss, 1992]. During the therapeutic window of 
opportunity there is a mismatch between the CBF and metabolic demands of the 
neurones [Heiss, 1992]. This leads to the release of inhibitory substances that can act 
initially to quell the metabolic demand e.g. GAB A, Adenosine [Shimada et al., 1990; 
Matsumoto et al., 1992]. A sustained period of ischaemia can eventually overcome 
this mechanism and the release of glutamate and free radical production leads to the 
damage of neurones in the core and recruitment of peri-focal (penumbral tissue) into 
the ischaemic infarct [Siesjo, 1992a].
The patterns of ischaemic neuronal damage in transient global or forebrain 
ischaemia are different because the ischaemic period is transient and associated with a 
marked reduction in CBF [Pulsinelli et al., 1982b; Smith et al., 1984]. The marked 
reduction in CBF in global ischaemia results in the loss of membrane function and 
ionic homeostasis [Siesjo, 1992b].
Cerebral Blood Flow and Cerebral Ischaemic Damage
The impairment of neuronal function is dependent on the level of cerebral 
blood flow and the duration of the reduction in cerebral blood flow. In the ischaemic 
territory there is a failure of the autoregulatory capacity of cerebral blood vessels. 
Thus, increasing cerebral blood flow in the ischaemic territory provides a mechanism 
for reducing ischaemic brain damage. The use of vasodilator agents, such as L-type 
calcium channel antagonists and papaverine could have the effect of increasing
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cerebral blood flow in the ischaemic territory above the thresholds for the 
development of ischaemic damage [Date & Hossmann, 1984; Kazda et al., 1982; 
Hossmann et al., 1973; Brandt et al., 1983] (Figure 2). However, these agents induce 
systemic hypotension and cerebral blood flow could be reduced and ischaemic brain 
damage could be exacerbated.
The regulation of cerebral blood flow is critical in the post-ischaemic phase. 
The administration of vasodilator agents may facilitate the increase of cerebral blood 
flow into the ischaemic territory. However, the reductions in cerebral blood flow are 
the result of complex mechanisms. There has been speculation on the mechanisms 
resulting in sustained reduction in cerebral blood flow including, active 
vasoconstriction, increased tissue oedema causing the obstruction of collateral vessels 
and occlusion of the microvasculature have been suggested mechanisms [Hatashita & 
Hoff, 1986; Dimagl et al., 1994; del Zoppo, 1994]. The use of vasodilator agents such 
as nimodipine assumes that the alleviation of the vasoconstriction will facilitate the 
increasing cerebral blood flow above the thresholds for the development of neuronal 
damage. However, recent evidence has indicated that the occlusion of the cerebral 
microvasculature by the platelets and leucocytes may be a significant mechanism for 
the reductions in cerebral blood flow. The activation of cell adhesion molecules may 
serve to exacerbate the occlusions of the microvasculature and the role o f the 
intercellular adhesion molecules in cerebral ischaemia is being explored.
1.2.3 Experimental models of cerebral ischaemia
Experimental models of cerebral ischaemia are an important aspect for the 
understanding of the ischaemic process. Although the models of ischaemia used are 
wide and varied, an important factor linking them is their reproducibility. Models of 
ischaemia have been developed to examine cerebrovascular and neuronal alterations 
following permanent focal ischaemia, transient focal ischaemia, transient global 
cerebral ischaemia and models of head injury such as subdural haematomas.
A number of important issues are raised when deciphering the descriptions 
such as the species used, the type of ischaemic injury and the physiologic status o f the
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animals. As described in an earlier section, there are a number of inter-species 
differences in the cerebrovascular anatomy. The structure of the circle of Willis as 
seen in the gerbil compared to other species, the anastomotic links between the ACA, 
MCA and PCA and the resulting collateral channels have implications for the severity 
and extent of ischaemic damage [Coyle & Jokelainen, 1982; Mchedlishvili & Kuridze,
1984], The type of ischaemic insult, the duration of ischaemia and the size of the 
ischaemic penumbra are important for the neuroprotective strategies [Jones et al., 
1981], Since these factors determine the level of CBF which are important for the 
various neuronal functions (see previous section).
The factors mentioned above become less significant because the majority of 
studies are carried out in a small number of species with the rat being the most 
common. One of the reasons for the use of this species is the ease of the development 
of the model and the cost of conducting the experiments. Despite the apparent 
standardisation of the models of ischaemia, there is a great deal of variability between 
the various groups carrying out the studies. The physiologic status of the animal 
(arterial blood gas status, plasma glucose levels, haematocrit, body and brain 
temperature and MABP) are important contributors to the variability.
Reductions in the arterial pC>2 levels outwith the autoregulatory limits (<50 
mmHg) results in an increase in CBF and at levels below 20 mmHg result in the 
cessation of cerebral function [Paulson et al., 1990]. In contrast an increase in pCC>2 
progressively increases CBF [Paulson et al., 1990]. The effects o f plasma glucose 
levels on the degree of ischaemic injury is also an important variable in experimental 
ischaemia [Chopp et al., 1988; Yip et al., 1991]. Hyperglycaemia facilitates acidosis 
and results in the exacerbation of the ischaemic injury [Chopp et al., 1988]. 
Alterations in the haematocrit results in either increasing viscosity of the blood, thus 
impaired flow through the capillary network or reduced oxygen carrying capacity 
inducing hypoxia to the target area. Brain temperature has in recent years become a 
controversial issue in experimental ischaemia. Investigations of Busto et al. (1987) 
have demonstrated that reductions in brain temperature by 4°C in transient global or 
focal ischaemia results in a substantial reduction in the size of infarct [Minanisawa et
al., 1990; Morikawa et al., 1992]. The regulation of rectal and brain temperature in 
experimental studies will facilitate the reproducibility of the insult [Ridenour et al., 
1992; Busto et al., 1987; Minanisawa et al., 1990; Morikawa et al., 1992; Zhang et al.,
1993]. The impact of MABP on CBF and ischaemic damage has been well 
documented. The autoregulatory capacity of cerebral vessels is impaired in ischaemia 
and CBF varies passively with alterations in MABP [Paulson et al., 1990]. 
Hypotension below the lower limit of autoregulation results in increase in infarct size 
following a focal ischaemic insult [Osborne et al., 1987]. Haemorrhagic hypotension 
is also used in transient forebrain ischaemia to exacerbate the extent o f ischaemia 
[Smith et al., 1984]. Prolonged hypotension per se can result in ischaemic damage in 
the border zones of the three cerebral arteries.
The experimental models are important for the understanding to the 
mechanism associated with cerebral ischaemia and also for the development of 
therapeutic strategies for the amelioration of ischaemic damage.
Subdural Haematoma
Subdural haematomas are associated with ischaemic neuronal damage and 
high mortality. The neuronal damage may be ipsilateral to the haematoma or 
occasionally bilateral. Surgical intervention is the main course of treatment and -50%  
of patients die and 25-25% of patients are left with disabilities [Sahuquillo-Barris,
1988], The subdural haematoma is associated with increases in intracranial pressure, 
herniation of the brain and a reduction in cerebral perfusion pressure [Sahuquillo- 
Barris, 1988; Bullock & Teasdale, 1990].
The model of subdural haematoma used in the present investigation was 
developed in the rat [Miller et al., 1990]. Autologous venous blood (-400 jil) was 
injected slowly into the subdural space [Miller et al., 1990]. The volume o f blood 
injected has been previously demonstrated to be the optimal amount necessary for the 
induction of consistent brain lesions [Miller et al., 1990]. The blood was injected over 
5-7 min to allow for the formation and discrete location of the haematoma (a rapid 
injection of the blood into the subdural space did not result in the formation of a
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haematoma) [Miller et al., 1990]. The slow injection of blood may be analogous to the 
clinical situation where there may be a slow leak of blood from the ruptured vessels 
into the subdural space [Gennarelli & Thibault, 1982],
The neuronal damage associated with the subdural haematoma is the result of a 
number of factors. The mass of the subdural haematoma may result in the herniation 
o f the brain across the midline and increased pressure on the brainstem in humans. 
These alterations are associated with increases in intracranial pressure and acute 
swelling of the brain probably due to cytotoxic oedema. The brain is also vulnerable to 
the constituents of blood such as thrombin and platelet activating factor that facilitate 
the progression of the ischaemic injury. The presence of blood in the subdural space 
may trigger the release of vasoconstrictor agents such as 5-HT and endothelins. The 
constriction of arterioles on the surface may be a contributing factor to the 
development of the ischaemic lesion. The pattern of neuronal damage and CBF 
following subdural haematoma in the rat are dependent on the distribution of the clot 
with the greatest extent of ischaemic damage directly under the greatest mass of the 
haematoma and the alterations becoming more diffuse as the haematoma spreads over 
the convexity of the brain.
Focal Ischaemia
A focal ischaemic insult is one of the most common forms of stroke in man. 
The middle cerebral artery is the most commonly affected artery in man and this has 
led to the development of animal models where the patterns of ischaemic following 
MCA occlusion are modelled [Derouesue et al., 1993]. An experimental model of 
focal ischaemia was first described in the rat where the MCA was ligated [Robinson et 
al., 1975]. Neuronal damage was observed in the cerebral cortex but the size o f the 
lesion was variable [Robinson et al., 1975]. Subsequently, Tamura and colleagues 
(1981a &b) developed a model of focal ischaemia in the rat which involved the 
pennanent occlusion of the MCA and its lenticulostriate branches, using diathermy, 
and a lesion in the caudate nucleus and neocortex was obtained. In the rat occlusion of 
the MCA and its branches results in the ischaemic damage in the territory of the MCA
47
and the histologic changes associated with focal cerebral ischaemia are observed 3-4 
hours following the insult [Tamura et al., 1981a & 1981b; Kaplan et al., 1991].
O'Brien and Waltz (1973) described a transorbital technique for the occlusion 
of the MCA in the cat. Permanent occlusion of the MCA and lenticulostriate branches 
results in an ischaemic lesion within the territory of the MCA. There are a number of 
advantages in using a larger animal species such as the cat over the rat. The cat is a 
gyrencephalic species, like man, and may be a more representative model for the 
processes underlying ischaemia [O'Brien & Waltz, 1973; Strong et al., 1983a & b]. 
Depolarisation caused by the efflux of potassium ions result in a wave of the 
depolarisation rapidly traversing the surface of the brain. The propagation of the 
waves of spreading depression following ischaemia are thought to exacerbate the 
extent of ischaemic damage. Actions of neuroprotective agents, such as MK-801, in 
the rat have been attributed to their ability to attenuate the waves o f spreading 
depression. The stability o f cardiovascular and respiratory parameters is of paramount 
importance in ischaemia studies. The cat has a greater stability under prolonged 
anaesthesia than the rat (over a period of 4-6 hours for acute studies). The larger blood 
volume in the cat allows greater cardiovascular stability under conditions of repeated 
sampling of blood for gases and plasma drug levels that are necessary in a focal 
cerebral ischaemia study.
The occlusion of the MCA in the rat and cat is an invasive procedure. The 
craniectomy and surgical exposure of the MCA involves a degree of local tissue 
damage. The larger brain size in the cat means that the damage caused by the exposure 
has a smaller contribution to the overall volume of the damage in the cat than in the 
rat. The neuroprotective drug strategies in focal ischaemia rely on the salvage of tissue 
in the peri-focal regions (penumbra) [Chen et al., 1991a, Mackay et al., 1993b; 
Bullock et al., 1994]. There is a greater distance of the penumbra from the site o f 
surgery and a larger volume of salvageable tissue in the gyrencephalic species.
There is an increase in the number of anastomotic links between the cerebral 
arterioles [Mchedlishvili & Kuridze, 1984] and investigations of flow enhancing 
strategies will be facilitated in the larger animal species. The surgical manipulation of
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the MCA may affect the vascular reactivity of vessels in more distal regions and the 
greater distance of the cerebral arterioles to be examined from the site of surgery 
would minimise such effects.
Global Ischaemia
Experimental models of global cerebral ischaemia have been developed to gain 
insight into the mechanism of brain damage associated with cardiac arrest. There are a 
variety of animal models of global cerebral ischaemia and the techniques involve the 
occlusion of arteries in the neck [Pulsinelli et al., 1979; Smith et al., 1984]. The 
species used for models of global cerebral ischaemia include dog, cat, gerbil and rat. 
The rat is most commonly used species and the models used are a four vessel 
occlusion model described by Pulsinelli et al. (1979) and a 2 vessel occlusion with 
haemorrhagic hypotension described by Smith et al (1984).
In the four vessel occlusion model, the vertebral arteries are cauterised and 
global cerebral ischaemia induced by ligation of the carotid arteries for between 5-30 
min [Pulsinelli et al., 1979]. There is a marked reduction in CBF <5% of baseline 
during the ischaemic period and the release of the carotid ligatures results in a 
transient hyperaemic response followed by a period of delayed post-ischaemic 
hypoperfusion [Pulsinelli et al., 1979] (Figure 4). In the two vessel occlusion model, 
the carotid arteries are ligated for 5-20 min and haemorrhagic hypotension induced 
[Smith et al., 1984]. The occlusion of the carotid arteries results in a moderate 
reduction in CBF and the induction of haemorrhagic hypotension is necessary to 
induce cerebral ischaemia [Smith et al., 1984]. The release of the carotid ligatures and 
restoration of mean arterial blood pressure results in similar alterations in CBF [Smith 
et al., 1984].
The interest in global ischaemia has been concentrated on the patterns o f 
selective neuronal vulnerability [Schmidt-Kastner & Freund, 1991], The neuronal 
damage is observed primarily in the CA1 region of the hippocampus, neocortex and 
some damage in the corpus striatum [Kirino et al., 1984; Schmidt-Kastner & Freund,
1991]. Additionally, selective neuronal vulnerability observed in the hippocampus is
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Figure 4 Schematic diagram illustrating the 
transition from hyperaemia to hypoperfusion 
following transient global cerebral ischaemia
observed in humans following cardiac arrest [Brierley & Graham, 1984; Petito et al., 
1987].
Delayed post-ischaemic hypoperfusion observed following global or forebrain 
ischaemia has been attributed to a number of factors [see discussion]. Manipulations 
with calcium channel antagonists have indicated that the maintenance of post- 
ischaemic hypoperfusion may be the result of a loss of dilator tone or the release of 
vasoconstrictor factors [Kazda et al., 1982].
The availability of animals models of cerebral ischaemia allows us address a 
number of issues. The rigorous control of cardiovascular and respiratory parameters 
facilitates the understanding of the mechanisms of ischaemic neuronal damage. 
Animal models of cerebral ischaemia made im portant contributions in the 
development of therapeutic agents for the amelioration of ischaemic damage.
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1.3 Endothelin: a vasoconstrictor peptide
Discovery
The vascular endothelium is the source of many vasoactive factors. Recent 
research on the vascular endothelium has shed light on the multiple roles o f the 
endothelins in the regulation of vascular tone. The main factors that have been isolated 
are the vasodilator substances endothelium derived relaxing factor (EDRF), 
prostacyclin and endothelium derived contracting factor (EDCF) [Moncada et al., 
1976; Furchgott & Zawadski, 1980; Hickey et al., 1985]. The importance of the role of 
EDRF and prostacyclin in the maintenance of vascular tone has been well 
documented. EDRF has subsequently been suggested to nitric oxide or a nitrosothiol. 
However, the identification and role of EDCF has proved to be elusive.
The initial existence of an endothelium derived vasoconstrictor factor was 
suggested. The discovery of the EDCF was facilitated by the discovery o f a 
vasoconstrictor substances from endothelial cell cultures by Hickey et al. (1985). The 
culture medium from aortic endothelial cells triggered a vasoconstrictor response that 
developed slowly but had a prolonged duration of action. These actions could not be 
attributed to any of the known vasoconstrictors and additionally it was demonstrated 
that this vasoconstrictor factor was of peptidergic origin. These observations were 
subsequently repeated by various other groups.
In 1988 Yanagisawa and colleagues published a seminal paper describing the 
isolation, cloning and sequencing of a peptidic EDCF that they termed endothelin 
(ET). The endothelin peptide was isolated initially from bovine aortic endothelial cell 
cultures. The effects of this peptide were similar to effects described by Hickey and 
colleagues, i.e., slow developing contraction and prolonged duration of action. The 
endothelin peptide described by Yanagisawa and colleagues was a 21 amino acid 
peptide and there appeared to be no sequence homology with any other peptides of 
mammalian origin. Subsequently a peptide isolated from snake venom (Atracaspis 
engaddensis, Israeli burrowing asp) was described to have a structure very similar to 
the endothelins.
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Structure
The endothelin family of peptides comprises three isopeptides called 
endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3). These peptides are 
encoded by three distinct genes and sequences for these have been previously 
published [Yanagisawa et ah, 1988], The three isopeptides share large degrees of 
sequence homology and the mature peptides consist of 21  amino acids with the 
distinguishing feature of double disulphide bridges between cysteine residues at 
positions 1 - 1 5  and 3-11. The differences between the amino acid sequences of ET-1, 
ET-2 and ET-3 are shown in figure 5.
Synthesis
The processing of pre pro endothelin peptide is carried out in 3 stages. The 
first stage involves the removal of the signal peptide by a dibasic peptidase to give a 
pre pro endothelin of 212 amino acid residues. The second stage involves the 
formation of pro endothelin or big endothelin (41 amino acid residues) by a carboxy 
peptidase [Doherty, 1992; Battistini et al., 1993; Rubanyi & Polokoff, 1994]. The final 
stage is the production of the 21  amino acid mature endothelin peptide by the 
endothelin converting enzyme [Opgenorth et al., 1992; Schmidt et al., 1995; 
Deschepper et al., 1995] [Figure 6 ]. The conversion of the big-ET form to the mature 
endothelin peptide is an important phase because the vasoconstrictor activity o f the 
big-ET form is approximately 100 fold less than the endothelin.
Synthesis of the mature endothelin peptides (s) relies on their conversion from 
the big endothelin form. This processing is carried out by an enzyme putatively termed 
endothelin converting enzyme (ECE). The initial descriptions of this enzyme indicated 
that it may be a chymotrypsin like enzyme (serine protease). However, serine 
pro teases inhibitors failed to inhibit the vasoconstriction actions of BET-1. Further 
analysis demonstrated two protease enzymes, an aspartic protease from bovine and 
porcine aortic endothelial cell cultures, bovine adrenal medulla and rat lung, and a 
metalloprotease isolated from bovine and porcine aortic endothelial cell cultures, 
porcine vascular smooth muscle cells and from human and rat brain. These enzymes
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Figure 5 The structure of the mature endothelin peptides. The 21 
amino acid peptide molecules are characterised by the two 
disulphide bridges between the cysteine amino acids present at 
1, 3, 11, 15. The shaded amino acids (black)indicate the 
differences between ET-2, ET-3 and ET-1.
Post-translational Processing of PrePro Endothelin-1
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Figure 6 The processing of the prepro-endothelin peptide to the 
mature endothelin peptide. The processing is facilitated bya 
carboxypeptidase and Endothelin Converting Enzyme (ECE). ECE 
is a metalloprotease and specific ECE's may involved in the 
processing of ET-1, ET-3 and ET-3.
functioned at different optimal pH (pH 5.5 for the aspartic protease and pH 7.4 for the 
metalloprotease protease). These observations suggested that there may be 2 or more 
forms of ECE and they may be involved in the conversion of BET-1 to ET-1 in 
endothelial cells or on vascular smooth muscle cells because of its optimal pH. The 
metalloprotease is more commonly known as the Neutral Endopeptidase (NEP 24.11) 
and facilitates the conversion of BET-1 to ET-1 and is inhibited by phosphoramidon 
while thiorphan ( also an NEP inhibitor) had no effect on BET-1 conversion. The 
acidic protease is inhibited by pepstatin. Phosphoramidon prevented the conversion of 
BET-1 released from endothelial cells to ET-1. The aspartyl protease inhibitors had 
no effect on BET-1 conversion and hence the NEP form was thought to be 
physiologically relevant. Additionally, phosphoramidon reduced the MABP in SHR 
rats and inhibited the vasoconstrictor effects of BET in vivo. The phosphoramidon 
sensitive ECE was identified in the membrane fraction in porcine aortic endothelial 
cells. The activity of the membrane fraction was not influenced by thiorphan and the 
cytosolic was insensitive to phosphoramidon. ECE activity in vascular smooth muscle 
cells have demonstrated similar acidic and neutral and pH forms. Since the release of 
endothelin (BET) is polarised towards the vascular smooth muscle, the presence of 
ECE on these surfaces maybe involved in the conversion to mature ET peptide.
Paradoxically, NEP 24.11 (enkephalinase) has been described as the enzyme 
involved in the degradation of the endothelin peptide amongst other biological 
peptides such as ANP, enkephalins, bradykinin and substance P. NEP is also inhibited 
by phosphoramidon and physiologic ECE may be an NEP-like enzyme.
Endothelin Receptors and Functions
The isolation of the endothelin isopeptides was rapidly followed by the cloning 
and identification of cDNA encoding two endothelin receptors, ETa  and ETg [Arai et 
al., 1990; Sakurai et al., 1990; Masaki et al., 1994]. The pharm acologic 
characterisation of these receptors was carried out on the basis of the rank order of 
potencies of the endothelin isopeptides. The endothelin ETa  receptor showed 
increased selectivity for ET-1 and ET-2 over ET-3 [Arai et al., 1990]. The three
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isopeptides are equipotent at the ETb receptor [Sakurai et al., 1990]. A receptor 
displaying increased selectivity for ET-3 over ET-1 or ET-2 has been described in 
amphibian melanocytes [Kame et al., 1993]. This receptor has putatively been called 
the endothelin ETc receptor, however, a mammalian correlate of this receptor has not 
been isolated or cloned.
There is a high degree of sequence homology in the structure of endothelin 
receptors (approximately 50% of amino acids in a variety o f species), similar to 
endothelin peptides [Arai et al., 1990; Sakurai et al., 1990]. The endothelin receptors 
belong to the rhodopsin superfamily of G-protein linked receptors. The two receptor 
subtypes have seven transmembrane spanning domains that is characteristic o f this 
family.
These contractile actions are meditated by the increase in intracellular calcium 
and there are a number different mechanisms that can facilitate this increase in 
intracellular calcium. These mechanism include G-protein activated phospholipase C 
(PLC) resulting in an increase in phosphotidyl inositol hydrolysis (PI hydrolysis) and 
production of diacyl glycerol (DAG), the activation of protein kinase C (PKC) by 
DAG, activation of phospholipase A2 (PLA2) and arachidonic acid metabolism and 
activation of phospholipase D (PLD) [Rubanyi & Polokoff, 1994]. The increases in 
intracellular calcium results in the activation of the contractile mechanism of the 
smooth muscle and the contraction of the vasculature and other smooth muscle tissues 
[Rubanyi & Polokoff, 1994; Tamirisa et al., 1995].
The vasoconstrictor effects of the endothelins are primarily mediated via the 
endothelin ETa receptor [Doherty, 1992; Rubanyi & Polokoff, 1994; Gandhi et al., 
1994]. Vasodilatation is mediated by ETg receptors in vivo and in vitro [Rubanyi & 
Polokoff, 1994; Fukuroda et al., 1990; Clozel et al., 1992; Shetty et al., 1993], 
however, E T b  receptor mediated vasoconstrictions have been described in some 
vascular beds e.g. kidney and pulmonary circulation [Rubanyi & Polokoff, 1994; 
Clozel et al., 1992; Shetty et al., 1993; Seo et al., 1994]. The pulmonary vasculature 
demonstrates a vasoconstrictive response that is mediated via both endothelin E T a  and 
endothelin E T b  receptors [Rubanyi & Polokoff, 1994; Warner et al., 1993; Bax et al.,
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1993; Fukuroda et al., 1994; Cardell et al., 1993]. Smooth muscle from the guinea pig 
fundus and small intestine in demonstrate endothelin ETa  receptor mediated 
dilatation [Lin & Lee, 1990 & 1992]. The detailed effects of the endothelins in the 
periphery have been reviewed elsewhere [Rubanyi & Polokoff, 1994; Gandhi et al.,
1994]. The varied effects of the endothelins at the ETb receptor have led to the 
subdivision of the ETb receptor into ETbi receptors that mediate vasodilatation and 
ETB2 receptors that mediate vasoconstriction [Masaki et al., 1994; W arner et al.,
1993].
Endothelin-1 elicits a vasoconstriction of vessels in the renal, mesenteric and 
coronary circulations [Clozel et al., 1989; Gellai et al., 1994; Wallace et al., 1989]. 
The intravenous administration of endothelin-1 effects a transient decrease followed 
by a sustained increase in mean arterial blood pressure. The available evidence 
indicates that the endothelin E T a  receptors mediate the vasoconstrictor response in 
blood vessels and are located on the vascular smooth muscle [Rubanyi & Polokoff, 
1994; Masaki et al., 1994]. The vasoconstrictor effects of endothelin-1 are calcium 
dependent and are attenuated by the calcium channel antagonists nitrendipine and 
nifedipine [Rubanyi & Polokoff, 1994; Godfraind et al., 1989; Egashima et al., 1990; 
Encabo et al., 1992]. The transient decrease in blood pressure has been attributed to 
endothelial E T b  receptor activation and is a result of NO or PGI2 release [Fozard & 
Part, 1992; Ishikawa et al.., 1994; Hirata et al., 1993].
Endothelin Receptors in Cerebral Vessels
The potent vasoconstrictor actions of exogenous endothelin-1 have been 
demonstrated in isolated cerebral arteries and arterioles in a variety of species 
[Hardebo et al., 1989; Saito et al., 1989 & 1991] (see Table 13 in section 4.1 ). The 
vasoconstrictor actions of endothelin-1 have also been demonstrated on cerebral 
resistance arterioles and intracerebral arterioles in vivo [Salom et al., 1995; Willette & 
Sauermelch, 1990; Faraci, 1989; Robinson & McCulloch, 1990]. The systemic 
administration of exogenous endothelin demonstrated alterations in cerebral blood 
flow. However, the alterations in cerebral blood flow were related to the increases in
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m ean arterial blood pressure and not the result o f direct effect on the 
cerebrovasculature. Systemic exogenous endothelin does not gain access to the 
abluminal surface of the cerebrovasculature. The in vitro investigations of Saito and 
colleagues (1991) demonstrated that endothelin exerts its contractile effects following 
its abluminal application. The release of endogenous endothelins is polarised towards 
the cerebrovascular smooth muscle [Yoshimoto et al., 1990; Wagner et al., 1992; 
Mima et al., 1989] and this is thought to be the location of the constrictor endothelin 
ETa  receptors [Takayanagi et al., 1990; Davenport et al., 1990]. Transient vasodilator 
effects have been demonstrated in isolated cerebral arteries and the effects have been 
attributed to endothelin ETb receptor activation [Salom et al., 1995].
The role of the endothelins in the regulation of cerebrovascular tone and CBF 
remains controversial. Investigations in endothelial and vascular smooth muscle cell 
cultures have indicated that there may be a basal release of endothelin-1 which may be 
involved in the regulation of vascular tone [Yoshimoto et al., 1990; Kobayashi et al., 
1991; McCarron et al., 1993; Durieu-Trautmann et al., 1993]. However, other 
investigations in vivo have indicated that there is minimal basal endothelin mediated 
tone (demonstrated by the non-effect of endothelin receptor antagonists) and 
endothelin may not be involved in the regulation of arterial or arteriolar calibre or 
CBF. (See Section 4.1 for current concepts in endothelin receptor classification in the 
cerebrovasculature)
Endothelin Receptors in the Central Nervous System
Endothelin receptor binding sites have been described in glial cells (astrocytes) 
and neurones (e.g. dorsal root ganglia) [Niwa et al., 1992; Jones et al., 1989; Giaid et 
al., 1989; MacCumber et al., 1990; Greenberg et al., 1992; Koseki et al., 1989]. 
Binding studies with radiolabelled endothelin-1 have indicated the presence of binding 
sites in the cerebellum, cerebral cortex, dentate gyrus in the hippocampus and in 
nuclei in the brainstem [Jones et al., 1989; Kurihara et al., 1990; Nambi et al., 1990]. 
The indications are that the predominant receptor subtype is the endothelin ETb 
receptor [MacCumber et al., 1990; Nambi et al., 1990; Vigne et al., 1991]. The
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presence of ET mRNA has been described in glial cells (astrocytes) and neurones 
(e.g. dorsal root ganglia) [Niwa et al., 1992; Jones et al., 1989; Giaid et al., 1989; 
MacCumber et al., 1990]. Early investigations provided evidence for ET mRNA in 
cells of the hypothalamus, striatum and also the spinal cord [Giaid et al., 1989; Lee et 
al., 1990]. Secretion of endothelin-1 by astrocytes has been reported and can be 
stimulated by thrombin and platelet derived growth factor (PDGF) [MacCumber et 
al., 1990; Lysko et al., 1991; Marsault et al., 1990; Levin et al., 1992], The role of 
endothelins in the CNS is unclear, but, stimulation of immediate early gene expression 
(c-fos) and nerve growth factor in astrocytes indicates that these peptides may play a 
role in the regeneration of nerve cells following a cerebrovascular injury [Ladenheim 
et al., 1993].
A number of investigators have performed functional studies to examine the 
effects of exogenous endothelins in the brain. Injections of endothelin-1 into the 
cistema magna or microinjections into discrete brainstem nuclei in the rat have elicited 
marked alterations in cardiovascular parameters with systemic hypertension and 
bradycardia being the most prominent [Siren et al., 1989; Ferguson & Smith, 1990; 
Macrae et al., 1991]. The measurement of CBF in the rat brainstem following an 
intracistemal injection of endothelin-1 demonstrated a marked reduction in CBF to 
pathological levels [Macrae et al., 1991]. Other investigations have indicated that the 
endothelins may play a role as neuromodulators in the locomotor system or in the 
release of pituitary hormones [Gross et al., 1993 & 1994]- The intracerebroventricular 
injection of endothelin-1 elicited behavioural effects such as barrel rolling and oculo- 
clonic seizures [Gross et al., 1993 & 1994] and are associated with alterations in CBF 
and cerebral glucose utilisation in peri-ventricular regions and areas distal to the site 
o f injection [Gross et al., 1993 & 1994]- These observations suggest a role for the 
endothelins as neuromodulators or neuropeptides [Gross et al., 1994; Berrino et al.,
1994]. The alterations in CBF and glucose utilisation were attenuated by the calcium 
channel and endothelin antagonists. However, the effects of endothelin receptor 
antagonists per se on neuronal function has not been examined.
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Endothelin Receptor Antagonists
The development of endothelin receptor antagonists was important for 
understanding the role of endothelins in vascular pathophysiology. The first 
antagonists described were natural by-products of the fermentation of Streptomyces 
misakiensis (BE-18257B) [Ihara et al., 1991]. This compound demonstrated low 
potency at endothelin receptors in binding and functional bioassays (IC50 E T a 1.4|iM; 
E T q > 1 0 0 |iM) [Ihara et al., 1991]. Structure activity relationship studies have led to 
modifications of the peptide structures of the endothelins and to the development of a 
series of peptide endothelin E T a , endothelin E T q and combined endothelin E T a /E T b  
endothelin receptor antagonists [Ishikawa et al., 1994; Ihara et al., 1992a; Cody et al., 
1993; Itoh et al., 1993] [Table 2]. BQ-123 is the most potent of this series and is 
selective for the endothelin ETa receptor [Ihara et al., 1992a].
The distinguishing feature of the cerebral circulation is the blood-brain barrier. 
The blood-brain barrier is formed of tight junctions between endothelial cells and 
prevents paracellular transport of large and charged molecules [Edvinsson et al.,
1993]. The absence of pinocytotic vesicles prevents transcellular transport of 
molecules across the blood-brain barrier [Ermisch et al., 1993]- The presence of the 
blood-brain barrier means that therapeutic agents, such as the endothelin receptor 
antagonists, that are targeted at the brain must penetrate this barrier to gain access to 
the cerebrovascular smooth muscle and neurones. There are a num ber of 
disadvantages in the use of peptide endothelin receptor antagonists as therapeutic 
agents for cerebrovascular diseases. The peptide antagonists would undergo rapid 
hydrolysis by peptidases present in the systemic circulation or in the gastro-intestinal 
tract if administered intravenously or orally. More importantly, the peptide endothelin 
antagonists do not penetrate the blood-brain barrier when administered systemically 
[Clozel et al., 1993]. The importance of blood-brain barrier permeability for 
endothelin antagonist was demonstrated by the failure of intravenous administration of 
peptide endothelin receptor antagonist (BQ-123) to attenuate cerebral vasospasm or 
vasoconstrictor action of exogenous endothelin-1 applied to cerebral arterioles 
[Clozel & Watanabe, 1993].
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T able 2
Endothelin receptor agonists and antagonists used in cerebrovascular research. Data are 
expressed as the concentration of drug that inhibited binding of [125I]-endothelin-1 to 
endothelin-A (ETa) and endothelin-B (ETb) receptors by 50% (IC50).Abbreviations 
indicate the tissue used in the assays.
Compound Action
Peptide molecules
ETa selective
BQ123 Antagonist
BQ485 Antagonist
FR139317 Antagonist
ETb selective
BQ3020 Agonist
ETa (nM) ETb (nM) Reference
IRL1620
BQ788
IRL1038
Agonist
Antagonist
Antagonist
Combined ETa/ETb 
PD 142893 Antagonist
PD 145065 Antagonist
TAK044 Antagonist
Non-peptide molecules 
ETa selective 
PD 155080 Antagonist
PD 156707 Antagonist
BM S182874 Antagonist
Combined ETa/ETb 
Bosentan Antagonist
Ro46-2005 Antagonist
L754142 Antagonist
L751281 Antagonist
SB209670 Antagonist
22 (PVSM)
3.4 (PVSM)
1 (HR)
940 (PVSM) 
0.016 (PLM) 
280 (PCA)
9 (RLM)
40 (CRRA)
3.5 (CRRA) 
3.8 (RVM)
7.8 (HR)
0.31 (HR)
48  (HR)
4.7 (HR)
220 (HVSM) 
0.06 (PVSM) 
0.64 (PVSM) 
0.22 (HR)
SB217242 Antagonist 1.1 (HR)
1800 (PCM) Ihara et al., 1992 
2 6 0 0 0  (PCM) Itoh et al., 1993 
7300 (HR) Sogabe et al., 1993
0.2 (PCM) 
0.2 (PLM) 
0.9 (PCM) 
700 (RAM)
40 (RCM)
15 (RCM) 
130 (RBCM)
Ihara et al., 1992 
Tanaki et al., 1992 
Ishikawa et al., 1994 
Urade et al., 1992
Cody et al., 1993 
Cody et al., 1993 
Watanabe et al., 1995
3500 (HR) 
420 (HR) 
> 50000  (HR)
95 (HR)
1000 (RAEC) 
2.2 (PCM) 
13.1 (PCM) 
11 (HR)
Doherty et al., 1995 
Doherty et al., 1995 
Webb et al., 1995
Clozel et al., 1994 
Clozel et al., 1993 
Williams et al., 1995 
Walsh et al., 1995 
Nambi et al., 1994
111 (HR) Lago et al., 1995
Abbreviations: CRRA = Cultured Rabbit Renal Artery Vascular Smooth Muscle Cells; HR = Human 
Receptors expressed in Chinese Hamster Ovary cells; HVSM = Human Vascular Smooth Muscle 
Cells;PCA = Porcine Coronary Artery Smooth Muscle Cells; PCM = Porcine Cerebellar Membrane; 
PLM = Porcine Lung Membranes; PVSM = Porcine Vascular Smooth Muscle; RAEC = Rat Aortic 
Endothelial Cells; RAM = Rat Aortic Membranes; RCM = Rabbit Cerebellar Membranes; RCM = Rat 
Cerebellar Membranes; RLM = Rat Lung Membranes; RVM = Rabbit Ventricular Membranes
Recently there has been the development of non-peptide endothelin receptor 
antagonists [Table 2]. The first non peptide endothelin receptor antagonist described 
was Ro46-2005 and its therapeutic potential was demonstrated in experimental 
subarachnoid haemorrhage [Clozel et al., 1993b]. A number of other potent non­
peptide endothelin receptor antagonists selective for the endothelin E T a and combined 
endothelin ETa/ETb receptors have been developed. We have examined the ability of 
non-peptide endothelin receptor antagonists to gain access to the cerebrovascular 
smooth muscle and attenuate the vasoconstriction induced by the adventitial 
application of endothelin-1 and demonstrated the potential o f these antagonists as 
therapeutic agents. However, the non-peptide structure o f an endothelin receptor 
antagonist does not necessarily confer blood-brain barrier perm eability (e.g. 
SB209670) [Ohlstein et al., 1994].
The attenuation of the effects o f endogenous endothelins in cerebrovascular 
disease may also be achieved by endothelin converting enzyme inhibitors. The cDNA 
encoding endothelin converting enzyme(s) (ECE) have recently been cloned and will 
facilitate the development of enzyme inhibitors selective for ECE [Deschepper et al., 
1995; Schmidt et al., 1995]. In contrast to the rapid development o f endothelin 
receptor antagonists, only a few ECE inhibitors have been developed e.g. 
Phosphoramidon, CGS26303, CGS26393 [Fukami et al., 1994; De Lombaert et al.,
1995]. The utility of the ECE inhibitors has been examined in preliminary studies in 
focal cerebral ischaemia [Duverger et al., 1993]. (See Section 4.1.2 for description of 
effects of endothelin receptor antagonists in the cerebrovasculature)
Pathophysiological Role o f  Endothelins
The potent constrictor actions of endothelins have implicated them in a variety 
o f vascular and non vascular pathologies [Rubanyi & Polokoff, 1994]. There is 
evidence for a role of the endothelins in cardiac ischaemia, renal ischaemia and 
hypertension [Rubanyi & Polokoff, 1994] (see Table 3).
The effects of the endothelins were initially examined in isolated blood vessels 
and their effects on mean arterial blood pressure. The intravenous infusion of ET-1
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T ab le  3
Putative Role of Endothelins in Pathophysiology
• Hypertension
• Pulmonary Hypertension
• Renal Hypertension
• Cardiac Ischaemia
• Congestive Heart Failure
• Renal Ischaemia
• Bronchoconstriction
• Subarachnoid Haemorrhage
• Stroke
elicited a biphasic response on mean arterial blood pressure, an initial transient 
vasodilatation followed by a prolonged and sustained vasoconstriction [Yanagisawa et 
al., 1988; De Nucci et al., 1988]. Subsequent investigations using endothelin receptor 
subtype selective antagonists have identified the vasodilator response being mediated 
by endothelin E T b  receptors localised on the vascular endothelium and the release of 
nitric oxide [Fozard & Part, 1992; Bazil et al., 1992]. The dilator responses were 
inhibited by the endothelin E T b  receptor selective antagonists and the nitric oxide 
synthetase inhibitors [Fozard & Part, 1992; Bazil et al., 1992; Ishikawa et al., 1994]. 
The endothelin ETa receptors have been localised to the vascular smooth muscle. The 
rank order of potency of the endothelin receptor agonists for mediating the pressor 
responses were ScTx 6b> E T -l» S cT x  6 c> ET-3. This indicated an endothelin E T a  
receptor mediated response. The vasoconstrictor actions were attenuated by the 
endothelin E T a  receptor antagonists e.g. BQ-123 [Bazil et al., 1992; Ihara et al., 1992; 
McMurdo et al., 1992]. The contractile agents 5-HT and noradrenaline potentiated the 
vasoconstrictor actions of ET-1 and ET-1 potentiated the actions o f 5-HT and 
noradrenaline [Tabuchi et al., 1989; Yang et al., 1990].
In cardiac tissue, ET-1 production was observed in cultured endocardial cells 
[Siney & Lewis, 1994]. Additionally, the mRNA for pre pro endothelin-1 was 
identified in rat cardiac myocytes [Rubanyi & Polokoff, 1994]. Receptor binding sites 
specific for endothelins were identified in cardiac myocytes, cardiac membranes and 
in the atrio-ventricular node [Hirata et al, 1989; Gu et al., 1990; Yamasaki et al.,
1989]. Messenger RNA for the endothelin E T a /E T b  receptor subtypes were localised 
in the atrial and ventricular myocardium [Molenaar et al., 1993]. In isolated perfused 
hearts, ET-1 induced a positive chronotropic and inotropic effect and increased the 
duration o f the cardiac action potential [Firth et al., 1990; Watanabe et al., 1989]. 
Exogenous ET-1 induced coronary vasoconstriction and a reduction in cardiac 
function. The positive inotropic effect elicited by ET-1 was observed in isolated 
perfused hearts, atria and ventricular cells from a variety of species [Rubanyi & 
Polokoff, 1994]. In isolated rat hearts ET-1 induced a dose dependent increase in the 
heart rate [Ishikawa et al., 1988]. The positive chronotropic effect was delayed in
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onset and had a prolonged duration of action [Ishikawa et al., 1988]. The intravenous 
injection of ET-1 induced bradycardia, although, the bradycardic responses were 
thought to be secondary to the reduction in coronary blood flow [Lerman et al., 1992].
Exogenous endothelin-1 is potent constrictor of the coronary circulation. The 
constriction of the coronary vessels results in a reduction in coronary blood flow and 
may even result in the occlusion of the coronary arteries [Kurihara et al., 1989; Clozel 
& Clozel, 1989; Horn et al., 1992]. Exogenous endothelin-1 induces myocardial 
ischaemia and ventricular fibrillation in the canine heart [Hori et al., 1991; Muramatsu 
et al., 1991]. A reduction in cardiac output has been observed by some authors but the 
effect may be related to the coronary vasoconstriction. The actions of ET-1 in cardiac 
myocytes have been related to increases in [Ca2+]i, a result of increased hydrolysis of 
phosphotidyl inositol [Kelly et al., 1990].
Cardiac ischaemia has been another area where there has been speculation 
about the role of the endothelins [Watanabe et al., 1990]. The available evidence has 
indicated that there is an increased synthesis and release of ET-1 and elevated plasma 
ET-1 levels associated with cardiac ischaemia/hypoxia [Brunner et al., 1992; Rubanyi 
& Polokoff, 1994]. The increased binding of ET-1 to ischaemic tissue and increased 
reactivity of coronary blood vessels to ET-1 during ischaemia and reperfusion has 
further fuelled speculation [Rubanyi & Polokoff, 1994]. Antibodies raised against 
endothelin, endothelin receptor antagonists and the ECE inhibitor phosphoramidon 
have been demonstrated to reduce myocardial ischaemic damage [Grover et al., 1992; 
Watanabe et al., 1990].
There is an increase in the endothelin-1 induced coronary vasoconstriction 
following coronary artery occlusion and reperfusion [Neubauer et al., 1991]. 
Exogenous ET-1 is a pro-arrhythmic agent in the canine myocardium in vivo and in 
vitro [Muramatsu et al., 1991; Horn et al., 1992; Salvati et al., 1991]. Increased 
binding of ET-1 to cardiac membranes and increased synthesis/ release of ET-1 has 
been demonstrated following ischaemia and reperfusion in the rat and canine heart 
[Liu et al., 1990; Nayler et al., 1992; Neubauer et al., 1991]. The intracoronary 
infusion of ET-1 induced myocardial ischaemia while the topical administration of
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ET-1 on the myocardium in the canine caused a localised ischaemia [Grover et al., 
1992; Hori et al., 1991]. The intracoronary infusions o f ET-1 are associated with 
reductions in coronary blood flow, disturbances in the A-V node and ventricular 
fibrillation [Muramatsu et al., 1991].
Cardiac ischaemia and reperfusion can increase ET-1 production and increase 
the size of infarct [Velasco et al., 1993]. The responses may the result o f an increased 
ET-1 production as much as the loss of dilator tone (endothelium damage and loss of 
nitric oxide release) [Neubauer et al., 1991; Saito et al., 1992]. The alterations in 
endothelin binding to the ischaemic myocardium have generated mixed results. Some 
authors have reported elevations in the binding of ET-1 to cardiac membranes while 
others have reported the absence of such changes [Liu et al., 1990; Neubauer et al., 
1991; Nayler et al., 1992]. In some studies in cardiac ischaemia and reperfusion, a 
reduction of ET-1 production during the ischaemic period was reported while an 
increase was reported during the reperfusion phase [Brunner et al., 1992]. In patients 
with myocardial ischaemia a seven fold increase in plasma ET-1 levels and in some 
cases elevations in urine ET-1 levels have been reported [Watanabe et al., 1990 &
1991].
In experimental and clinical investigations elevations in plasma ET levels were 
reported in patients with congestive heart failure [Cody et al., 1993; Wei et al., 1994]. 
The reasons for the elevations in plasma ET levels were unclear but a reduction in the 
clearance of ET-1 from the lungs and increased production of ET-1 were two 
suggested causes [Cavero et al., 1990; Resink et al., 1990]. The endothelin receptor 
antagonist FR139317 reduces systemic MABP in a canine model of congestive heart 
failure and improves outcome [Clavell et al., 1995]. In patients bosentan has been 
demonstrated to exert similar effects. Arginine vasopressin and angiotensin II 
stimulate the release of ET-1 in vitro. In congestive heart failure the circulating levels 
o f AVP and angiotensin II are elevated and they may stimulate the release o f the 
endothelins [Kiowski et al., 1995].
ET-1 is also a potent constrictor of isolated blood vessels. The prolonged 
vasoconstriction in isolated blood vessels are antagonised by the endothelin ETa
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receptor antagonists indicating endothelin ETa receptor mediated events [Rubanyi & 
Polokoff, 1994], Recent investigations have demonstrated the existence of endothelin 
ETb receptor mediated vasoconstriction in the pulmonary, renal and coronary 
circulations in some species [Cardell et al., 1992; Warner et a l, 1992; Shetty et al.,
1993]. The investigations also alluded to the greater sensitivity of veins than arteries to 
the constrictor effect of ET-1 [Rubanyi & Polokoff, 1994]. In the lungs, the pulmonary 
arteries are more sensitive that the pulmonary veins to the constrictor actions of ET-1 
[Cardell et al., 1990]. The reasons for these observations are unclear but in vitro 
investigations have demonstrated an increased sensitivity of pulmonary arteries to ET- 
1 following hypoxia. Isolated microvessels and resistance arterioles from a variety of 
vascular beds, including the skin, kidney, heart, gastric mucosa and lung, 
demonstrated vasoconstriction following exposure to ET-1 [Gandhi et al., 1994; 
Rubanyi & Polokoff, 1994]. The constrictor action of ET-1 could be reversed by the 
prostanoid PGI2 and L- type calcium channel antagonists (verapamil, nifedipine, 
nitrendipine) [Rubanyi & Polokoff, 1994], In hypertensive strains of rats and models 
o f hypertension, ET-1 was a more potent constrictor of microvessels than in the 
normotensive animals. The elevation in MABP was mediated by the endothelin ET a 
receptors.
ET-1/ET-3 stimulated the release of EDRF from bovine endothelial cell 
cultures and in blood vessels [Emori et al., 1991a, Warner et al., 1992; Namiki et al.,
1992]. Endothelium dependent relaxations elicited by ET-1 could not be attenuated by 
the endothelin ETa receptor antagonists [Rubanyi & Polokoff, 1994]. However, the 
combined endothelin ETa/ETb receptor antagonists and NOS inhibitors attenuated the 
vasodilator responses elicited by ET-1 [Gandhi et al., 1994; Rubanyi & Polokoff,
1994]. ET-l/ET-3 also stimulated the release of PGI2 from human and bovine vascular 
endothelial cell cultures [Emori et al., 1991b; D'Orleans-Juste et al., 1992]. PGI2 
mediated vasodilatation elicited by ET-l/ET-3 has been demonstrated in vivo and in 
vitro.
The importance of peripheral vasoconstriction in the developm ent of 
hypertension and the potent vasoconstrictor actions of ET-1 has formed the rational
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basis of these conclusions. The increased release of ET-1 has been identified in animal 
models of hypertension but increases in circulating plasma levels have not been 
identified [Battistini et al., 1993]. In patients with essential hypertension, some authors 
have reported elevations in plasma ET-1 levels while others have suggested that no 
such increases are measurable [Davenport et al., 1991; Saito et al., 1991]. Most 
investigations measuring plasma ET-1 levels have used radioimmunoassay and the 
cross-reactivity of the antibodies with the other endothelin isopeptides and may 
account for the discrepancies. More importantly, there is increasing evidence that the 
release of endothelins is polarised towards the basement membrane and vascular 
smooth muscle [Wagner et al., 1992]. Thus, the concentrations of ET-1 detected in the 
circulation would not reflect the local concentrations which may be higher by a few 
orders of magnitude.
In other forms of hypertension such as malignant hypertension, pre-eclampsia, 
arteriosclerosis and renal hypertension, elevated plasma ET-1 levels have been 
detected [Battistini et al., 1993; Rubanyi & Polokoff, 1994], The observations that 
blood vessels from hypertensive animals display a reduced responsiveness to ET-1 can 
be explained by receptor tachyphylaxis or downregulation of receptor numbers [Dohi 
& Luscher, 1991; Hollenberg et al., 1993]. There is evidence that endothelium 
dependent vasodilatation may be impaired under conditions of hypertension and this 
may enhance the vasoconstrictor effect of ET-1 [Dohi & Luscher, 1991; Luscher et al., 
1991; Tamirisa et al., 1995]. The most controversial aspect of the role of endothelins 
in hypertension is the effects of endothelin receptor antagonists and biosynthesis 
inhibitors [Bazil et al., 1992; Clozel et al., 1993; Nishikibe et al., 1993; Tamirisa et al.,
1995]. The inhibitor of ECE, phosphoramidon reduces the MABP in the 
spontaneously hypertensive rat (SHR) [McMahon et al., 1991]. In a similar model the 
endothelin E T a  antagonist BQ-123 reduces the MABP in the stroke prone SHR while 
no alterations are observed in the SHR [Nishikibe et al., 1993], The combined 
endothelin E T a /E T b  receptor antagonists have been demonstrated to reduce the 
MABP in some SHR and DOCA-salt SHR [Clozel et al., 1993].
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Elevations in plasma ET-1 levels in patients suffering from pulmonary 
hypertension have been detected [Stewart et al., 1991]. The lung is the main organ 
involved in the clearance of ET-1 from the systemic circulation (approximately 80% 
of circulating ET-1 cleared from the lung) and there are suggestions that the aetiology 
of pulmonary hypertension may include the impaired clearance of ET-1 and resulting 
in pulmonary vasoconstriction. Increased expression of ET-1 mRNA in experimental 
models and in patients with pulmonary hypertension have been measured [Shirakami 
et al., 1991; Elton et al., 1992; Chang et al., 1993]. The hypoxia induced stimulation of 
ET-1 release in the lung and increased sensitivity of pulmonary arteries and arterioles 
to the contractile actions of ET-1 have implicated the endothelins in the development 
of pulmonary hypertension [Shirakami et al., 1991].
A role for the endothelins in the control of renal blood flow, glomerular 
filtration rate and Na+/water transport has been suggested [Cao & Banks, 1990; Chou 
et al., 1990; Perico et al., 1991]. Expression of pre pro ET-1 mRNA has been 
demonstrated in bovine glomerular endothelial cells and mRNA expression could be 
enhanced by bradykinin, thrombin, ATP and platelet aggregating factor (PAF) [Lopez- 
Farre et al., 1991]. Glomerular epithelial cell cultures release endothelin-1 and ET-1 
binding sites have been identified in the glomeruli and medulla [Kohzuki et al., 1989; 
Kloog & Sokolovsky, 1989]. The systemic infusion of ET-1 in the renal cortex and 
medulla are mediated by ETb receptors [Pollock & Opgenorth, 1993]. Alongside the 
reductions in renal blood flow, intravenous administration of ET-1 also reduces the 
glomerular filtration rate and sodium excretion [Cao & Banks, 1990; Perico et al.,
1991]. ET-1 stimulates mitogenesis in mesangial cells and stimulates the production of 
PDGF and the immediate early genes (Fos, Jun) [Jaffer et al., 1990; Simonson et al.,
1992]. Increases in ET-1 binding and receptor numbers have been reported following 
renal ischaemia and reperfusion [Clozel et al., 1991; Nambi et al., 1993]. Interventions 
with ET antibody or receptor antagonist such as BQ-123, SB209670 and bosentan 
prevent renal failure and damage to renal tubules following renal ischaemia [Mino et 
al., 1992; Clozel et al., 1993; Douglas et al., 1995].
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Tracheal epithelial cell cultures also secrete ET-1. The production of ET-1 in 
these cultures can be regulated by TGF-13, cytokines, interleukins and thrombin [Endo 
et al., 1992]. ET-1 is a potent constrictor of tracheal and bronchial smooth muscle in 
vivo and in vitro [Rubanyi & Polokoff, 1994] and a role for the endothelins in the 
mediation of respiratory disorders has been suggested [Gandhi et al., 1994; Rubanyi & 
P o lokoff, 1994]. The contractions of the tracheal and bronchial smooth muscle are 
potentiated following the removal of the endothelium [Cardell et al., 1993; Hay et al.,
1993]. These observations indicated that relaxant mediators such as PGI2 may be 
released and attenuate the contractile effects of endothelin [Satoh et al., 1992].
In the gastro-intestinal tract, pre pro ET-1 mRNA has been identified in 
myenteric neuronal cells [Ota et al., 1991]. Gastric epithelial cells produce ET-1. ET-1 
is a potent constrictor of stomach smooth muscle in vivo and in vitro [Ota et al., 1991]. 
The contractions are thought to be mediated by the endothelin E T a  receptors, 
however, in the guinea pig ileum ET-1 elicits a biphasic response [Lin & Lee, 1992]. 
The efficacy of endothelin ETb receptor antagonists has suggested that the dilatation 
may be mediated by endothelin E T b  receptors [Lin & Lee, 1992; Hiley et al., 1992]. 
In longitudinal sections of the ileum, endothelin E T b  receptor antagonists attenuate 
the ET-1 mediated contractions [Urade et al., 1992; Yoshinaga et al., 1992].
There has been speculation on the role of the endothelins in the development 
of cerebrovascular disease. Experimental and clinical data from a number of 
investigators have demonstrated increases in plasma and cerebrospinal fluid (CSF) 
endothelin immunoreactivity following subarachnoid haemorrhage and ischaemic 
stroke [Ziv et al., 1992; Gang-zhi et al., 1993; Barone et al., 1994]. Elevations in 
endothelin immunoreactivity in brain tissue and CSF has been demonstrated in 
experimental models focal and global cerebral ischaemia [Barone et al., 1994; 
Giuffrida et al., 1992; Yamashita et al., 1994; Willette et al., 1992]. There is some 
controversy regarding the temporal profile for these increases in cerebral ischaemia 
since some investigators have demonstrated increases in the acute phase following 
ischaemia (2-3 hr) while others have reported increases at chronic time points (>24 
hours) [Barone et al., 1994; Duverger et al., 1992]. The significance of the alteration
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in endothelin levels at acute and chronic time points is at present unclear but has 
important implications for the administration of endothelin receptor antagonists 
following a cerebral ischaemic episode.
Exogenously applied endothelin-1 does not demonstrate neurotoxic potential 
when applied to cortical neuronal cell cultures and has no effect on the markers of 
neuronal cell viability [Lustig et al., 1992; Nikolov et al., 1993]. The administration of 
exogenous endothelin-1 into the cerebroventricular system exacerbated the neuronal 
damage associated with focal cerebral ischaemia in the mouse [Nikolov et al., 1993]. 
The intracistemal administration of exogenous endothelin-1 in rats, results in 
brainstem ischaemia [Macrae et al., 1991]. The topical administration of endothelin-1 
onto a major cerebral artery, e.g. the middle cerebral artery, induces marked 
reductions in CBF in the cortex and striatum and ischaemic neuronal damage m these 
areas [Fuxe et al.., 1992; Robinson et al., 1990; Macrae et al., 1993; Sharkey et al.,
1993].
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Aims of Thesis
Since the primary publication describing the structure and functions of the 
endothelins, there have been rapid developments describing the role of the endothelins 
in physiology and pathophysiology and the therapeutic potential of the endothelin 
receptor antagonists. The primary aim of this thesis was to examine the physiologic 
and pathophysiologic role of the endothelins in the cerebral circulation by using 
endothelin receptor antagonists (notably bosentan) whose cerebrovascular 
pharmacology has been described in this thesis.
In the peripheral vasculature the constrictor and dilator effects of the 
endothelins are mediated variously by endothelin ETa and endothelin ETb receptors. 
In contrast, there is a paucity of information regarding the endothelin receptors and 
their anatomical location in cerebral arteries and arterioles. In the present thesis the 
endothelin receptor subtypes in cerebral arteries and arterioles were examined. These 
investigations utilised functional in vitro and in vivo techniques in cerebral blood 
vessels. The functional in vitro investigations utilised the rabbit basilar artery. The 
identification of receptor subtypes was performed using ET-1, ET-3, the endothelin 
E T a selective receptor antagonist BQ-123, the combined endothelin ETa/ETb 
receptor antagonist Bosentan and the endothelin ETb receptor agonist BQ-3020. The 
in situ characterisation of endothelin receptor subtypes was performed in feline 
cerebral resistance arterioles. BQ-123 was used as an antagonist for endothelin ETa 
receptors while BQ-3020 was used as an endothelin ETb receptor agonist.
The cerebrovasculature (particularly the vessels which contribute to 
cerebrovascular resistance) is minimally affected by intravascular agents which poorly 
penetrate the blood-brain barrier. It has been argued that endothelin-1 and endothelin 
receptor antagonists must gain access to the adventitial surface of cerebral blood 
vessels (e.g. intraventricular or topical administration) to produce direct vasomotor 
effects in vivo in the cerebral circulation. The investigation were designed to evaluate 
the efficacy of the non-peptide combined endothelin ETa /ETb receptor antagonist 
Bosentan and its ability to penetrate the blood-brain barrier. The investigations were 
carried out in cerebral resistance arterioles using the cranial window preparation in the
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cat. The efficacy of Bosentan was assessed by the perivascular co-application of 
Bosentan with exogenous ET-1. The blood-brain barrier permeability was assessed by 
the ability of the intravenous administration o f Bosentan to attenuate the 
vasoconstriction induced by the perivascular application of exogenous ET-1. The 
cerebrovascular effects of Bosentan were contrasted with the effects of a non-peptide 
endothelin ETa receptor antagonist PD 155080 and the peptide endothelin ETa/ETb 
receptor antagonist PD 145065.
Recent evidence has indicated a pathophysiologic role for the endothelium in 
cerebrovascular diseases. The availability of non-peptide endothelin receptor 
antagonists that penetrate the blood-brain barrier has facilitated investigations into the 
cerebrovascular role of the endothelins. The investigations in this thesis examined the 
potential role of endothelins in regulating cerebral blood flow following cerebral 
ischaemic injury.
Transient global cerebral ischaemia in the rat often results in a period of post- 
ischaemic hypoperfusion. The aetiology of post-ischaemic hypoperfusion is unclear 
but vasoconstriction of the cerebral arterioles has been suggested. The ability of 
Bosentan to alter post-ischaemic cerebral hypoperfusion following transient global 
cerebral ischaemia was examined using two severities of ischaemia and two 
techniques to measure CBF ((14C)-iodoantipyrine autoradiography and hydrogen 
clearance). Severe global cerebral ischaemia was induced by the bilateral occlusion of 
the common carotid arteries and the induction of haemorrhagic hypotension for 15 
min. Moderate global cerebral ischaemia was induced by the bilateral occlusion of the 
common carotid arteries for 15 min.
Brain injury involving haemorrhage, e.g. subarachnoid haemorrhage and 
subdural haematoma, is often associated with marked reductions in cerebral blood 
flow and ischaemic neuronal damage. The mediators of the reductions in cerebral 
blood flow and neuronal damage are unclear but the release of vasoactive substances 
from the blood has been speculated. The ability of Bosentan to alter CBF following 
subdural haematoma was also examined. CBF was m easured using (14C)- 
iodoantipyrine autoradiography and at 2.5 hours following the induction of the
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subdural haematoma. Despite the existence of multiple homeostatic mechanism to 
protect blood flow to brain, constrictor mechanisms which limit tissue mechanisms 
which limit tissue perfusion to the ischaemic and peri-ischaemic regions are well 
recognised in cerebral ischaemia. A variety of mechanisms including vasoconstriction, 
have been proposed to account for the submaximal dilatation in the ischaemic 
penumbra following focal cerebral ischaemia. The role of the endothelins in the 
regulation of post-ischaemic vascular diameter was examined following permanent 
occlusion of the MCA in the cat. The ability of Bosentan to alter the calibre of post­
occlusion cerebral resistance arterioles was contrasted with the effects of the 
endothelin ETa  receptor antagonist PD 155080 in the same preparation.
70
CHAPTER 2 
MATERIALS AND METHODS
2.1 Rabbit Basilar Artery in vitro 
Surgical Preparation
Adult male New Zealand white rabbits (weight 2.5-4 kg) were killed by an 
overdose of sodium pentobarbitone (Euthatal, 200 mg/ml) administered into the 
marginal ear vein. The brain was dissected out and placed in oxygenated ice cold 
Krebs' buffer ( mM concentrations: NaCl 118; KC1 4.7; KH2PO4  1.2; NaHCC>3 25; 
MgSC>4 1.2; CaCl2 2.5; Glucose 11). Potassium (50 mM) substituted Krebs' was 
made by the direct substitution of NaCl with KC1 The basilar artery was carefully 
freed of the surrounding arachnoid membrane using a dissecting microscope and 2-4 
mm segments were mounted on to stainless steel hooks (diameter ~ 2 0 0 pm) 
positioned through the lumen of the artery.
Experimental protocol
The vessel segments were placed in 10 ml siliconised organ baths. One hook 
was secured to the bottom of the bath and the other was secured to an isometric 
tension transducer and a resting tension of 500 mg applied. The preparations were 
suspended in Krebs' buffer at 37°C continuously perfused with 95% O2  / 5% CO2 .
Vessel segments were allowed to equilibrate for a period of 60 min during which time 
the fluid in the bath was replaced every 10-15 min.
After the equilibration period, the bathing medium was replaced with 50 mM 
K+ substituted Krebs' buffer and the contraction due to potassium  induced 
depolarisation was measured. The vessels were allowed to attain a stable baseline and 
acetylcholine (10 pM) was added to check for the integrity of the endothelium. The 
buffer was replaced with normal Krebs' buffer and a recovery period of 15 min was 
allowed. Previous investigations have indicated that concentration of acetylcholine 
used in the present studies would have elicited marked relaxant responses on the rabbit 
basilar artery [Rand & Garland, 1992; Plane & Garland, 1993]. However, no 
histological evidence for the de-endothelialisation of the basilar artery segments was 
obtained.
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The vessel segments were incubated with vehicle (DMSO), BQ-123 (0.1 - 10 
pM) or Bosentan ( 1 - 1 0  (iM) for a period 30 min before cumulative concentration 
response curves to ET-1, ET-3 or BQ-3020 were constructed. Single cumulative 
concentration response curves were constructed on each segment. At the lower 
concentrations (0.1 nM - 1 nM) of ET-1, ET-3 and BQ-3020, an equilibration period 
of 2 - 3 min was permitted before the next concentration of agonist added [Trace A]. 
At the higher concentrations (>1 nM), the contractile responses were allowed to 
plateau before the next concentration of agonist was added [Trace A], The plateau of 
the response was typically reached in 30-60 seconds.
Statistical Analysis
The mean EC30 values were analysed using a one way analysis o f variance 
(ANOVA) and Student's t - test with Bonferroni correction factor for multiple group 
comparisons. The pA2 values were calculated from the method described by 
Arunlakshana and Schild (1959). Briefly, dose ratios (DR) were calculated from the 
concentration of agonist (ET-1 or ET-3) required to produce a response that was 30% 
of the maximum. The dose ratios were calculated in the presence and absence of the 
endothelin receptor antagonists. The pA2 was calculated using the equation:
-log (DR-1) + log (concentration o f antagonist)
The pA2 values at each concentration of antagonist used were averaged to give a mean 
PA2 .
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2.2 Measurement of calibre of feline pial arterioles in situ
Surgical Preparation
The experiments were performed on 22 adult cats of either sex weighing 
between 2-3 kg. Anaesthesia was induced using alphaxolone/alphadolone (Saffan, 
Glaxo) administered into the radial vein. The animal was then intubated and positive 
pressure ventilation with N2 O/O2 (70%/30%) initiated. The femoral arteries and veins
were cannulated for the monitoring of arterial blood pressure and arterial blood status 
gas and for the administration of fluid and drugs respectively. Anaesthesia was 
maintained using a-chloralose (60 mg/kg) and further supplements of 1-2  ml o f a -  
chloralose ( 1%) were administered to prevent the return of the comeal reflex.
Arterial blood samples were taken at regular intervals for monitoring of blood 
gases. The animals were maintained normocapnic by adjusting the stroke volume and 
metabolic acidosis was controlled by the administration of sodium bicarbonate (8.4%). 
Core temperature was measured with a rectal thermometer and the temperature 
m aintained at 37°C by means of a heating blanket controlled by the rectal 
thermometer.
The animal was placed in a stereotactic frame. After a midline incision, the 
scalp was retracted and sutured onto a metal ring to form a well over the calvarium. 
The temporalis muscle was retracted and a rectangular craniectomy (2.5 cm x 1.5 cm) 
was made over the parietal cortex using a saline cooled dental drill. The exposed 
dura was bathed with mineral oil at 38°C. There was a continuous flow of oil at the 
rate of approximately 1 ml/min. With the aid of a stereomicroscope (Bausch & Lomb) 
the dura was excised and then reflected laterally. Bipolar diathermy was used to 
control bleeding from the dural vessels. The inspired gas mixture was then altered to 
O2  supplemented air (approximately 25% O2 ). In a separate group of animals the
lingual artery was exposed and catheterised. The catheter was advanced into the 
carotid artery and subsequently used for the intravascular infusions of the ETb 
receptor agonist BQ-3020.
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Measurement of Arteriolar Calibre
Arteriolar calibre was measured by the method of Baez (1966) using an image 
splitter linked through a closed circuit video display system. The system was 
calibrated at x40 and x70 against threads of known diameter and this allowed for the 
direct measurement of vascular diameter in absolute units (|im). The individual pial 
vessels were viewed through a stereomicroscope and the arteriolar diameter was 
measured from the degree of shear applied to the image splitter in order to tangentially 
appose the two images. The shearing screw on the image splitter was connected to a 
chart recorder allowing a calculation of the calibre of pial arterioles. The image of the 
arteriole on the video monitor was split using the image shearing device and multiple 
measurements of the split image were taken [Trace B]. Following the measurements, 
substances were injected into the perivascular space, the split image realigned and 
m ultiple measurements of the realigned image were taken. The addition o f 
vasoconstrictor agents such as ET-1 resulted in an increase in the gap between the split 
image, while the addition of vasodilator agents such as BQ-3020 resulted in an 
overlap of the split image. The vessel diameter was typically measured pre-insertion, 
pre-injection and post-injection and the vessel diameter was monitored over a period 
o f 1-2 min. The diameter of the pial arterioles was measured at the peak o f the 
alteration in the arteriolar calibre (typically between 30-45 seconds following the 
perivascular microinjection) [Trace B]. The peak of the vasoconstrictor response 
elicited by endothelin-1 was followed by a sustained reduction in arteriolar calibre 
(plateau phase) [Trace B]. The plateau phase may be indicative of the contractile 
response attaining an equilibrium.
Administration of Drugs
Sharp glass micropipettes (tip diameter 10-12|im) were vacuum filled with 
either artificial cerebrospinal fluid (CSF), 10 mM K+ CSF or drugs dissolved in CSF. 
The composition of the CSF was Na+ 156 mM, K+ 3 mM, Ca^+ 2.5 mM, HCO3 - 12 
mM, Cl" 152 mM with the pH adjusted to 7.2 by aeration with 5% C0 2 /9 5 % O2 . 
Solutions containing K+ 10 mM were prepared by equimolar substitution of KC1 for
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NaCl. Alkalotic CSF (pH 7.45) were prepared by equimolar substitution of 
Na+HC0 3 " (22 mM) for NaCl. All solutions were prepared freshly for each study.
The filled pipettes were stored under mineral oil until required. The substances were 
applied by subarachnoid microapplication using a micromanipulator to position the 
pipettes in the perivascular space around the vessel. Small volumes (5|il) were 
delivered by a pressure ejection system. Individual sites on the arterioles were 
studied on only a single occasion. Perivascular microapplication of endothelin-1 (10 
nM) were employed as the challenge dose as this concentration is the EC5 0  value in
this preparation (Robinson and McCulloch, 1990).
The effects of Bosentan (0.3 - 300 }iM), PD155080 (0.3 - 30 |iM), PD145065 
(0.03 - 3 |iM), BQ-123 (0.1 - 10 ^iM), BQ3020 (0.001 - 1 \lM) and autologous blood 
were examined following their perivascular microapplication. Bosentan (17 |imol/kg), 
the choline salt o f PD155080 (19.2 p.mol/kg) and PD145065 (30 |imol/kg) were 
dissolved in isotonic saline and administered as slow intravenous injections (5-7 min). 
The choline salt of PD 155080 elicited transient alterations in mean arterial pressure 
during the intravenous injection and resulted in pauses in the drug delivery until they 
subsided. The investigations were repeated using choline chloride dissolved in 
isotonic saline administered intravenously as a vehicle control for the PD 155080 
investigations. Perivascular microapplications of endothelin-1 (10 nM) and alkalotic 
CSF (7.45) were made 15-75 min after vehicle, Bosentan, PD 155080 or PD 145065 
administration. The effect of intravenous Bosentan on the constrictions elicited by the 
microapplication of blood was examined. In the studies examining the effects of 
PD 145065, an intravenous bolus dose of endothelin-1 (1 nmol/kg) was administered 
120 min after the initial administration of PD 145065.
The ability of Bosentan and PD155080 to reverse an established ET-1 induced 
vasoconstriction was also examined. The calibre of the arteriole was recorded for 5 - 
15 minutes following the perivascular microapplication of ET-1 (10 nM). CSF, 
Bosentan (30 jiM) or PD155080 (30 |iM) were applied to the ET-1 constricted vessels 
between 5 and 15 minutes subsequent to application of ET-1. The vessel diameter was 
measured pre-insertion of micropipettes, pre- and post- injection of substances and the
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vessel diameter was monitored over a period of 1 - 2 minutes. BQ-3020 for 
intravascular infusions was dissolved in 0.9% saline and infused at a rate o f 0.15 
ml/min.
Statistical Analysis
The results were analysed using a one way analysis of variance followed by 
Student's /-test using a Bonferroni correction factor for multiple group comparisons. 
The ability of Bosentan or PD 155080 to reverse ET-1 induced vasoconstriction was 
assessed by unpaired Student's t- test. Data are expressed as mean ± S.E.M. of the 
percent change in pial arteriolar calibre from pre-injection baseline; n = the number of 
arterioles examined.
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2.3 Cerebral Blood Flow following Bilateral Common Carotid Artery
Occlusion with Concomitant Haemorrhagic Hypotension in the Rat
Surgical Preparation
The experiments were carried out in 29 adult male Sprague Dawley rats (305 - 
439 g). The animals were initially anaesthetised with 4% halothane, tracheotomised 
and mechanically ventilated with a gas mixture of 70% N2 O / 30% O2 containing 
halothane (0.75 - 1.5%). Both femoral arteries and veins were catheterised for the 
monitoring of arterial blood pressure, blood gas status and for the administration of 
drugs and fluids. The common carotid arteries were isolated from surrounding tissue 
by blunt dissection and loose loop ligatures (2 -0  silk suture) placed around the arteries.
Hydrogen electrode placement
The animals were positioned in a stereotactic frame (Kopf instruments) and, 
following a midline incision, the surface of the skull exposed . Two burr holes were 
drilled to expose the surface of the dura. The dura was incised and teflon coated 
platinum  electrodes ( 250 |im  outer diameter, 1 mm tip exposed, Clark 
Electromedical) positioned in the left caudate nucleus (co-ordinates Anterior 1 mm; 
Medial 3 mm; Dorso-Ventral 4 mm) and in the right parietal cortex (Posterior 2.4 
mm; Medial 4 mm; Dorso-Ventral 1 mm). The co-ordinates were taken (relative to 
bregma) from the atlas of the rat brain of Paxinos and Watson (1986). The burr holes 
were sealed with cyanoacrylate glue and the platinum electrodes cemented in place 
using dental cement. A silver reference electrode was placed subcutaneously on the 
back of the animals.
Experimental Protocol
Vehicle (0.9% saline) or Bosentan (17 |imol/kg) was administered as an 
intravenous bolus 10 min prior to the induction of ischaemia. The intravenous 
injections were carried out over a period of 3 minutes. The common carotid arteries 
were occluded and mean arterial blood pressure (MABP) reduced to between 40 - 50
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mmHg by concomitant arterial haemorrhage for 15 min (Smith et al., 1984). The 
haemorrhaged blood was stored in a water bath at 37°C. Cerebral blood flow was 
restored by the removal of the carotid ligatures and the re-infusion of the blood via the 
femoral vein.
CBF measured by Hydrogen Clearance
Following an equilibration period of approximately 30 min, the platinum 
electrodes were connected to a reference circuit and polarised to +700 mV. A further 
period of 30 min was allowed for stabilisation following polarisation. Prior to the 
measurement o f cerebral blood flow (CBF), the inspired gas mixture was altered to 
45% O2 , 35% H2 and 20% N 2O with 0.75% - 1.5% halothane. A saturation period of 
10 min was allowed followed by 10 min for clearance. The CBF data were collected 
over a period of 1 min., 1 min. after the H2 mixture had been switched off (to reduce 
artefacts due to recirculation of hydrogen). The data were fitted to an experimental 
curve and blood flow calculated using the initial slope index technique [Doyle et al., 
1975; Young, 1980]. Measurements of cerebral blood flow were carried out prior to 
occlusion, 7.5 min after the occlusion of the carotid arteries, 5 min following the 
release of the carotid ligatures and at 30 min intervals for 3 hours during the 
reperfusion phase.
CBF measured by [ l4C]- Iodoantipyrine Autoradiography
At 90 min following the release of the carotid ligatures, cerebral blood flow 
was measured using [14C]- Iodoantipyrine as the radiotracer. The method utilised was 
modified from the method of Sakurada et al., 1978. Briefly, 50 jiCi of radioisotope in 
1.5 ml saline was administered as a ramped intravenous infusion over a period of 30 
seconds. The infusion rate during the first 5 seconds was 50% of the final infusion 
rate. During the infusion 1 5 - 1 8  samples of arterial blood were collected on pre­
weighed filter discs. At the end of the infusion o f isotope, the animals were 
decapitated and the brain removed and frozen in isopentane at -42°C. The filter discs
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Operational Equation for the Calculation of Cerebral Blood 
Flow using [ 14C]- Iodoantipyrine
i
Ci (T) = AK.J Ca e ‘K  (T_t) dt
0
Ci (T) = tissue concentration of tracer at given time (T) after intravenous injection 
of tracer
X =  tissue blood partition coefficient
Ca = tracer concentration in arterial blood
t = variable time
K = constant defined as ~j^
where m =1 (diffusion of tracer across blood-brain barrier) 
F/W = rate of blood flow per unit mass of tissue
The rate of cerebral blood flow per unit mass (F/W) can be calculated from the final 
concentration of the C in cerebral tissue (Ci (T) obtained from autoradiograms), 
the concentration of [14C] - iodoantipyrine in arterial blood from time 0 to time T 
and the blood partition coefficient of [ 14C]- iodoantipyrine (0.79)
(Sakurada et al., 1978)
were re-weighed and a 30% solution of hydrogen peroxide added to bleach the blood 
from the discs. [14C] radioactivity was determined by liquid scintillation counting.
Twenty micron sections of the frozen brains were cut serially in a cryostat at 
-20° C and at 140 Jim intervals, sections were collected onto glass coverslips and 
rapidly dried at 60°C. The coverslips were mounted onto cards and apposed to Kodak 
SB-5 film for 4 - 6 days. Pre-calibrated [14C] standards (concentration range 44 - 2500 
nCi/g tissue equivalents) were placed in the film cassettes. The autoradiograms were 
analysed using a computer based image analysis system (M4 MCID, Imaging 
Research Inc.). Six bilateral readings were taken from sections where the structure 
could be identified from the rat brain atlas of Paxinos and Watson (1986).
The values of cerebral blood flow were determined from the equation of 
Sakurada et al., 1978, with the knowledge of arterial blood history of [14C], tissue 
levels of [14C] and the tissue blood partition coefficient (0.79).
Statistical Analysis
The data for the two treatment groups, Bosentan and vehicle, were analysed 
using a Student's unpaired two tailed /-test. The data are expressed as mean ± S.E.M. 
of the percent change of CBF from pre occlusion baseline for the hydrogen clearance 
investigations and expressed as mean ± S.E.M. for the [ l4C]-Iodoantipyrine CBF 
investigations (ml/lOOg/min).
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2.4 C erebral Blood Flow following Bilateral Common C arotid  Occlusion in 
the Rat
Surgical Preparation
The experiments were carried out in 30 adult male Sprague Dawley rats (303 - 
432 g). Surgical preparation was carried out as in 2.3.
Hydrogen electrode placement
Hydrogen electrode placement was carried out as in 2.3
Experimental Protocol
Vehicle (0.9% saline) or Bosentan (17 jimol/kg) was administered as an 
intravenous bolus 10 min prior to the induction of ischaemia. The intravenous 
injections were carried out over a period of 3 minutes. Unlike the protocol described 
in section 2.3, in these experiments the common carotid arteries were occluded for 15 
min w ithout the induction of systemic haemorrhagic hypotension. Cerebral blood 
flow was restored by the removal of the carotid ligatures. Plasma glucose samples 
were taken prior to occlusion and at 30 min into the reperfusion phase. At each flow 
determination a blood sample was taken to measure arterial blood gas status .
CBF measured by hydrogen clearance
CBF measured by hydrogen clearance was carried out as in 2.3
CBF measured by [l4C]- Iodoantipyrine Autoradiography
CBF measured by [14C]- Iodoantipyrine Autoradiography was carried out as in
2.3
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Statistical Analysis
The data for the two treatment groups, Bosentan and vehicle, were analysed 
using a Student's unpaired two tailed r-test. The data are expressed as mean ± S.E.M. 
of the percent change of CBF from pre occlusion baseline for the hydrogen clearance 
investigations and expressed as mean ± S.E.M.. for the [ l4C]-Iodoantipyrine CBF 
investigations (ml/lOOg/min).
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2.5 Cerebral Blood Flow following Subdural Haematoma in the Rat
Surgical Preparation
The experiments were carried out in 12 adult male Sprague Dawley rats (309 - 
423 g). The animals were initially anaesthetised with 4% halothane, tracheotomised 
and mechanically ventilated with a gas mixture of 70% N2 O / 30% O2 containing 
halothane (0.75 - 1.5%). Both femoral arteries and veins were catheterised for the 
monitoring of arterial blood pressure, blood gas status and for the administration of 
drugs and fluids.
The animals were positioned in a stereotactic frame (Kopf instruments) and, 
following a midline incision, the surface of the skull exposed. A burr hole (2 mm 
diameter) was drilled over the parietal cortex (co-ordinates Anterior 1 mm; Medial 3 
mm relative to bregma [Paxinos & Watson, 1986]) and the dura excised. A blunt 25G 
J-shaped needle was positioned under the dura, the burr hole sealed with 
cyanoacrylate glue and cemented in place using dental cement.
Experimental Protocol
Vehicle (distilled water) or Bosentan (17 p.mol/kg) was administered as an 
intravenous bolus 10 min prior to the induction of the haematoma. The intravenous 
injections were carried out over 3 minutes. Venous blood (400|il) was withdrawn from 
the femoral catheter and the haematoma induced by the infusion of the blood, via the 
subdural needle, over a period of 7 minutes.
CBF measured by [14C]- Iodoantipyrine Autoradiography
At 150 min following the induction of the haematoma, cerebral blood flow was 
measured using [14C]- Iodoantipyrine as the radiotracer. The method utilised was 
modified from the method of Sakurada et al. (1978) and as described in section 2.3.
Twenty micron sections of the frozen brains were cut serially in a cryostat at 
-20°C and at 140 |im  intervals, sections were collected onto glass coverslips and 
rapidly dried at 60°C. The coverslips were mounted onto cards and apposed to Kodak
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BMR-2 film for 3 days. Pre calibrated [14C] standards (concentration range 44 - 2500 
nCi/g tissue equivalents) were placed in the film cassettes. The autoradiograms were 
analysed by two approaches using a computer based image analysis system (M4 
MCID, Imaging Research Inc.). In the first approach 6 bilateral readings were taken 
from sections where the structure could be identified from the rat brain atlas of 
Paxinos and Watson (1986).
The second approach determined volume o f cerebral tissue in both 
hemispheres perfused with various levels of CBF using cumulative frequency 
distribution analysis. The image analyser was set for optical density thresholds 
corresponding to pre-determined increments of cerebral blood flow, i.e., 0 - 1 0 , 10 - 
20, 20 - 30, 30 -40, 40 - 50, 50 - 60, 60 - 70, 70 - 80, 80 - 90, 90 - 100, 100 - 150, 
>150 ml/lOOg/min. The distribution of cerebral blood flow in both hemispheres was 
assessed at the 8 coronal planes used for volumetric quantification of ischaemic 
damage, stereotactic co-ordinates (relative to bregma) anterior 10.5 mm, anterior 8.92 
mm, anterior 7.19 mm, anterior 6.06 mm, anterior 5.15 mm, anterior 3.75 mm, 
anterior 2.18 mm, anterior 1.02 [Osborne et al., 1987]. The area of each hemisphere 
(on 3 sections) was delineated on the image analyser and distribution of CBF and area 
recorded. The area of tissue corresponding to each of the levels o f blood flow was 
calculated and the volume of tissue at these levels of blood flow was determined by 
the integration of the areas at 8 coronal planes [Osbome et al., 1987].
Brain swelling in the ipsilateral hemisphere was calculated by subtracting the volume 
of the ipsilateral hemisphere from the volume of the contralateral hemisphere.
The values of cerebral blood flow were determined from the equation o f 
Sakurada et al. (1978) with the knowledge of arterial blood history of [14C], tissue 
levels of [14C] and the tissue blood partition coefficient (0.79).
Statistical Analysis
The data from frequency distribution of cerebral blood flow, the cerebral blood 
flow in the individual structures and the brain swelling were analysed using an 
unpaired Student's t-test. The differences in the cerebral blood flow between structures
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in the ipsilateral hemisphere and contralateral hemisphere were analysed using a 
paired Student's /-test.
8 6
2.6 Measurement of Pial Arteriolar Calibre following Permanent
MCA Occlusion in the Cat
Surgical preparation
The experiments were performed on 7 adult cats of either sex weighing 
between 2-3 kg. Anaesthesia was induced using alphaxolone/alphadolone (Saffan, 
Glaxo) administered into the radial vein. The animal was then intubated and positive 
pressure ventilation with N2 O/O2 (70%/30%) initiated. The femoral arteries and veins
were cannulated for the monitoring of arterial blood pressure and arterial blood status 
gas and for the administration of fluid and drugs respectively. Anaesthesia was 
maintained using a-chloralose (60 mg/kg) and further supplements of 1-2  ml of a -  
chloralose ( 1%) were administered to prevent the return of the corneal reflex.
Arterial blood samples were taken at regular intervals for monitoring of blood 
gases. The animals were maintained normocapnic by adjusting the stroke volume and 
metabolic acidosis was controlled by the administration of sodium bicarbonate (8.4%). 
Core temperature was measured with rectal thermometer and the temperature 
m aintained at 37°C by means of a heating blanket controlled by the rectal 
thermometer.
The animal was placed in a stereotactic frame. After a midline scalp incision, 
the scalp was retracted and sutured onto a metal ring to form a well over the 
calvarium. The temporalis muscle was retracted and a rectangular craniectomy (2.5 
cm x 1.5 cm) was made over the parietal cortex using a saline cooled dental drill. The 
exposed dura was bathed with mineral oil at 38°C. There was a continuous flow of 
oil at the rate o f approximately 1 ml/min. With the aid of a stereomicroscope (Bausch 
& Lomb) the dura was excised and then reflected laterally. Bipolar diathermy was 
used to control bleeding from the dural vessels. The inspired gas mixture was then 
altered to O2 supplemented air (approximately 25% O2).
The left middle cerebral artery (MCA) was exposed and occluded via a 
transorbital approach by a neurosurgeon (Mr. Galbraith). Briefly, with microsurgical
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techniques, the contents of the left orbit were exenterated and the optic foramen 
enlarged with a dental drill to expose the dura mater overlying the MCA close to its 
origin. Under the operating microscope the dura was incised and the MCA exposed. 
The trunk of the MCA, all collateral vessels and all visible branches of the 
lenticulostriate arteries were coagulated with bipolar diathermy and sectioned with 
microscissors.
Measurement o f Arteriolar Calibre
Arteriolar calibre was measured by the method of Baez (1966) using an image 
splitter linked through a closed circuit video display system. The system was 
calibrated at x40 and x70 against threads of known diameter and this allows for the 
direct measurement of vascular diameter in absolute units (|im). The individual pial 
vessels were viewed through a stereomicroscope and the arteriolar diameter was 
measured from the degree of shear applied to the image splitter in order to tangentially 
appose the two images. No perivascular microinjections were made during the first 30 
min after MCA occlusion. During this period, the vasomotor responses o f 25 pre­
selected vessels were monitored intermittently and their calibre after MCA occlusion 
contrasted with their calibre immediately prior to occlusion. CSF, Bosentan (30 (iM) 
or PD155080 (30 (iM) were applied to arterioles in the period 30 - 210 min following 
MCA occlusion. The vessel diameter was typically measured pre-insertion, pre­
injection and post-injection and the vessel diameter was monitored over a period of 1 - 
2 min. A detailed description of the surgical preparation and measurement technique 
has appeared previously (Robinson and McCulloch, 1990).
Administration o f Drugs
Sharp glass micropipettes (tip diameter 10-12 |im) were vacuum filled with 
either artificial cerebrospinal fluid (CSF), 10 mM K+ CSF or drugs dissolved in CSF. 
The composition of the CSF was Na+ 156 mM, K+ 3 mM, Ca2+ 2.5 mM, HCO3- 12 
mM, C l' 152 mM with the pH adjusted to 7.2 by aeration with 5% CC>2/9 5 % O2 . All 
solutions were prepared freshly for each study. CSF, Bosentan (30[iM) or PD 155080
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(30pM ) were applied to arterioles in the period 30 - 210 min following MCA 
occlusion. The substances were applied by subarachnoid microapplication using a 
micromanipulator to position the pipettes in the perivascular space around the vessel. 
Small volumes (5 pi) were delivered by a pressure ejection system. Individual sites 
on the arterioles were studied on only a single occasion.
Statistical Analysis
The data from the vessels overlying the parasagittal gyrus and the dilated and 
constricted vessels overlying the suprasylvian and ectosylvian gyri were analysed 
(Bosentan or PD155080 versus CSF) using an unpaired Student's t-test. A two way 
analysis of variance with time as a co-variant was used to analyse the temporal 
component of the effects of Bosentan and CSF on post-ischaemic dilated vessels, All 
results are expressed as mean ± S.E.M.. of the percent change of pial arteriolar calibre 
from pre-injection baseline; n = the number of arterioles examined.
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CHAPTER 3 
RESULTS
3.1 E n d o t h e l in  R e c e p t o r s  in  t h e  C e r e b r o v a s c u l a t u r e
3.1.1 Rabbit Basilar Artery in vitro
All the segments utilised in the study elicited a contraction when exposed to 
50 mM Potassium substituted Krebs' (50 mM K+). The mean response was 348 ±21 
mg (n = 42). The application of acetylcholine (10 |iM) resulted in a small relaxation 
o f the 50 mM K+ response (<10%) indicating the absence o f any significant 
endothelium dependent relaxation. Previous investigations have indicated that 
concentration of acetylcholine used in the present studies would have elicited marked 
relaxant responses on the rabbit basilar artery [Rand & Garland, 1992; Plane & 
Garland, 1993]. However, no histological evidence for the de-endothelialisation of the 
basilar artery segments was obtained.
The addition of endothelin-1 (at a concentration greater than 1 nM) to the 
organ baths resulted in a contraction of the basilar artery segments. The contractile 
responses reached a plateau, at each concentration, in approximately 30-45 seconds. 
However, a maximal contraction was not achieved with a concentration of 10-7 m  of 
endothelin-1 .
Bosentan
The addition of Bosentan at a concentration of 1 or 10 (iM did not induce any 
contractile or relaxant effects on rabbit basilar artery segments. At a concentration of 1 
|iM , Bosentan did not appear to have any effect on the dose response curve to ET-1. 
However, 10 [iM Bosentan elicited a rightward shift in the dose response curve that is 
consistent with the feature of competitive antagonism. However, the rightward shift 
was also accompanied by what appeared to be a steepening of the dose response curve 
[Figure 7]. The estimated pA2 value for Bosentan in this preparation was 5.1. There 
were no significant differences in the mean EC50 values [Table 4].
BQ-123
91
Rabbit basilar artery in v itro
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Figure 7 Concentration response curves 
demonstrating the antagonism of ET-1 
induced vasoconstriction by bosentan (top) 
and BQ-123 (bottom) in the rabbit basilar 
artery. Data are expressed as mean ± S.E.M 
(n = 2 - 12 in each group). The pA2 values 
obtained were 5.1 for bosentan and 5.3 for 
BQ-123.
Ta
bl
e 
4
Po
ten
cy
 
of 
en
do
th
el
in
 
re
ce
pt
or
 a
go
ni
sts
 a
nd
 
an
ta
go
ni
sts
 i
n 
the
 
ra
bb
it 
ba
sil
ar
 a
rte
ry
 
in 
vi
tr
o
c n  i n  cn i n
vO <-*o'- e in ' On
O
W
p ON On NO NO
cn O ON 00CN CN CN| cn
cn in ON CN CN
o ON PO NO
rf r- ■n- r^in p cn oo p
r-I oo •n -rf CN* CN
NOcn
CNON
CN
NONO
CN
r
0^0
CN
i
CNO
TfON
oo
cn
i
oor-
oCN-rf
CN
S s s £
=L =t =t n n 3._ o *—1 1 o >—•
©
c fi03 cn cn cn m
c c CN CN CN CNO O 1 7*C/3O C/3O a a a a
PQ PQ PQ PQ PQ PQ
+ + + + + +
| ’—I i—• cn cn
H H H H H H
1
H
1
H
W W W W W W W W
cnCN
I
a
PQ
+
5  W
o  o
o « >VC -ti cd ^
1j p5-1 l-D 4>0 O
P3 Cs  sI-1 h<u
C+^ l+H * ** * ^  T3 "O 
—*
1 |o  o
s  s
§b §b • 4 ^C/3 C/3
© p  
© ©
V V
Oh CU 
* -J—
<uC/3GOa,
C/3<D
5 -i
6
5
B
o
''v
ocn
OX),e
os*T3O
5—iex
- t - JCO
"2O00
cd
1 + - Co
eo2 6 O • *-
<uoc<u*oISaooo  m
U •-!
w o
The addition of BQ-123 at the concentrations (0.1 - 10 |iM ) did not elicit any 
discernible contractile or relaxant effects on rabbit basilar artery segments. At 
concentrations of 1 (iM and 10 (iM BQ-123 elicited a rightward shift in dose response 
curve to endothelin suggesting competitive antagonism of ET-1 induced contractile 
effect [Figure 7]. This gave an estimated pA2 value of 5.3. There was no significant 
difference in the mean EC30 values [Table 4].
ET-3
The addition of ET-3 elicited marked contractions of the rabbit basilar artery 
segments. ET-3 was approximately 100 fold less potent than ET-1 in eliciting a 
contractile response in the rabbit basilar artery. BQ-123 ( 1 fiM) effected a rightward 
shift of the ET-3 concentration response curve indicating competitive antagonism of 
endothelin ET a receptors. The pA2 value obtained was 7.2 which is approximately 
100 fold greater than the pA2 obtained for BQ-123 against ET-1 in the same tissue 
[Figure 8]. There was significant difference in the mean EC30 values between ET-3 
and BQ-123 treated segments and the segments treated with BQ-123 and ET-1 or ET- 
3 [Table 4],
BQ3020
The addition of BQ3020 to the bath resulted in a small contraction of the 
basilar artery. The magnitude of this response was most marked at concentrations in 
excess of 0.1 fiM, although the response was much smaller than the contractile 
responses elicited by ET-1 or ET-3 [Figure 8].
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Figure 8 Concentration response curves 
demonstrating vasoconstriction induced by 
ET-1, ET-3 and BQ-3020 (top) and the 
antagonism of ET-3 induced vasoconstriction 
by BQ-123 (bottom) in the rabbit basilar 
artery. Data are expressed as mean ± S.E.M 
(n = 4 - 11 in each group). The p ^  value 
obtained was 7.1 for BQ-123.
3.1.2 Feline Cerebral Arterioles in situ
At the outset of the study, mean arterial blood pressure (MABP) was 97 ± 3 
mmHg, arterial carbon dioxide tension was 30 ± 1 mmHg and arterial oxygen tension 
was 201 ± 5 mmHg. During the course of the study, the physiological variables did 
not vary significantly from the levels at the outset. The pre-injection calibre of the 
arterioles ranged from 42 - 334 Jim. The perivascular microinjection investigations 
were carried out in 8 cats and each concentration of BQ-3020 per se, BQ-123 per se 
and BQ-123 and ET-1 was examined in at least 4 cats. The investigations utilising the 
intracarotid infusion of BQ-3020 were performed in 3 additional cats.
Perivascular Microapplication o f BQ-123 per se
The adventitial microapplications of CSF (pH 7.2) had minimal effect on pial 
arteriolar calibre [-0.93 ± 1.6% from pre injection baseline; n = 14]. Similarly, the 
adventitial microapplications of BQ-123 per se (0.1 - 10 jiM) had minimal effect on 
pial arteriolar calibre [Figure 9].
Perivascular co-application o f ET-1 (10 nM) and BQ-123
The adventitial microapplication of ET-1 (10 nM) effected a marked 
constriction of the pial arterioles examined [-29.1 ± 2.2 % from pre injection baseline; 
n = 9]. The adventitial co-application of ET-1 (10 nM) and BQ-123 demonstrated a 
dose dependent attenuation of the ET-1 mediated vasoconstrictive response [Figure 9]. 
The concentration o f BQ-123 that produced a half maximal attenuation (EC50) was 
estimated to be approximately 0.7 |iM.
Perivascular and intravascular administration o f  BQ-3020
The adventitial microapplication of CSF had minimal effect on arteriolar 
calibre, whereas, the adventitial microapplication of BQ-3020 (0.001 - 1 jiM) effected 
dose dependent dilatations of pial arterioles examined (EC50  30 nM) [Figure 10]. The 
intracarotid infusion of 0.9% saline had minimal effect on pial arteriolar calibre or 
arterial blood pressure. The magnitude of the response of arterioles to BQ-3020 (100
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Figure_9(Top) Vasomotor responses of pial arterioles to the adventitial 
microapplication of BQ-123 per se. There were no significant alterations in the 
pial arteriolar calibre at any concentration of BQ-123 examined. Data are 
expressed as percent alteration from baseline of pial arteriolar calibre. Data 
are presented as mean ± S.E.M (n, number of arterioles examined = 6 for each 
concentration).
(Bottom) Vasomotor responses of pial arterioles to adventitial co-application of 
endothelin-1 (10 nM) and BQ-123. BQ-123 significantly attenuated the 
endothelin-1 induced vasoconstrictions ( ** P < 0.01 for the comparison with 
endothelin-1 alone). Data are expressed as percent alteration from baseline of 
pial arteriolar calibre. Data are presented as mean ± S.E.M (n, number of 
arterioles examined = 5-12 for each concentration).
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Figiire_10(Top) Vasomotor responses of pial arterioles to the adventitial 
microapplication of BQ-3020 per se. BQ-3020 effected a dose dependent 
vasodilatation of the pial arterioles examined (** P < 0.01 for the 
comparison with CSF). Data are expressed as percent alteration from 
baseline of pial arteriolar calibre. Data are presented as mean ± S.E.M ( n, 
number of arterioles examined = 7-13 for each concentration).
(Bottom) The dependence of the pial arteriolar dilatation elicited by 
BQ-3020 on the calibre of arteriole examined. Pial arteriolar diameter 
was determined prior to the adventitial microapplication of BQ-3020. The 
arteriolar responses are expressed as the percent change from 
pre-injection baseline. (r2= 0.36; P O .01).
nM and l|iM ) was dependent on the pre-injection calibre of the arteriole examined. 
Cerebral arterioles less than 100 pm demonstrated an increased reactivity to BQ-3020 
[Figure 10]. No such correlation was demonstrated with the arterioles to which CSF 
(pH 7.2) was applied. The intracarotid infusion of BQ-3020 (0.5 - 500 pmol/min) had 
minimal effect on pial arteriolar calibre [Figure 11]. The intracarotid infusion of BQ- 
3020 at a rate of 500 pmol/min elicited a transient decrease in mean arterial blood 
pressure ( 16.3 ± 8.6 mmHg from pre infusion baseline) and the blood pressure 
returned to baseline within 5 min.
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Figure 11 Vasomotor responses of pial arterioles to the 
intracarotid infusion of BQ-3020. BQ-3020 or saline 
had minimal effect on pial arterioles examined. Data 
are expressed as percent alteration from baseline of 
pial arteriolar calibre. Data are presented as mean ± 
S.E.M (n, number of arterioles examined = 11 for each 
concentration).
3.2 e v a l u a t i o n  o f  E n d o t h e l i n  r e c e p t o r  A n t a g o n i s t s  i n  t h e
CEREBROVASCULATURE OF THE CAT
3.2.1 Cerebrovascular effects of Bosentan in vivo
At the outset of the study of pial arteriolar responses mean arterial blood 
pressure was 85 ± 3 mmHg, arterial carbon dioxide tension was 32.0 ± 0.9 mmHg and 
arterial oxygen tension was 195 ± 6 mmHg. During the course of the study, these 
physiological variables did not change significantly from the levels at the outset. The 
pre-injection calibre of the arterioles ranged from 58-319 |Ltm. The perivascular 
micro injection investigations were carried out in 5 cats and each concentration of 
Bosentan per se and Bosentan and ET-1 was examined in every cat. The effects of the 
intravenous administration of Bosentan on the perivascular effects of ET-1 were 
examined in the same 5 cats.
Perivascular Microapplication o f Bosentan
The perivascular microapplication of artificial CSF minimally altered pial 
arteriolar calibre (alteration in calibre 0.8 ± 1.7%, n=7). Perivascular microapplication 
of Bosentan in the range 0.3 to 300 (iM had minimal effect on pial arteriolar calibre 
when compared to CSF injections [Figure 12].
Perivascular co-Application o f Bosentan and Endothelin-1
The perivascular microapplication of endothelin-1 (10 nM) resulted in a 
marked constriction of pial arterioles (calibre reduced from pre injection baseline by
39.2 ± 2.7%, n=13). Perivascular co-administration of Bosentan with endothelin-1 (10 
nM) produced a dose-dependent attenuation of endothelin-induced contractions; the 
concentration of Bosentan in the co-injectate which would have produced half 
maximal inhibition was estimated to be approximately 1 |iM [Figure 12]. Perivascular 
microapplication of alkalotic CSF (pH 7.45; HCO3" 22 mM) effected significant 
reductions in pial arteriolar calibre compared to CSF alone (calibre reduced from pre
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Figure 12 (Top) Vasomotor responses of pial arterioles to perivascular 
microapplication of bosentan. There were no significant alterations in pial 
arteriolar calibre at any concentration o f bosentan examined. Data are 
expressed as the percent alteration from baseline in pial arteriolar calibre. 
Data are presented as mean ± S.E.M (n, number of arterioles examined = 
7-11 for each concentration).
(Bottom )Vasom otor responses of pial arterioles to perivascular 
co-application of endothelin-1 (lOnM) and bosentan. Bosentan significantly 
attenuated the constrictions induced by endothelin-1. (**P<0.01 for the 
comparison with endothelin alone.). Data are expressed as the percent 
alteration from baseline in pial arteriolar calibre. Data are presented as mean 
± S.E.M (n, number of arterioles examined = 7-13 for each concentration).
injection baseline by 16.6 ± 2.7 %, n= 7). Alkalotic CSF containing Bosentan (30 
|iM) effected a reduction in pial arteriolar calibre of a similar magnitude to alkalotic 
CSF (pH 7.45; HC0 3 " 2 2  mM) (calibre reduced from pre injection baseline by 14.9 ± 
1.9 %, n= 7 ).
Reversal o f ET-1 induced vasoconstrictions
Normal pial arterioles were constricted (-29.1 ± 1.9% from baseline; n = 12) 
by the perivascular microapplication of endothelin-1 (10 nM). Bosentan (30 jiM) or 
CSF (pH 7.2) was applied to these vessels 5-15 minutes following the application of 
endothelin-1. Bosentan (30 jiM) effected a marked increase in vessel calibre from the 
ET-1 constricted baseline (22.4 ± 3.6% from baseline ; n = 7; P < 0.01 for the 
comparison with the effects of CSF (pH 7.2)) [Figure 13], The reversal or dilatation 
was transient with a typical duration of approximately 30 seconds before the vessel 
returned to pre Bosentan injection calibre [Figure 13]. The application of CSF on 
these constricted vessels had minimal effect on the vessel calibre (-1.9 ± 1.8% from 
ET-1 constricted baseline ; n = 6) [Figure 13].
Perivascular Microapplication o f Endothelin 1 after Intravenous Administration o f  
Bosentan
The intravenous administration of Bosentan (17 pmol/kg) had minimal effect 
on mean arterial blood pressure. Perivascular microapplication of endothelin-1 (10 
nM) in the period 15-75 min.. after the intravenous injection of Bosentan (17 
jimol/kg) produced minimal alterations in pial arteriolar calibre [Figure 14]. The 
significant constrictions produced by perivascular microapplication of alkalotic CSF 
(pH 7.45) were not influenced by the intravenous injection of Bosentan [Figure 14].
Subarachnoid microapplications of autologous arterial blood produce 
immediate marked significant reductions in pial arteriolar calibre; the acute 
constrictions produced by microapplications of blood were not influenced by the 
intravenous injection of Bosentan [Figure 14].
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F igure 13 (Top) Vasomotor response of a normal pial arteriole to 
the perivascular microapplication o f ET-1 (10 nM). Perivascular 
microapplication of Bosentan (30 pM ) elicited a transient reversal 
o f the ET-1 induced vasoconstriction.
(B ottom ) R eversal o f exogenous ET-1 (10 nM ) induced  
vasoconstriction o f normal pial arterioles. M icro injections o f  CSF, 
Bosentan (30 JiM) and PD155080 (30 pM ) were carried out 5 -15 
m in following the m icroapplication o f ET-1 (10 nM ). D ata are 
presented as mean ± S.E.M percent change from pre-in jection 
baseline (n= 7-12 in each group). * P<0.01 for the com parison 
between ET-1 and Bosentan or PD155080
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Figure 14 Vasomotor responses of pial arterioles to subarachnoid 
perivascular microapplications of endothelin-1 (10 nM), blood or 
alkalotic CSF (7.45) after the intravenous injection of bosentan 
(17|im ol/kg). The pial arteriolar constrictions induced by 
endothelin-1 were significantly attenuated by intravenous bosentan 
whereas the constrictions induced by subarachnoid blood or alkalotic 
CSF were minimally affected (**P<0.01 for the comparison with 
endothelin alone).Data are expressed as the percent alteration from 
baseline in pial arteriolar calibre. Data are presented as mean ± S.E.M 
(n, number of arterioles examined = 7-13 for each concentration).
3.2.2 C erebrovascular effects o f PD155080 in vivo
At the outset of the study of pial arteriolar responses mean arterial blood 
pressure was 93 ± 3 mmHg, arterial pH was 7.4 ±0.01, arterial carbon dioxide tension 
was 31.5 ± 0.7 mmHg and arterial oxygen tension was 206 ± 6 mmHg. During the 
course of the study, these physiological variables did not change significantly from the 
levels at the outset. The pre-injection calibre of the arterioles ranged from 56-334 p.m. 
The perivascular microinjection investigations were carried out in 4 cats and each 
concentration of PD155080 per se and PD155080 and ET-1 was examined in every 
cat. The effects of the intravenous administration of PD 155080 on the perivascular 
effects of ET-1 were examined in the same 4 cats. The effects of perivascular choline 
chloride per se, choline chloride and ET-1 and the intravenous choline chloride were 
examined in 3 separate cats.
Perivascular Microapplication o f PD155080
The subarachnoid perivascular microapplication of CSF minimally altered pial 
arteriolar calibre. Microapplication of PD 155080 (0.3-3 |iM) did not significantly alter 
pial arteriolar calibre relative to CSF [Figure 15]. Perivascular microinjection of CSF 
containing choline chloride (30 pM) did not significantly alter pial arteriolar calibre 
(mean change in calibre 0.3 ± 2.6%; n=5).
Perivascular co-application o f PD155080 and Endothelin-1
The subarachnoid perivascular microapplication of endothelin-1 (10 nM) 
effected marked constriction of cortical pial arterioles. Co-adm inistration of 
PD 155080 with endothelin-1 resulted in attenuation of the vasoconstrictor effects of 
endothelin. The IC5Q value was approximately 1 jiM [Figure 15].
Reversal o f ET-1 induced vasoconstrictions
The perivascular administration of CSF to pial arterioles constricted with 
endothelin-1 (5 min. previously) had minimal effect on calibre (mean change in
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Figure 15 Vasomotor responses o f pial arterioles to perivascular 
microapplication of PD 155080, a non-peptide antagonist, (Top) and 
co-application of endothelin-1 (10 nM) and PD 155080 (Bottom). There 
were no significant alterations in pial arteriolar calibre at any 
concentration of PD155080 examined. PD155080 significantly attenuated 
the constrictions induced by endothelin-1. (**P<0.01 for the comparison 
with endothelin alone.). Data are expressed as the percent alteration from 
baseline in pial arteriolar calibre. Data are presented as mean ± S.E.M (n, 
number of arterioles examined = 6-13 for each concentration).
calibre from pre-CSF injection 0.8 ± 1.4%; n=6) [Figure 13]. The perivascular 
administration of PD155080 (30jiM) to a pial arteriole constricted with endothelin-1 
resulted in a significant increase in calibre from the level immediately prior to 
PD 155080 injection (mean change in calibre 21 ± 2.4%; n=8) [Figure 13]. 
Approximately 5 min. after microapplication of PD 155080, the calibre had returned to 
its pre-drug constricted diameter.
Intravenous administration o f PD155080
The intravenous administration of PD 155080 (19.2 p.mol/kg) produced marked 
alterations in arterial blood pressure during the course o f the injection. The 
intravenous injection of choline chloride (71.6 fimol/kg) in isotonic saline (vehicle) 
produced similar alterations in arterial blood pressure. After completion of the 
injection of either PD 155080 or choline chloride, arterial blood pressure returned 
rapidly to its pre-injection level.
The perivascular microapplication of endothelin-1 (10 nM) in choline chloride 
treated cats resulted in significant reductions in pial arteriolar calibre [Figure 16]. In 
contrast, the perivascular microapplication of endothelin-1 had minimal effect on pial 
arteriolar calibre in the period 15 to 75 min.. after the intravenous injection of 
PD155080 (19.2 fimol/kg) [Figure 16]. The perivascular microapplication of alkalotic 
CSF (pH 7.45) resulted in reductions of pial arteriolar calibre of a similar magnitude 
in cats which received either vehicle or intravenous PD 155080 [Figure 17].
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F ig u re  16 Vasomotor responses of pial arterioles to perivascular 
m icroapplications o f endothelin-1 (10 nM) after the intravenous 
injection o f PD 155080 (19.2 |im ol/kg) or choline chloride (72 
pmol/kg). The pial arteriolar constrictions induced by endothelin-1 
w ere significantly  attenuated by in travenous PD 155080 and 
m inim ally affected by intravenous choline chloride (**P<0.01 for 
the comparison with endothelin alone). Data are expressed as the 
percent alteration from baseline in pial arteriolar calibre. Data are 
presented as mean ± S.E.M (n, number o f arterioles exam ined = 
6-12 in each group).
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F ig u re  17 Vasom otor responses o f pial arterioles to perivascular 
microapplications o f endothelin-1 (10 nM) or alkalotic CSF (pH 7.45) 
after the intravenous injection of PD155080 (19.2 p,mol/kg). The pial 
arteriolar constrictions induced by endothelin-1 were significantly 
attenuated by intravenous PD 155080 w hereas the constrictions 
induced by alkalotic CSF were minimally affected (**P<0.01 for the 
comparison with endothelin alone). Data are expressed as the percent 
alteration from baseline in pial arteriolar calibre. Data are presented 
as mean ± S.E.M (n, number o f arterioles examined = 6-12 in each 
group).
3.2.3 C erebrovascular effects o f PD145065 in vivo
At the outset of the study of pial arteriolar responses mean arterial blood 
pressure was 92 ± 2 mmHg, arterial pH was 7.42 ± 0.01, arterial carbon dioxide 
tension was 30.7 ± 0.7 mmHg and arterial oxygen tension was 225 ± 4 mmHg. 
During the course of the study, these physiological variables did not change 
significantly from the levels at the outset. The pre-injection calibre of the arterioles 
ranged from 38-283 Jim. The perivascular microinjection investigations were carried 
out in 6 cats and each concentration of PD145065 per se and PD145065 and ET-1 was 
examined in at least 4 of the cats. The effects of the intravenous administration of 
PD145065 on the perivascular effects of ET-1 were examined in at least 4 cats.
Perivascular Microapplication o f PD145065
The subarachnoid perivascular microapplication of CSF minimally altered pial 
arteriolar calibre. Microapplication of PD145065 (0.03-3 (iM) had minimal effect on 
pial arteriolar calibre when compared to CSF injections [Figure 18].
Perivascular co-Application ofPD145065 and Endothelin-1
The subarachnoid perivascular microapplication of endothelin-1 (10 nM) 
effected marked constriction of cortical pial arterioles. Co-administration of 
PD 145065 with endothelin-1 resulted in a dose dependent attenuation of the 
vasoconstrictor effects of endothelin. The IC50 value was approximately 0.1 |iM 
[Figure 18].
Perivascular Microapplication o f Endothelin 1 after Intravenous administration o f  
PD145065
The intravenous administration of PD 145065 (30 |imol/kg) had minimal effect 
on mean arterial blood pressure. The perivascular microapplication of ET-1 (10 nM) 
resulted in a marked reduction in arteriolar calibre. The intravenous administration of 
PD 145065 (30 (imol/kg) demonstrated no significant attenuation o f the
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F igure 18 Vasomotor responses of pial arterioles to perivascular 
application of PD145065 a peptide antagonist (Top) and co-application 
of endothelin-1 (10 nM) and PD 145065 (Bottom). There were no 
significant alterations in pial arteriolar calibre at any concentration of 
PD 145065 examined. PD 145065 significantly attenuated the 
constrictions induced by endothelin-1. (**P<0.01 for the comparison 
with endothelin alone.). Data are expressed asthe percent alteration from 
baseline in pial arteriolar calibre. Data are presented as mean ± S.E.M 
(n, number of arterioles examined = 6-25 for each concentration).
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Figure 19 Vasomotor responses of pial arterioles to perivascular 
microapplications of endothelin-1 (10 nM) after the intravenous 
injection of PD155080 (19.2 |imol/kg) or PD145065 (30 fimol/kg). 
The pial arteriolar constrictions induced by endothelin-1 were 
significantly attenuated by intravenous PD 155080 but minimally 
affected following the intravenous administration of PD 145065 
(**P<0.01 for the comparison with endothelin alone). Data are 
expressed as the percent alteration from baseline in pial arteriolar 
calibre. Data are presented as mean ± S.E.M (n, number of arterioles 
examined = 8-25 in each group).
vasoconstrictive response as a result of the perivascular microapplication o f ET-1 
indicating the failure of the peptide endothelin receptor antagonist to gain access to the 
cerebrovascular smooth muscle [Figure 19].
The adequacy of the dose of PD145065 used and its antagonistic activity in the 
periphery was examined by administering an intravenous bolus of ET-1 (1 nmol/kg) at 
120 min. following the initial intravenous administration of PD 145065. There was a 
marked attenuation of both the depressor and pressor responses to ET-1 demonstrating 
that the dose of PD 145065 used significantly inhibited the peripheral effects of 
systemic ET-1 administration [Figure 20].
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Figure 20 Alterations in the mean arterial blood pressure (MABP) 
in cat following the intravenous administration of endothelin-1 (1 
nmol/kg). In a separate group of animals ET-1 (1 nmol/kg) was 
administered 120 min. following the intravenous administration of 
PD 145065 (30 |imol/kg). The pressor and depressor responses 
induced by endothelin-1 were significantly attenuated by 
intravenous PD 145065 (*P<0.05 for the comparison with 
endothelin alone). Data are expressed as the alteration in MABP 
from baseline . Data are presented as mean ± S.E.M (n = 4 animals 
in each group).
3.3 Pa t h o p h y sio l o g ic  S ig n ific a n c e  of  En d o t h e l in s  in  t h e  C e r e b r a l
C ir c u l a t io n
3.3.1 Cerebral Blood Flow following Bilateral Common Carotid Occlusion 
with Concomitant Haemorrhagic Hypotension in the Rat
Cardiovascular and Respiratory Variables
Hydrogen clearance: There were no significant differences in the cardiovascular and 
respiratory variables in either the drug or vehicle treated animals following bilateral 
common carotid artery occlusion and systemic hypotension. The mean arterial blood 
pressure (MABP) at the outset was 97 ± 1 mmHg in vehicle treated animals and 102 ± 
2 mmHg in the Bosentan treated animals [Figure 21]. Arterial pC02 was 39.5 ± 1 
mmHg (vehicle group) and 39.2 ± 1 (Bosentan group) at the outset of the experiment 
and did not vary significantly from these levels [Table 5]. The mean rectal temperature 
was 37.0 ± 0.1 °C (vehicle group) and 36.9 ± 0.1°C (Bosentan group) and did not 
vary significantly from these levels [Table 5]. The MABP was maintained between 42 
- 50 mmHg during the period of occlusion [Figure 21]. On the release of the ligatures 
around the carotid arteries, the blood pressure was restored to pre occlusion levels by a 
slow intravenous infusion of blood. The administration of Bosentan (17 jimol/kg) had 
minimal effect on mean arterial blood pressure.
Autoradiography: There were no significant differences in the cardiovascular and
respiratory variables in either the drug or vehicle treated animals subjected to bilateral 
common carotid artery occlusion and systemic hypotension. The mean arterial blood 
pressure was maintained at 46 ± 1 mmHg (Bosentan) and 46 ± 2 mmHg (vehicle) 
during the period of occlusion [Table 6]. Prior to start of the blood flow determination, 
MABP was 95 ± 3 mmHg (Bosentan) and 105 ± 5 mmHg (vehicle) [Table 6]. Arterial 
p C 0 2 was 40.1 ± 0.9 mmHg (Bosentan) and 39.8 ± 0.6 mmHg (vehicle) prior to the 
start of the blood flow determination [Table 6].
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F igm-g 21 Mean arterial blood pressure in animals 
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Hydrogen Clearance
In the caudate nucleus, cerebral blood flow (CBF) was reduced by 5 ± 1% (of 
pre occlusion baseline) on the occlusion of the common carotid arteries and induction 
of hypotension. A similar drop in cerebral blood flow was obtained in the drug treated 
animals [5 ± 3% of pre occlusion baseline]. The release of the carotid ligatures 
resulted in a marked hyperaemic response in both drug and vehicle treated group [160 
± 26% of baseline (Bosentan); 142 ± 30% of baseline (vehicle)]. The post ischaemic 
hypoperfusion lasted from 30 min to 180 min (end of experimental period). The 
hypoperfusion phase saw cerebral blood flow reduced by approximately 50% (of pre­
occlusion baseline). Pre-treatment with Bosentan did not alter the level of 
hypoperfusion [Figure 22].
In the parietal cortex the occlusion of the common carotid arteries and 
induction of haemorrhagic hypotension resulted in similar reductions in CBF in the 
cerebral cortex [15 ± 5% of pre occlusion baseline (Bosentan); 10 ± 3% of pre 
occlusion baseline (vehicle)]. On the release of the carotid ligatures a hyperaemic 
response was measured in animals pre-treated with Bosentan [128 ± 38% of baseline]. 
However, no such response was measured in vehicle treated animals. The reasons for 
the differences are unclear but could be attributed to the time of the blood flow 
measurement immediately following the release of the carotid ligatures. The level of 
hypoperfusion in the cerebral cortex stabilised after 60 min of reperfusion at 
approximately 45% of pre occlusion baseline [Figure 22]. There was no alteration in 
the level of hypoperfusion following the pre-treatment with Bosentan.
A utoradiography
The reduction in cerebral blood flow following transient global cerebral 
ischaemia is illustrated in figure 23. There were no significant alterations in cerebral 
blood flow, between animals treated with vehicle or Bosentan, in any o f the 35 
regions examined [Table 7; Figure 24]. Qualitative assessment of the autoradiograms 
suggested a rostro- caudal variation in the pattern of cerebral blood flow. In the
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Figure_22(Top)Alterations in cerebral blood flow in the caudate nucleus, 
determined by hydrogen clearance, in animals subjected to transient 
bilateral common carotid artery occlusion and systemic haemorrhagic 
hypotension. Bosentan (17 |imol/kg) was administered as an intravenous 
bolus 10 min. prior to the induction of ischaemia. Data are expressed as 
mean ± S.E.M (% of pre-occlusion baseline) (n = 6 in each group).
(Bottom) Alterations in cerebral blood flow in the parietal cortex, 
determined by hydrogen clearance, in animals subjected to transient 
bilateral common carotid artery occlusion and systemic haemorrhagic 
hypotension. Bosentan (17 (imol/kg) was administered as an intravenous 
bolus 10 min. prior to the induction of ischaemia. Data are expressed as 
mean ± S.E.M (% of pre-occlusion baseline) (n = 6 in each group).
Figure 23 Autoradiograms illustrating the reductions in cerebral blood flow in the 
caudate nucleus and sensory motor cortex following transient global cerebral ischaemia 
in the rat. Cerebral blood flow was measured using [ 14C]-Iodoantipyrine 
autoradiography at 90 min. following the restoration of blood flow.
Figure 23
Cerebral H ypoperfusion: Spatial Distribution
Cerebral Blood Flow: 14C-Iodoantipyrine Autoradiography
Sham
Carotid  O cclusion with Hypotension
T able 7
Transient Bilateral Common Carotid Artery Occlusion with Concomitant Haemorrhagic Hypotension in 
the Rat
Region Vehicle Bosentan (17 |imol/kg) t
Cerebellum
Cerebellar Cortex 109 + 5 122 ± 7 1.48
Medulla /  Pons
Superior Olivary Nucleus 308 ± 28 362 ± 39 1.10
Pontine gray matter 139 ± 11 160 + 16 1.05
Mesencephalon
Inferior Colliculus 238 + 24 276 ± 23 1.14
Superior Colliculus 168 ± 16 198 ± 20 1.15
Red Nucleus 181 + 14 207 ± 21 1.00
Substantia Nigra (pars 119 ± 6 138 ± 10 1.58
compacta)
Substantia Nigra (pars 108 ± 8 121 ± 10 1.57
reticulata)
Diencephalon
Medial Geniculate body 132 ± 16 165 ± 21 0.99
Sub Thalamic Nucleus 154 ± 14 176 ± 26 0.72
Lateral Geniculate Nucleus 114 ± 23 144 ± 29 0.80
Lateral Habenular Nucleus 180 ± 12 220 ± 22 1.54
Hypothalamus 107 ± 12 107 ± 9 0.00
Mediodorsal Thalamic Nucleus 114 + 16 132 ± 21 0.67
Ventrolateral Thalamic Nucleus 115 ± 10 151 ± 20 1.55
Anterior Thalamic Nucleus 176 ± 32 222 ± 53 0.72
Telencephalon
Visual Cortex (layer IV) 132 ± 26 152 ± 34 0.46
Hippocampus (Molecular 122 ± 19 136 ± 20 0.50
Layer)
Dentate Gyrus 119 ± 14 143 ± 19 0.99
Auditory Cortex (layer IV) 131 ± 22 153 ± 25 0.65
Posterior Cingulate Cortex 180 ± 38 206 ± 48 0.42
Entorhinal Cortex 133 ± 19 144 ± 23 0.36
Amygdaloid nucleus 92 ± 14 100 ± 16 0.37
Globus pallidus 60 ± 9 68 ± 12 0.52
Caudate Nucleus 77 ± 17 84 ± 21 0.25
Sensory Motor Cortex (layer 95 ± 15 115 ± 19 0.81
IV)
Nucleus Accumbens 119 ± 27 127 ± 24 0.22
Anterior Cingulate Cortex 126 ± 36 136 ± 41 0.18
Frontal Cortex 91 ± 14 101 ± 16 0.46
Primary Olfactory Cortex 308 ± 50 290 ± 36 0.30
Parietal Cortex 88 ± 15 98 ± 14 0.49
Myelinated Fibre Tracts
Cerebellar White Matter 56 ± 4 60 ± 3 0.81
Corpus Callosum 41 + 5 51 ± 8 1.03
Internal Capsule 44 ± 5 49 ± 4 0.79
Genu 37 ± 8 38 ± 8 0.09
Local cerebral blood flow (ml/lOOg/min) was measured at 90 min following global ischaemia.
Data are expressed as mean ±  S.E.M. (n= 8-9 in each group). Two tailed t-test; critical t = 2.13 (15 
df) for P<0.05. None o f the regions examined were significantly different from vehicle.
forebrain regions, e.g. caudate nucleus and sensory motor cortex, a marked reduction 
in flow was observed in a majority of animals (7/8 vehicle treated; 8/9 Bosentan 
treated) [Figure 23]. This was in stark contrast to the observations made in more 
caudal areas of the brain. Reductions in cerebral blood flow were observed in cerebral 
cortical regions e.g. parietal, visual ( 7 / 8  (vehicle); 5/ 9 (Bosentan)). The 
hippocampus showed a greater heterogeneity with CBF appearing to be normal in 3/8 
vehicle treated animals and 5/9 Bosentan treated animals. The deep structures of the 
diencephalon e.g. the medial geniculate body appeared to have "normal" cerebral 
blood flow in a majority of animals (6/8 vehicle treated; 7/9 Bosentan treated). The 
differences in the patterns of blood flow may correspond to the variations in the 
territorial distribution of the arteries supplying the brain.
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Figure 24 Effect of Bosentan (17 |imol/kg) on 
cerebral blood flow in the cerebral cortex of animals 
subjected to transient bilateral common carotid artery 
occlusion and systemic haemorrhagic hypotension. 
CBF was measured using ^-Iodoan tipy rine  
autoradiography at 90 min. following the end of 
ischaemia. Bosentan was adm inistered as an 
intravenous bolus 10 min. prior to theinduction of 
ischaemia. Data are expressed as mean ± S.E.M 
(ml/lOOg/min) (n = 8 (vehicle); n=9 (bosentan)).
3.3.1 Cerebral Blood Flow following Bilateral Common Carotid Occlusion in 
the Rat
Cardiovascular and Respiratory Variables
Hydrogen clearance: There were no significant differences in the cardiovascular and 
respiratory variables in either the Bosentan or vehicle treated animals subjected to 
bilateral common carotid artery occlusion. The MABP at the outset was 101 ± 2  
mmHg in vehicle treated animals and 103 ± 1 mmHg in the Bosentan treated animals 
[Table 8; Figure 25]. Arterial pC02 was 39.3 ± 0.9 mmHg (vehicle group) and 39.4 ± 
0.9 mmHg (Bosentan group) at the outset of the experiment and did not vary 
significantly from these levels [Table 8]. The mean rectal temperature was 37.1 ± 
0.1 °C  (vehicle group) and 36.8 ± 0.1°C (Bosentan group) and did not vary 
significantly from these levels [Table 8]. There was a slight increase in the mean 
arterial blood pressure in animals following to bilateral common carotid artery 
occlusion. On the release of the ligatures the blood pressure returned to pre occlusion 
baseline levels. Intravenous administration of Bosentan (17 pmol/kg) had minimal 
effect on MABP.
Autoradiography: There were no significant differences in the cardiovascular and 
respiratory variables in either the Bosentan or vehicle treated animals subjected to 
bilateral common carotid artery occlusion. The mean arterial blood pressure was 106 
± 6 mmHg (Bosentan group) and 108 ± 7 mmHg (vehicle group) during the period of 
occlusion [Table 6]. Prior to start of the blood flow determination, MABP was 92 ± 2 
mmHg (Bosentan group) and 97 ± 3 mmHg (vehicle group) [Table 6]. Arterial pCC>2 
was 40.7 ± 0.4 mmHg (Bosentan group) and 40.4 ± 0.4 mmHg (vehicle group) prior to 
the start of the blood flow determination [Table 6].
Hydrogen Clearance
In the caudate nucleus, the occlusion o f the common carotid arteries 
substantially reduced cerebral blood flow to 58 ± 9% of pre occlusion baseline in
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Figure 25 Mean arterial blood pressure in animals subjected to 
transient bilateral common carotid artery occlusion (hydrogen 
clearance study). Bosentan (17 |imol/kg) was administered as 
an intravenous bolus 10 min. prior to the ligation of the 
common carotid arteries. Data are expressed as mean ± S.E.M 
(n = 6 in each group).
T
ab
le
 
8
Tr
an
sie
nt
 B
ila
te
ra
l 
Co
m
m
on
 
Ca
ro
tid
 
Ar
ter
y 
O
cc
lu
si
on
 
Ph
ys
io
lo
gi
c 
V
ar
ia
bl
es
: 
Hy
dr
og
en
 
Cl
ea
ra
nc
e 
St
ud
y
U
atu
3
esuata.
=
atH
at
at
04
>253
OJD
SCa
£
oa.
0t
5Ao
CQ
Inat
>
s
-w
Satwo
CQ
O -s
cs
a
at 
at
at
>
s3
Sat
o
CQ
a^t
2at
>
oo oo oo CN On r~~o o o o O o
o’ © o' d d d d d
+1 +1 +1 +1 +1 +1 +1 +1
00 00 On p ON On
NO NO NO NO O' NOCO CO CO CO CO CO CO CO
ON 00 00 <N O’ CSo o O o o 1—1 cs
o' d d d d d d d
+1 +1 +1 +1 +1 +1 +1 4-1
cs ON ON p —
no' NOCO CO CO CO CO CO CO CO
CO ■O’
o' d
+1 +1
00
On d
IT) NO
© d
+1 +1
cs
d d
■ 1
m r- 00 O’ NO r- in <n
44 +1 +1 +1 +1 +1 +1 4-1
o o r- CO in o mCO co CO CO CO cs CO
,""H 1
00 ■*r ^r CO CO O’ "O’ CO
+1 +1 +1 +1 +1 +1 +1 4-1
rr CO /yN in oo O’ oo'O’ r^ ^r ■O’ CO CO CO1 1 N
OJO
SCa
e,
No
uQ.
s
cat
«Ao
CQ
at
73
2
at
>
—* cs —
4-1 +1 4-1 4-1 4-1
On ON NO o OnCO CO CO CO
tT
d
+1
ONm
+1 +1
orf Onco
*—• «—1 1—t 1—1
4-1 +1 4-1 4-1 4-1 4-1 4-1 4-1
On On ON r- ON ON ON ONCO CO CO co CO CO CO CO
SCa
s3
Satt/j
o
CQ
at
73
2
at
>
—H i—i cs csO o O o o o © o
d o o d d d d d
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1
o o o o On ON o oif rr r^ CO CO "4’
K
o ,o o o o O o o o
d o d d o d d d
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1T—1 cs cs o ON■4" ■o- tt ■o- tj- CO
r-' K
s
jo
(AJ3
73o
O
atu
Cu
c#o
CAs
ato
CA
s
•mm
B
o
CO NO oOn cs
a a
oIT) 18
0 
m
in
s 
7.
40
 
±
0.
01
 
7.
38
 
±0
.0
1 
39 
±1
 
39 
±1
 
14
0 
±6
 
13
2 
± 
7 
37
.0 
±0
.1
5 
36
.9
 
±
0.
11
Da
ta 
are
 
ex
pr
es
se
d 
as 
me
an
 
± 
S.E
.M
 
(n 
= 
6 
in 
ea
ch
 
gr
ou
p)
. 
Th
ere
 
we
re 
no 
sig
ni
fic
an
t 
di
ffe
re
nc
es
 
be
tw
ee
n 
the
 
ve
hi
cle
 
and
 
Bo
se
nt
an
 
tre
at
ed
 
gr
ou
ps
 i
n 
any
 
of 
the
 
pa
ra
m
et
er
s 
m
ea
su
re
d.
Bosentan treated animals and 50 ± 7% of pre occlusion baseline in vehicle treated 
animals. The release of the carotid ligatures was followed by a small transient 
hyperaemic response in only the drug treated animals. Cerebral blood flow, in 
Bosentan treated animals, was elevated by between 111 - 125% of pre occlusion 
baseline during the first 2 hours of reperfusion [Figure 26]. This increase in blood 
flow was not statistically significant at any of the time points examined (at 90 min. P = 
0.06 (two tailed Student's r-test t = 2.09; 10 degrees of freedom)).
In the parietal cortex, the occlusion of the common carotid arteries resulted in a 
reduction of cerebral blood flow [40 ± 6 % of pre occlusion baseline (Bosentan); 41 ± 
4 % of pre occlusion baseline (vehicle)]. Cerebral blood flow was elevated in 
Bosentan treated animals (for the 2 hours post occlusion) whereas it was reduced by 5 
- 13% of pre occlusion baseline in the vehicle treated animals [Figure 26], The small 
increases in cerebral blood flow were not statistically significant (at 90 min. P= 0.32 
(two tailed Student's Mest t = 2.09; 10 degrees of freedom)).
A utoradiography
There were no significant alterations in cerebral blood flow in either the 
vehicle or the Bosentan treated animals . There were no significant increases in 
cerebral blood flow in any of the 35 regions examined [Table 9, Figure 27].
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Figure 26 (Top)Alterations in cerebral blood flow in the caudate 
nucleus, determined by hydrogen clearance, in animals subjected to 
transient bilateral common carotid artery occlusion. Bosentan (17 
fimol/kg) was administered as an intravenous bolus 10 min. prior to 
the occlusion of the carotid arteries. Data are expressed as mean ± 
S.E.M (% of pre-occlusion baseline) (n = 6 in each group).
(Bottom)Alterations in cerebral blood flow in the parietal cortex, 
determined by hydrogen clearance, in animals subjected to transient 
bilateral common carotid occlusion. Bosentan (17 p,mol/kg) was 
administered as an intravenous bolus 10 min. prior to the ligation of 
the common carotid arteries. Data are expressed as mean ± S.E.M (% 
of pre-occlusion baseline) ( n = 6 in each group).
T able 9
Transient Bilateral Common Carotid Artery Occlusion in the Rat
Region Vehicle Bosentan (17 p.mol/kg) t
Cerebellum
Cerebellar Cortex 110 ± 4 117 ± 3 1.40
Medulla /  Pons
Superior Olivary Nucleus 300 ± 25 327 + 23 0.79
Pontine gray matter 155 ± 6 173 ± 10 1.54
Mesencephalon
Inferior Colliculus 253 ± 17 273 ± 15 0.88
Superior Colliculus 200 + 8 217 ± 18 0.86
Red Nucleus 207 ± 8 210 ± 13 0.20
Substantia Nigra (pars 129 ± 4 131 ± 7 0.25
compacta)
Substantia Nigra (pars 112 ± 3 120 ± 9 0.84
reticulata)
Diencephalon
Medial Geniculate body 192 ± 18 201 ± 19 0.34
Sub Thalamic Nucleus 206 ± 9 214 ± 16 0.44
Lateral Geniculate Nucleus 146 ± 12 175 ± 24 1.08
Lateral Habenular Nucleus 237 ± 15 232 ± 11 0.27
Hypothalamus 116 ± 7 123 ± 8 0.66
Mediodorsal Thalamic Nucleus 162 ± 11 178 ± 15 0.86
Ventrolateral Thalamic Nucleus 161 ± 7 155 ± 7 0.61
Anterior Thalamic Nucleus 200 ± 20 265 + 30 1.80
Telencephalon
Visual Cortex (layer IV) 177 ± 13 201 + 17 1.12
Hippocampus (Molecular 161 ± 10 181 ± 13 1.22
Layer)
Dentate Gyrus 157 ± 7 165 ± 8 0.75
Auditory Cortex (layer IV) 219 ± 12 247 ± 26 0.98
Posterior Cingulate Cortex 239 ± 28 284 + 36 0.99
Entorhinal Cortex 177 ± 11 199 ± 13 1.29
Amygdaloid nucleus 121 ± 7 137 ± 8 1.51
Globus pallidus 102 ± 6 103 + 6 0.18
Caudate Nucleus 190 ± 6 199 ± 7 0.98
Sensory Motor Cortex (layer 176 ± 8 190 + 9 1.16
IV)
Nucleus Accumbens 167 ± 11 202 ± 14 1.97
Anterior Cingulate Cortex 222 ± 24 317 ± 53 1.63
Frontal Cortex 185 ± 7 193 ± 11 0.61
Primary Olfactory Cortex 331 ± 18 368 ± 32 1.01
Parietal Cortex 170 ± 8 197 ± 16 1.51
Myelinated Fibre Tracts
Cerebellar White Matter 60 ± 3 64 ± 2 1.11
Corpus Callosum 65 ± 2 65 ± 4 0.00
Internal Capsule 64 ± 3 60 ± 3 0.94
Genu 69 ± 2 77 + 5 1.49
Local cerebral blood flow (ml/lOOg/min) was measured at 90 min following carotid occlusion.
Data are expressed as mean ± S.E.M. (n= 9 in each group). Two tailed t-test; critical t = 2.12 (16 df) 
for P<0.05. None of the regions examined were significantly different from vehicle.
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Figure 27 Effect of Bosentan (17 pmol/kg) on cerebral blood 
flow in the cerebral cortex of animals subjected to transient 
bilateral common carotidartery occlusion. CBF was measured 
using 14C-Iodoantipyrine autoradiography at 90 min. following 
the release of the carotid ligatures.Bosentan was administered as 
an intravenous bolus 10 min. prior to the ligation of the common 
carotid arteries. Data are expressed as mean ± S.E.M 
(ml/lOOg/min) (n = 9 in each group).
□  Vehicle
|  Bosentan (17 (xmol/kg)
3.3.3 Cerebral Blood Flow following Subdural Haematoma in the Rat
Cardiovascular and Respiratory Variables
The induction of the subdural haematoma in the rat had minimal effect on the 
cardiovascular and respiratory variables in either the vehicle or Bosentan treated 
animals [Table 10].
Effect o f  Bosentan on Cerebral Blood Flow following Subdural Haematoma
The patterns of cerebral blood flow following the induction of the subdural 
haematoma were assessed by cumulative frequency distribution analysis of cerebral 
blood flow in the ipsilateral and contralateral hemispheres. This analysis was carried 
out at eight pre-selected stereotactic levels as described by Gotoh et al., 1986:
Level 1 anterior 10.50 mm; Level 2 anterior 8.92 mm; Level 3 anterior 7.19 mm; 
Level 4 anterior 6.06 mm; Level 5 anterior 5.15 mm; Level 6 anterior 3.75 mm; Level 
7 anterior 2.18 mm; Level 8 anterior 1.02 mm (co-ordinates are relative to intraural 
line).
The reductions in cerebral blood flow induced by the subdural haematoma 
were confined to the cerebral cortex [Figure 28]. The severest reductions in cerebral 
blood flow appeared to be in the cortical regions immediately underlying the 
haematoma. These observations are reflected in the cumulative frequency distribution 
curves of cerebral blood flow and area. There were no significant differences in the 
relationship between the area of tissue and cerebral blood flow in levels 1 to 8 in the 
vehicle or Bosentan treated animals [Figures 29-36]. There were no significant 
differences in any of the 25 structures examined [Table 11].
The volumes of tissue in the ipsilateral hemisphere perfused by blood flow of 
less than 20 ml/lOOg/min, 20-50 ml/lOOg/min, 50-100 ml/lOOg/min and greater than 
100 ml/lOOg/min were calculated from the frequency distribution of blood flow. There 
was a n apparent decrease in the volume of tissue perfused by less than 20 
ml/lOOg/min in the Bosentan treated animals, although, this reduction was not 
statistically significant (/ = 0.91; P = 0.8) [Figure 37]. The volumes of tissue perfused
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F igure  28 Representative autoradiograms, from a single animal, illustrating the 
marked reductions in cerebral blood flow in the cortex (white areas) and swelling of the 
ipsilateral hemisphere at 2.5 hours following subdural haematoma in the rat. Cerebral 
blood flow was measured using [14C]-Iodoantipyrine autoradiography. The stereotaxic 
co-oridnates are taken relative to the intra-aural line.
Figure 28 
Subdural H a em a to m a  in the Rat 
Alterations in Cerebral Blood Flow
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Figure 29 Effects of Bosentan (17 |imol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 |imol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction of subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 10.5 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Figure 30 Effects of Bosentan (17 p,mol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 jimol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction o f subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels o f CBF was 
determined at stereotaxic co-ordinate anterior 8.92 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Figure 31 Effects of Bosentan (17 |imol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 pmol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction o f subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 7.19 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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F igure 32 Effects o f Bosentan (17 jimol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 }imol/kg) was administered 10 min. 
prior to the induction o f the haematoma and CBF 
measured 150 min. post-induction o f subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 6.06 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Anterior 5.15 mm
70-t IPSILATERAL
60-
50-
£  40-
20-
O Vehicle
•  Bosentan (17|J.mol/kg)
10-
0J
100 150 200
CBF (ml/lOOg/min)
250
CONTRALATERAL70 “I
60-
50-
40
30
20-
10-
0-
0 50 100 250150 200
CBF (ml/lOOg/min)
Figure 33 Effects of Bosentan (17 pmol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 pmol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction of subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 5.15 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Figure 34 Effects of Bosentan (17 |imol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 (imol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction of subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 3.75 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Figure 35 Effects of Bosentan (17 |imol/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 p.mol/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction o f subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels o f CBF was 
determined at stereotaxic co-ordinate anterior 2.18 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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Figure 36 Effects of Bosentan (17 jim°l/kg) on 
cerebral blood flow, determined by frequency 
distribution analysis, following subdural haematoma. 
Bosentan (17 |im°l/kg) was administered 10 min. 
prior to the induction of the haematoma and CBF 
measured 150 min. post-induction of subdural 
haematoma. Cumulative hemispheric area of tissue 
perfused by sequentially higher levels of CBF was 
determined at stereotaxic co-ordinate anterior 1.02 
mm (relative to bregma). Areas were determined in 
the contralateral and ipsilateral hemispheres. Data are 
presented as mean ± S.E.M (n = 6 in each group). 
There were no significant differences between the 
vehicle and bosentan treated animals.
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at the other blood flow thresholds were not significantly altered in the Bosentan 
treated animals [Figure 37]. There was a marked degree of swelling in the ipsilateral 
hemisphere of both Bosentan and vehicle treated animals [Figure 38].
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Subdural Haematoma in the rat
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Figure 37 Effect of Bosentan (17 p.mol/kg) on the volume of 
tissue in the ipsilateral hemisphere perfused at pre-determined 
levels of cerebral blood flow (ml/lOOg/min) following subdural 
haematoma in the rat. Bosentan was administered intravenously 10 
min. prior to the induction of the haematoma. CBF was 
determined at 150 min. following the induction of the haematoma. 
The volume of tissue was determined at CBF levels of <20 
ml/lOOg/min (densely ischaemic), 20-50 ml/lOOg/min (moderately 
ischaemic), 50-100 ml/lOOg/min (oligaemic) and >100 
ml/lOOg/min (normal tissue). Data are expressed as mean ± S.E.M 
(n = 6 in each group). There were no significant differences 
between the vehicle and Bosentan treated animals.
Brain Swelling following Subdural Haematoma
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(2.5 hours following SDH)
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Figure 38 Effect of Bosentan (17 jimol/kg) on the swelling of the 
ipsilateral hemisphere following subdural haematoma in the rat. 
Bosentan was administered intravenously 10 min. prior to the 
induction of the haematoma. Swelling was calculated from 
the difference between the volumes of the ipsilateral and 
contralateral hemispheres. Data are expressed as mean ± S.E.M 
percent of the contralateral hemisphere (n = 6 in each group). 
There were no significant differences between the vehicle and 
Bosentan treated animals.
3.3.4 Alterations in Pial Arteriolar Calibre following Permanent MCA
Occlusion in the Cat
At the outset of the study the mean arterial blood pressure was 86 ± 2 mmHg, 
arterial pH was 7.42 ± 0.02, arterial pC02 was 31 ± 2 mmHg and arterial p02 201 ± 5 
mmHg and were maintained within these ranges for the duration of experiment.
Post MCA occlusion alterations in vascular diameter
The cranial window in these investigations exposed the ectosylvian, 
suprasylvian and parasagittal gyri. The blood supply of the ectosylvian and 
suprasylvian gyri is normally derived from the middle cerebral artery whereas the 
supply for the parasagittal gyrus is derived primarily from the anterior cerebral artery. 
In the period immediately following MCA occlusion all vessels in all the regions of 
the preparation appeared to very labile. The vessels overlying the ectosylvian and 
suprasylvian gyri appeared to undergo an initial marked dilatation of approximately 
50% of pre occlusion vessel calibre. In 4 cats, all arterioles on the ectosylvian and 
suprasylvian gyri displayed sustained marked dilatation. In 2 cats, there were 
widespread zones of sustained marked vasoconstriction (reductions in arteriolar 
calibre of more than 50% from pre-occlusion levels) in both ectosylvian and 
suprasylvian gyri. In 1 cat, there was a circumscribed zone of constriction confined to 
the ectosylvian gyrus which was labile over time; elsewhere in the ectosylvian and 
suprasylvian gyri there were marked dilatations of the pial arterioles. The onset of 
vasoconstriction varied considerably among the vessels. In a few, it was well 
developed by 10 min. after MCA occlusion; in others it began to develop 20 min. 
after MCA occlusion. Once vasoconstriction had developed, it was generally 
sustained. O f the 25 vessels in total whose calibre was followed sequentially for 30 
min. post-occlusion, 15 displayed marked sustained dilatation; 10 displayed marked 
sustained vasoconstriction. The frequency of constriction/dilatation reflects anatomical 
bias in the selection of vessels for sequential assessment. The cerebral arterioles
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overlying the parasagittal gyrus appeared to undergo a marked vasodilatation that was 
sustained for the remainder of the experimental period.
Perivascular microapplication o f Bosentan and CSF on arterioles fo llow ing  
permanent MCA occlusion
Bosentan (30 pM) was applied into the perivascular space surrounding the post 
occlusion dilated and constricted arterioles overlying the ectosylvian and suprasylvian 
gyri. Bosentan (30 |LiM) effected a marked increase in post ischaemic pial arteriolar 
calibre of all vessels, constricted and dilated (29.3 ± 5.5% from baseline ; n = 51). 
The magnitude of the responses after microapplication of Bosentan (30 pM) was 
numerically greater in the vessels displaying post occlusion constriction (68.2 ± 16.5 
% from baseline; n = 13 ; P< 0.01 for the comparison with CSF (pH 7.2) on 
constricted vessels) [Figure 39] compared to vessels displaying post occlusion 
dilatation (16 ± 8.9 % from baseline; n = 38; P < 0.01 for the comparison with CSF 
(pH 7.2) on dilated vessels) [Figure 40]. The diameter of the post occlusion dilated 
vessels increased from 175 ± 10.8 pm  to 202.2 ± 12.9 pm following the 
microapplication of Bosentan. The diameter of the post occlusion constricted vessels 
increased from 97.2 ± 14 pm to 153 ± 20.7 pm following the microapplication of 
Bosentan. The responses of the dilated arterioles to the microapplication of Bosentan 
increased as the experimental period progressed [Figure 41; Figure 42].
The perivascular microapplication of CSF (pH 7.2) on post occlusion 
constricted and dilated vessels ( overlying the ectosylvian and suprasylvian gyri) 
resulted in small consistent vasoconstrictions of the arterioles (-8.6 ± 1 %  from 
baseline ; n = 52) . The magnitude of the CSF (pH 7.2) effect was similar on the 
dilated (-8.7 ± 0.9 % from baseline; n = 44) and constricted vessels (-7.9 ± 4.7 % 
from baseline; n = 8) overlying the suprasylvian and ectosylvian gyri [Figures 39 & 
40]. There appeared to be little variation in these responses over the experimental 
period [Figure 41; Figure 42].
Bosentan (30 pM) and CSF (pH 7.2) were also applied to the vessels overlying 
the parasagittal gyrus. These vessels appeared to undergo dilatation following middle
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Focal cerebral ischaemia in the cat:
Post-Occlusion Constricted Pial Arterioles
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Figure 39 (Top) Vasomotor responses of a post-occlusion 
constricted pial arteriole to the microapplication of Bosentan 
(30 |iM). Perivascular microapplication of Bosentan elicited a 
transient increase in the calibre of the arteriole.
(Bottom) Alterations in the calibre of post-occlusion 
constricted pial arterioles. M icroapplications of CSF, 
Bosentan (30 pM) and PD155080 (30 |iM) were carried 
30-210 min. following MCA occlusion. Data are expressed as 
mean ± S.E.M percent change from pre-injection baseline (n 
= 8-13 in each group). *P<0.01 for the comparison between 
CSF and Bosentan or PD 155080
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Focal cerebral ischaemia in the cat:
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Figure 40 (Top) Vasomotor responses of a post-occlusion 
dilated pial arteriole to the microapplication of Bosentan (30 
p.M). Perivascular microapplication of bosentan elicited a 
transient increase in the calibre of the arteriole.
(Bottom) Alterations in the calibre of post-occlusion dilated 
pial arterioles. Microapplications of CSF, Bosentan (30 |iM) 
and PD 155080 (30 [iM) were carried out 30-210 min. 
following MCA occlusion. Data are expressed as mean ± 
S.E.M percent change from pre-injection baseline (n = 36-44 
in each group). *P<0.01 for the comparison between CSF and 
Bosentan or PD 155080
cerebral artery occlusion. CSF (pH 7.2) elicited a small vasoconstrictive response ( 
-7.1 ± 3% from baseline; n = 5) and the microapplication of Bosentan (30 jiM) had 
minimal effect on vessel calibre (-2.1 ± 2.1% from baseline ; n = 7).
Perivascular Microapplication o f PD155080 and CSF on arterioles fo llow ing  
permanent MCA Occlusion
The perivascular microapplication of standard CSF resulted in small consistent 
reductions in arteriolar calibre in the post-occlusion period (-8.6 ± 1.0%; n=52). The 
magnitude of the reduction in calibre produced by CSF was similar in vessels 
displaying post-ischaemic constriction and post-ischaemic dilatation. The magnitude 
o f the reduction in calibre produced by CSF was relatively constant throughout the 
post-ischaemic period evaluated [Figure 41; Figure 42].
The perivascular microapplication of PD155080 in standard CSF resulted in 
increases in arteriolar calibre in the post-occlusion period (21.2 ± 4.7%; n=44, 
p<0.001 compared to CSF). The magnitude of the increase in calibre after 
microapplication of PD155080 was numerically greater in vessels displaying post- 
ischaemic constriction compared to vessels displaying post-ischaemic dilatation 
[Figure 39; Figure 40]. The responses of arterioles to the m icroapplication to 
PD 155080 increased as the post-occlusion time period increased [Figure 41; Figure 
42].
PD 155080 (30 p.M) and CSF (pH 7.2) were also applied to the vessels 
overlying the parasagittal gyrus. These vessels appeared to undergo dilatation 
following middle cerebral artery occlusion. CSF (pH 7.2) elicited a small 
vasoconstrictive response (-7.1 ± 3% from baseline; n = 5) and the microapplication 
of PD155080 (30|iM) had minimal effect on vessel calibre ( -1.5 ± 3.1% from 
baseline ; n = 5).
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Focal cerebral ischaemia in the cat
Post-occlusion constricted pial arterioles
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F igu re  42 Responses o f individual pial arterioles to CSF, 
Bosentan (30 pM ) and PD155080 (30 pM ) at varying times 
after m iddle cerebral artery occlusion. All o f arterioles had 
displayed transient vasodilatation fo llow ed by sustained  
vasoconstriction after middle cerebral artery occlusion. Each 
point represents the response o f a single pial arteriole. The 
middle cerebral artery was occluded at tim e zero.D ata are 
expressed as percent change from pre-injection baseline.
CHAPTER 4 
DISCUSSION
The potent vasoconstrictor actions of the endothelins has led to the speculation 
of its potential role in health and disease. The identification of endothelin receptor 
subtypes and the subsequent development of endothelin receptor antagonist has greatly 
facilitated the understanding of the role of the endothelins. The role of the endothelins 
in the regulation of vascular tone was the comer stone of research, however, recent 
evidence has demonstrated that the endothelins may have a role as spasmogens, 
growth factors and as neuromodulators.
Since the primary publication describing the structure and functions of the 
endothelins, there have been an rapid developments describing the role of the 
endothelins in physiology and pathophysiology and the therapeutic potential of the 
endothelin receptor antagonists.
In the rabbit basilar artery in vitro, the ET-1 induced contractions were 
resistant to antagonism by either Bosentan or BQ-123. In contrast, the ET-3 induced 
contractions were markedly antagonised by BQ-123. The activation of endothelin ETb 
receptors demonstrated no significant contractile effect. These results suggested that 
the ET-1 induced contractions were mediated by an 'atypical' endothelin ETa receptor. 
The in situ investigations in the cat demonstrated the presence of vasoconstrictor 
endothelin ETa  receptors and dilator endothelin ETb receptors. The results in this 
thesis indicated that in addition to species differences in the profiles of endothelin 
receptors, there may be variations in the distribution of endothelin receptors across the 
cerebrovascular tree (from conduit vessels to cerebral resistance arterioles). The 
differences in the potency of endothelin receptors antagonist against ET-1/ET-3 in the 
rabbit basilar artery suggests that the current classification of endothelin receptors may 
not adequately describe the responses of the endothelin receptor agonists.
The investigations to evaluate the efficacy of Bosentan demonstrated that 
Bosentan antagonised the vasoconstriction induced by exogenous ET-1 in feline 
cerebral resistance arterioles. The ET-1 induced vasoconstriction was significantly 
attenuated following the intravenous administration of Bosentan. The intravenous 
administration of ETa receptor antagonist PD 155080 attenuated the vasoconstrictive 
effect of exogenous ET-1. In contrast, the intravenous administration of the peptide
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antagonist PD 145065 had no significant effect on the ET-1 induced vasoconstriction 
in feline cerebral arterioles. The present thesis contrasted the ability of the non-peptide 
endothelin receptor antagonists and inability of the peptide endothelin receptor 
antagonists to gain access to the abluminal surface of cerebral resistance arterioles 
following systemic administration. The investigation of the pathophysiologic role of 
the endothelins requires the use of non-peptide endothelin receptor antagonists.
Post-ischaemic cerebral hypoperfusion was observed following severe 
transient global cerebral ischaemia. The intravenous administration of Bosentan failed 
to alter post-ischaemic hypoperfusion assessed by hydrogen clearance and 
Iodoantipyrine autoradiography. No hypoperfusion was observed following moderate 
transient global cerebral ischaemia. The inability of Bosentan to alleviate post- 
ischaemic hypoperfusion following severe transient global cerebral ischaemia 
indicates that the endothelins may play a minor role in the maintenance of 
hypoperfusion. The reductions in hippocampal CA1 neuronal damage by endothelin 
receptor antagonists indicates that the endothelins may play a role in the development 
of neuronal damage.
Cerebrocortical regions underlying the subdural haematoma displayed a 
profound reduction in cerebral blood flow. There was an increase in cerebral oedema 
in the cerebral cortex underlying the haematoma. Bosentan failed to alter cerebral 
blood flow or brain swelling following subdural haematoma in the rat. The failure of 
an endothelin receptor antagonist to demonstrate efficacy suggests that the endothelins 
may have a minor role in the reductions in cerebral blood flow associated with a 
subdural haematoma. However, the small sample size prevents us from conclusively 
excluding a role for the endothelins in the mediation of the neuronal damage. The 
proven efficacy of the endothelin receptor antagonist in experimental subarachnoid 
haemorrhage suggests that the endothelins may have a delayed role following 
haemorrhagic injury in the brain.
The non-peptide endothelin ETa/ETb receptor antagonist Bosentan increased 
the post-ischaemic vascular diameter of cerebral resistance arterioles following 
permanent occlusion of the MCA in the cat. The magnitude of the increases in post­
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occlusion vascular diameter with the non-peptide endothelin ETa receptor antagonist 
PD 155080 was similar to Bosentan. These investigations demonstrated the existence 
o f an increased endothelin mediated tone in cerebral resistance vessels in the 
ischaemic penumbra. The demonstration of these effects provides a basis for 
examining the therapeutic role of the endothelin receptor antagonists in the regulation 
o f penumbral cerebral perfusion and ischaemic neuronal damage following a focal 
cerebral ischaemia.
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4.1 ENDOTHELIN RECEPTORS AND ENDOTHELIN RECEPTOR  
ANTAGONISTS IN THE CEREBROVASCULATURE
4.1.1 Endothelin Receptors
In contrast to the vast literature on the characterisation of endothelin receptors 
in the peripheral vasculature, there is a paucity of information concerning the 
endothelin receptors in the cerebrovasculature. A number of investigators have 
characterised the endothelin receptors in the major cerebral arteries (spinal, basilar, 
middle cerebral) in different species [Adner et al., 1993; Kitazono et al., 1993; Salom 
et al., 1993; Feger et al., 1994; Willette et al., 1994; Schilling et al., 1995]. 
Investigations in the peripheral vasculature indicate that the endothelin ETa receptor is 
the predominant receptor mediating ET-1 induced vasoconstrictions [Warner et al., 
1993; Masaki et al., 1994; Rubanyi & Polokoff, 1994]. The role of endothelin ETb 
receptors is more controversial with endothelin ETb receptor mediated vasodilatation 
and vasoconstriction reported in different vascular beds [Clozel et al., 1992; Sumner et 
al., 1992; Shettyet al., 1993].
In vitro investigations
The present investigations examined the effects o f endothelin receptor 
activation in the rabbit basilar artery. The receptor characterisation of the endothelin 
receptor subtypes in the middle cerebral arteries, basilar arteries and the spinal arteries 
from the goat, guinea pig, rat and dog have indicated that the contractile responses to 
the endothelins are mediated by the endothelin ETa receptors (similar to the effects 
described in most peripheral vessels) (see Table 12). Endothelin ETb receptor 
mediated vasodilatation has been described in in vitro investigations [Rubanyi & 
Polokoff, 1994].
In the present investigations the combined endothelin ETa /ET b receptor 
antagonist Bosentan and the endothelin ETa receptor selective antagonist BQ-123 
demonstrated rightward shifts of the endothelin-1 concentration response curves. 
These responses indicate that the antagonism elicited by these receptors is competitive
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in nature although the pA2 values, 5.1 and 5.3 respectively, suggested that the 
contractile responses of ET-1 were resistant to these antagonists. The pA2 values for 
Bosentan and BQ-123 in the present investigations are at variance with the values 
obtained in the peripheral vasculature (100 fold) and in cerebral vessels [Ihara et al., 
1992; Feger et al., 1994; Rubanyi & Polokoff, 1994], The characterisation of 
endothelin receptors in cerebral vessels in other species (goat, rat, guinea pig, dog) 
have indicated that the vasoconstrictor actions of the endothelins are mediated by the 
endothelin ETa receptors (see Table 13). The potency of the endothelin ETa receptor 
antagonists used in the investigations are comparable to the potencies obtained in the 
peripheral vasculature. The rabbit basilar artery was 100 fold less sensitive to ET-3 
mediated vasoconstrictions compared to ET-1, indicating an endothelin ETa receptor 
mediated contractile response. BQ-123 was more potent in antagonising the contractile 
actions of ET-3 than ET-1. The increased potency of endothelin receptor antagonist in 
attenuating the responses of ET-3 compared to ET-1 have been observed in the rat vas 
deferens [Eglezos et al., 1993]. In the rabbit basilar artery, the endothelin ETb receptor 
agonist BQ-3020 elicited contractions of reduced magnitude and sensitivity compared 
to ET-1. The results obtained in the present studies are in contrast to the observations 
in a rabbit model of subarachnoid haemorrhage where the combined endothelin 
ETa /ETb receptor antagonist PD 145065 demonstrated greater efficacy in attenuating 
vasospasm than the endothelin ETa antagonist BQ-610 [Zuccarello et al., 1994].
The segments of rabbit basilar artery used in the investigations were denuded 
of the endothelial layer. This was confirmed by the absence of any significant 
relaxation following the addition of 10 |iM acetylcholine. The presence of endothelin 
ETb receptors in the rabbit basilar artery were examined using the selective receptor 
agonist BQ-3020. The magnitude of the contractile response to BQ-3020 was 
substantially less than the contractile responses elicited by either ET-1 or ET-3. These 
observations indicated that in the rabbit basilar artery the endothelin mediated 
constrictions were mediated primarily by the endothelin ETa receptor. However, the 
differential potencies of BQ-123 in antagonising ET-1 or ET-3 suggests that the 
receptor may be a subtype of the endothelin ETa receptor [Bax & Saxena, 1994].
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The results obtained in the rabbit basilar artery indicate that the contractile 
responses effected by ET-1 and ET-3 may be mediated by an endothelin receptor that 
does not conform to current classification of endothelin ETa/ETb receptors [Bax & 
Saxena, 1994 ]. An ET-3 preferring receptor, putatively called the endothelin ETc 
receptor has been described in the amphibian [Kame et al., 1993]. There has been a 
report of a receptor specific for ET-3 in bovine cultured endothelial cells although the 
significance of such a receptor is yet to be identified [Morita et al., 1992]. Unlike the 
endothelin ETa and endothelin ETb receptors, the gene cloning the endothelin ETc 
receptor has not been isolated in mammalian species. Recently, there have been 
reports that the prolonged incubation of vascular segments in vitro with the endothelin 
receptor antagonists results in the degradation of the antagonists [Wu Wong et al., 
1995].
In the periphery, tissues where the rank order of potencies of the endothelin 
receptor agonists has suggested the presence of an endothelin ETa receptor (ET-1 
more potent than ET-3) [Rubanyi & Polokoff, 1994], The antagonism of the ET-3 
mediated constrictions were greater than the ET-1 mediated constrictions at these 
receptors with BQ-123 in the rat aorta and jugular vein [Sumner et al., 1992]. In the 
cerebral circulation, similar responses have been observed in the goat middle cerebral 
arteries where BQ-123 was more potent at antagonising the sarafotoxin 6b mediated 
constrictions than the ET-1 mediated vasoconstrictions [Salom et al., 1995]. The rank 
order of potencies of the sarafotoxins and the endothelins at the endothelin receptors 
indicates that sarafotoxin 6b is less potent at the endothelin ETa  receptors than ET-1 
[Rubanyi & Polokoff, 1994], The existence of atypical responses in tissues previously 
thought to contain endothelin ETb receptors has also been demonstrated (see Table 
13).
There are no clear explanations for the difference in the potency of BQ-123 in 
antagonising ET-1 or ET-3 in the rabbit basilar artery. The potency of BQ-123 as 
antagonist for the ET-1 mediated responses has been demonstrated in the rat basilar 
artery [Feger et al., 1994]. The investigations in the rat basilar artery indicated the 
presence of constrictor ETa receptors and vasodilator ETb receptors [Feger et al.,
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1994; Schilling et al., 1995]. In the present investigations the endothelin-1 
constriction appears to be mediated by E T a  receptors but the reduced potency of the 
BQ-123 suggests that there may be subtypes of endothelin receptors in the rabbit 
basilar artery. The hypotheses that have been explored include the possibility that the 
binding of ET-3 to the endothelin ETa receptor may be more reversible than the 
binding of ET-1 to same receptor and, thus, BQ-123 is more potent at antagonising the 
ET-3 mediated constrictions than the ET-1 mediated effects [Battistini et al., 1994; Wu 
Wong et al., 1994 &1995], Although one cannot discount the possibility of there being 
differences in the binding kinetics of the endothelin receptor agonists and antagonists, 
there is the possibility that the ET-1 and ET-3 may be exerting their effects via 
subtypes of the endothelin E T a  receptor and there may be differences in the affinities 
of the putative receptor subtypes for ET-1, ET-3 and BQ-123.
In vivo investigations
The cerebral resistance arterioles play the major role in the regulation of 
cerebral blood flow to the brain and there have been few investigations examining the 
effects of endothelin receptor activation in cerebral resistance arterioles in vivo. The 
present investigations have demonstrated that endothelin ETa receptors mediate 
vasoconstriction while endothelin ETb receptors mediate vasodilatation in feline small 
cerebral resistance arterioles in vivo. The failure of the intracarotid infusion o f BQ- 
3020 to alter cerebral arteriolar calibre indicates that the endothelin ETb receptors 
may not be readily accessible by intraluminal endothelin receptor agonists which are 
peptide analogues.
The role of endogenous endothelin in the regulation of vascular tone in 
peripheral and cerebral blood vessels has been suggested [Yoshimoto et al., 1990; 
Haynes & Webb, 1994]. In feline peripheral blood vessels, an absence o f basal 
endothelin mediated tone has been demonstrated [Ekelund et al., 1993; Ekelund et al., 
1994; Ekelund et al., 1995]. In the current investigations the adventitial 
microapplication of the endothelin ETa receptor antagonist BQ-123 had minimal 
effect of the calibre of the pial arterioles. The perivascular microapplication of other
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endothelin receptor antagonists, e.g. Bosentan, PD 145065, PD 155080, have 
demonstrated similar effects indicating that under the present experimental conditions 
there is minimal endothelin mediated tone in the cerebral resistance arterioles. These 
observations contrast with the reports of Yoshimoto et al. (1990) which suggest that 
there is a basal production of endothelin by cerebrovascular endothelial cells in 
culture, and those of Haynes and Webb (1994) which indicate the presence of basal 
endothelin mediated tone in human forearm vessels. The adventitial co-application of 
ET-1 with increasing concentrations of BQ-123 demonstrates a dose dependent 
attenuation of the ET-1 induced vasoconstriction. The estimated IC50 for BQ-123 
determined from these experiments is 0.7 jiM and this is comparable to the values 
obtained for this antagonist in other tissues [Ihara et al., 1991]. In feline skeletal 
muscle, the constriction of resistance arterioles is mediated by endothelin E T a  
receptors while endothelin-1 mediated vasodilatation is mediated by endothelin ETB 
receptors [Ekelund et al., 1993; Ekelund et al., 1994]. In cerebral resistance arterioles 
it appears that the vasoconstrictor effect of ET-1 is mediated primarily via endothelin 
E T a  receptors. The ability of BQ-123 to attenuate the effects o f exogenous ET-1 in 
cerebral resistance arterioles is similar to the responses obtained with the combined 
endothelin ETa/ETb receptor antagonists Bosentan and PD 145065 and endothelin 
E T a  receptor antagonist PD 155080.
Previous investigations of Armstead et al. (1989) in the piglet and Faraci 
(1989) in the rat indicated the existence of endothelin mediated vasodilatation in 
cerebral resistance arterioles. However, the absence of receptor selective agonist and 
antagonist prevented the characterisation of the endothelin receptor subtypes. In the 
present investigations, the adventitial microapplication o f BQ-3020 effected a dose 
dependent vasodilatation of cerebral resistance arterioles in vivo . These observations 
are in agreement with reports indicating that endothelin ETb receptors mediate 
vasodilatation in the rat basilar artery in vivo and in vitro [Kitazono et al., 1993; Feger 
et al., 1994; Schilling et. al., 1995]. Preliminary investigations have demonstrated that 
the BQ-3020 mediated vasodilatation can be attenuated by the combined endothelin 
ETa/ETb receptor antagonist Bosentan (T.R. Patel unpublished observations)
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suggesting that the endothelin ETbi receptor subtype may mediate vasodilatation in 
feline cerebral arterioles [Masaki et al., 1994]. The cranial window technique used in 
the present investigations allows us to examine cerebral resistance arterioles (40-350 
|im) under normal physiologic and neurogenic control. This in situ preparation 
facilitates the observation of vasodilator responses of cerebral arterioles without pre­
constriction. Previous investigations have demonstrated that the responses of cerebral 
resistance arterioles in vivo, to vasodilator or vasoconstrictor agents, may be dependent 
on the pre-injection calibre of arterioles in vivo [Kuschinsky & Wahl, 1975; Harper 
& MacKenzie, 1977; McCulloch & Edvinsson, 1980]. The present investigations have 
demonstrated that cerebral arterioles less than 100 fim elicited a greater vasodilator 
response following the adventitial application of BQ-3020. In the present study we 
have been unable to demonstrate a similar correlation following the adventitial 
application of ET-1 (10 nM). The absence of a correlation with ET-1 may be due to 
the small number of arterioles examined. We have re-examined the responses of 
cerebral arterioles to ET-1 from the present study and those conducted previously and 
can demonstrate a significant correlation between the pre-injection calibre of arterioles 
and response to adventitial ET-1 [Figure 43]. The responses of arterioles to the 
microapplication of CSF was not dependent on the calibre of the arterioles [Figure 43].
Intracarotid infusion of BQ-3020 failed to demonstrate a significant alteration 
in arteriolar calibre of cerebral resistance vessels. A distinguishing feature of the 
cerebral circulation is the blood-brain barrier. The blood-brain barrier can prevent the 
access of molecules, e.g. peptides, to the adventitial surface of cerebral arterioles 
[Ermisch et al., 1993]. Endothelin receptor agonists or antagonists targeted at the 
cerebrovasculature would have to gain access to the abluminal surface of cerebral 
arterioles in order to exert their effects. BQ-3020 with its peptide structure would not 
be expected to penetrate the blood-brain barrier and gain access to the abluminal 
surface of cerebral vessels. Previous investigations using intraluminal administration 
o f ET-1 have demonstrated alterations in cerebral blood flow and cerebral blood 
volume [Kobari et al., 1994a; Willette et al., 1990]. The investigations of Willette and 
colleagues (1990a, 1990b) demonstrated alterations in cerebral blood flow following
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Figure 43 The dependence of the pial arteriolar responses elicited by 
CSF (pH 7.2) and endothelin-1 (10 nM) on the calibre of arterioles 
examined. Pial arteriolar diameter was determined prior to the 
adventitial microapplication of CSF or endothelin-1. The arteriolar 
responses are expressed as the percent change from pre-injection 
baseline. There is no significant association between the arteriolar 
responses to CSF and the pre-injection calibre. Post hoc analysis of 
these responses have demonstrated significant association between the 
arteriolar response to endothelin-1 and pre-injection calibre (r2 =0.11; 
P <0.01). (see text for references).
the intravenous or intracerebroventricular administration of endothelin-1. The effects 
of low doses of endothelin administered elicited a hypotensive response and the 
increases in CBF observed would be related to a autoregulatory response. The 
intracerebroventricular administration of ET-1 may have the effect of inducing a local 
ischaemia at the site of action and may explain the reductions in CBF. The 
intraluminal infusions of ET-1 induces systemic hypertension, and hypertension per se 
produces alterations in cerebral arteriolar calibre as part of the cerebral autoregulatory 
response. ET-1 can also activate endothelin ETa and endothelin ETb receptors and 
for these reasons it was not examined in the present investigations. The failure of 
intracarotid infusions, in contrast to the adventitial application, of BQ-3020 to alter 
arteriolar calibre indicates that the endothelin ETb receptors may be located on the 
abluminal surface of cerebral resistance arterioles. In the present investigations, 
assuming a carotid blood flow of 5 ml/min., we estimate that the intravascular 
concentration of BQ-3020 (with these infusion rates) would be in the range 0.1-100 
nM. The adventitial microapplication of these concentrations of BQ-3020 elicit a 
dilatation of cerebral resistance arterioles. The failure of the intracarotid infusion of 
BQ-3020 to alter pial arteriolar calibre is at variance with the observations of Kobari et 
al. (1994b). The differences in the observations could be the result of the different 
methodological approaches employed in the two investigations. Kobari and colleagues 
(1994b) have used alterations in cerebral blood volume as an indicator of cerebral 
vasodilatation. Cerebral blood volume is a measure o f cerebral capacitance (a 
combination of arterial, arteriolar, capillary and venous diameters) and alterations in 
cerebral capacitance will not necessarily reflect increases in cerebral blood flow. In the 
present investigations, BQ-3020 was administered as a continuous infusion while 
Kobari and colleagues administered the agents as a bolus [Kobari et al., 1994b]. The 
alterations in cerebral blood volume reported may be the result of an injection artefact 
[Kobari et al., 1994b]. Evidence from in situ investigations have indicated the 
susceptibility of endothelin receptors to desensitisation [Hollenberg et al., 1993]. The 
initial intracarotid infusions of low doses of BQ-3020 could have resulted in the 
desensitisation of endothelin ETb receptors in the cerebral arterioles. The infusion of
121
500 pmol/min. of BQ-3020 resulted in a transient reduction in MABP indicating that 
the endothelin ETb receptors in the peripheral vasculature were activated.
In the rat basilar artery, endothelium dependent vasodilatation has been 
demonstrated following activation of endothelin ETg receptors [Feger et al., 1994; 
Schilling et al., 1995]. The vasodilatation in the rat basilar artery is mediated by nitric 
oxide [Feger et al., 1994; Schilling et al., 1995]. The mediation of the dilator response 
following the activation of endothelin ETb receptors is unknown but a functional link 
to either nitric oxide or prostacyclin has been suggested [Hirata et al., 1993]. The 
present investigations do not discount the existence of endothelin ETb receptors on the 
luminal surface of endothelial cells or on cerebrovascular smooth muscle since 
northern blot analysis and functional studies on human blood vessels have indicated 
the existence of receptors without a functional link to either nitric oxide or 
prostacyclin [Luscher, 1993; Seo et al., 1994].
The cat has been used for investigating the role of the endothelins in the 
pathophysiology of focal cerebral ischaemia. The present investigations indicate that 
the location of the endothelin ETb receptors is on the abluminal surface of cerebral 
resistance arterioles and that the endothelin E T b receptors mediate vasodilatation. The 
dilatation of cerebral resistance arterioles would result in an increase in cerebral blood 
flow. The ability of pharmacologic agents to increase cerebral blood flow would have 
beneficial effects in conditions of impaired cerebral blood flow e.g. stroke. In contrast 
to the description of endothelin E T b receptor mediated vasoconstriction in peripheral 
tissues, similar responses have not been observed in cerebral arteries or arterioles in 
vitro or in situ [Table 12; Table 14]. The present investigations indicate a 
vasoconstrictor action for endothelin E T a receptors in feline cerebral resistance 
arterioles. The present investigations suggest that antagonists selective for the 
endothelin ETa receptors may be of greater utility than the combined endothelin 
ETa/ETb receptor antagonists in cerebrovascular investigations.
Endothelin Receptors in the Central Nervous System
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The presence of endothelin-1 and endothelin-3 has been demonstrated in the 
brains of a variety of species [Gulati, 1995], Endothelin immunoreactivity has been 
demonstrated in neurones and glial cells in numerous brain regions including the 
paraventricular nuclei, supraoptic nuclei, hypothalamus, pituitary gland, hippocampus 
and the spinal cord neurones [Matsumoto et al., 1989; Yoshizawa et al., 1990; Shinmi 
et al., 1989a; Shinmi et al., 1989b; Giaid et al., 1989]. The regional distribution of 
endothelin-1 mRNA and immunoreactivity has indicated high concentrations in the 
cerebral cortices, hippocampus, hypothalamus cerebellar regions and the spinal cord in 
the rat and human brain [Matsumoto et al., 1989; Yoshizawa et al., 1990; Shinmi et 
al., 1989a; Shinmi et al., 1989b; Giaid et al., 1989; Lee et al., 1990]. The co­
localisation of endothelin converting enzyme with the endothelin-1 mRNA and 
immunoreactivity in human and rat brain suggests a potential role o f the endothelins 
as neuromodulatory agents [Gulati, 1995].
Endothelin receptor binding sites have been described in glial cells (astrocytes) 
and neurones (e.g. dorsal root ganglia) [Niwa et al., 1992; Jones et al., 1989; Giaid et 
al., 1989; MacCumber et al., 1990; Greenberg et al., 1992; Koseki et al., 1989]. 
Binding studies with radiolabelled endothelin-1 have indicated the presence of binding 
sites in the cerebellum, cerebral cortex, dentate gyrus in the hippocampus and in 
nuclei in the brainstem [Jones et al., 1989; Kurihara et al., 1990; Nambi et al., 1990], 
The indications are that the predominant receptor subtype in the cerebral cortex, 
cerebellum and astrocytes is the endothelin ETb receptor [MacCumber et al., 1990; 
Nambi et al., 1990; Vigne et al., 1991]. The presence of ET mRNA has been described 
in glial cells (astrocytes) and neurones (e.g. dorsal root ganglia) [Niwa et al., 1992; 
Jones et al., 1989; Giaid et al., 1989; MacCumber et al., 1990; Greenberg et al., 1992; 
Koseki et al., 1989]. Early investigations provided evidence for ET mRNA in cells of 
the hypothalamus, striatum and also the spinal cord [Giaid et al., 1989; Lee et al., 
1990]. Secretion of endothelin-1 by astrocytes has been reported and can be stimulated 
by thrombin and platelet derived growth factor (PDGF) [MacCumber et al., 1990; 
Lysko et al., 1991; Fuxe et al., 1992; Marsault et al., 1990; Ehrenreich et al., 1991; 
Federici et al., 1995; Levin et al., 1992]. The role of endothelins in the CNS is unclear,
but, stimulation of immediate early gene expression (c-Fos) and nerve growth factor in 
astrocytes indicates that these peptides may play a role in the regeneration o f nerve 
cells following a cerebrovascular injury [Ladenheim et al., 1993].
A number of investigators have performed functional studies to examine the 
effects of exogenous endothelins in the brain. Injections of endothelin-1 into the 
cistema magna or micro injections into discrete brainstem nuclei in the rat have elicited 
marked alterations in cardiovascular parameters with systemic hypertension and 
bradycardia being the most prominent [Siren & Feuerstein, 1989; Ferguson & Smith, 
1990; Macrae et al., 1991]. The measurement of cerebral blood flow in the rat 
brainstem following an intracistemal injection of endothelin-1 demonstrated a marked 
reduction in cerebral blood flow to pathological levels [Macrae et al., 1991]. Other 
investigations have indicated that the endothelins may play a role as neuromodulators 
in the locomotor system or in the release o f pituitary hormones [Gross et al., 1994; 
Gross et al., 1993]. The intracerebroventricular injection of endothelin-1 elicited 
behavioural effects such as barrel rolling and oculo-clonic seizures [Gross et al., 1994; 
Gross et al., 1993] and are associated with alterations in cerebral blood flow and 
cerebral glucose utilisation in peri-ventricular regions and areas distal to the site of 
injection [Gross et al., 1994; Gross et al., 1993]. These observations suggest a role for 
the endothelins as neuromodulators or neuropeptides [Gross et al., 1994; Berrino et al.,
1994]. The alterations in CBF and glucose utilisation were attenuated by the calcium 
channel and endothelin antagonists. However, the effects of endothelin receptor 
antagonists per se on neuronal function has not been examined.
The demonstration of high density of endothelin immunoreactivity and binding 
sites in the pituitary and hypothalamus suggests a role for the endothelins in the 
modulation of pituitary hormone release [Koseki et al., 1989; Nambi et al., 1990; Niwa 
et al., 1991]. The intravenous and intracerebroventricular administration of ET-1 and 
ET-3 has been dem onstrated to increase the plasm a concentrations o f 
adrenocorticotrophic hormone and inhibit the release of prolactin. There has been 
speculation on a role for ET-1 in stimulating the release of growth hormone, lutenising 
hormone, follicle stimulating hormone and gonadotropin releasing hormone [Samson
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et al., 1990]. Recent investigations have demonstrated the ability of ET-1 to increase 
plasma concentrations of arginine vasopressin and atrial natriuretic peptide. The 
mechanism of action of ET-1 in eliciting these increases is unclear.
The role o f the endothelins in the central control of cardiovascular and 
respiratory function has been an area of much interest from a therapeutic standpoint 
[Ferguson et al., 1995]. The intracistemal administration of ET-1 elicits a rise in mean 
arterial blood pressure and increased heart rate [Ferguson et al., 1995; Gulati et al.,
1995]. These observations have been combined with electrophysiologic studies which 
have demonstrated that the centrally administered ET-1 increases the neuronal firing in 
areas of the medulla that are specifically linked to the control of cardiovascular 
function [Ferguson et al., 1995; Gulati et al., 1995]. The conclusions drawn from these 
investigations suggested a role for the endothelins as neuromodulator. The direct 
administration of the endothelins into the cistema magna resulted in brain stem 
ischaemia and the reflex response increased the blood pressure and heart rate [Macrae 
et al., 1991]. Similarly, direct injection of ET-1 into discrete cardiovascular control 
nuclei in the brain would result in local ischaemia. The failure of a brain penetrating 
endothelin receptor antagonist to alter cerebral blood flow or blood pressure in the rat 
suggests that the control of basal CBF or blood pressure may not have a major 
endothelin component [McAuley et al., 1994]
Concluding Remarks
The in vitro and in vivo investigations conducted in the course of the present 
thesis have indicated that in the rabbit basilar artery and the feline cerebral resistance 
arterioles, the endothelin receptor mediated constrictions are mediated by endothelin 
E T a receptors. The observations are in broad agreement from the studies carried out in 
peripheral vascular tissues where a similar receptor profile was observed. Recent data 
from receptor binding investigations have demonstrated the presence of endothelin 
E T a receptors on the medial layer of the anterior cerebral artery in the rat [De Oliveira 
et al., 1995]. However, the species differences in the distribution of receptors in the
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various vascular beds precludes the direct extrapolation of information from one 
species to the other.
The studies carried out in the course of the present thesis, have utilised three 
different species, namely the rat, the cat and the rabbit. The investigations and results 
obtained are limited by the techniques used to classify the receptors in the species 
used. A critical appraisal of the in vitro and in situ techniques with respect to the 
quality of information that can be obtained from these techniques has been discussed 
in the following section.
A criticism of the attempts to characterise the receptors in cerebral vessels is 
the use of different species and different techniques to evaluate the functions of 
endothelin receptors in the cerebrovasculature. The studies conducted in the larger 
cerebral arteries, e.g. the middle cerebral artery, and basilar artery in the rat have 
indicated that the vasoconstriction is mediated by endothelin ETa  receptors while the 
existence of endothelin ETb receptors has been demonstrated on the abluminal surface 
and on the vascular endothelium (Table 13). The receptors mediating endothelin 
constriction and dilatation are broadly similar in peripheral tissue and the cerebral 
blood vessels across the species. Recent evidence has indicated that there may be a 
population of receptors that do not conform to the normal classification of endothelin 
receptors (see Table 13). The receptors mediating vasoconstriction in the rabbit basilar 
artery may indeed belong to this group.
The identification of the endothelin receptor subtypes in the cerebrovasculature 
could have been approached using receptor binding techniques as has been used by 
some authors [Pierre & Davenport, 1995; Davenport & Maguire, 1994], However, 
identification of the endothelin receptors in the cerebrovasculature would be limited by 
the size of vessels and the functional significance of endothelin receptors in the 
vessels. The existence of endothelin receptor binding sites is not a clear indication that 
the those receptors would be functionally linked to the signal transduction mechanisms 
[Luscher, 1993; Seo et al., 1994].
The application of exogenous endothelin on cerebral vessels can decrease 
cerebral blood flow to levels that induce ischaemic pathology [Macrae et al., 1993;
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Fuxe et al., 1992]. These observations have fuelled an increasing interest in the role of 
endothelins in cerebrovascular pathology. Increases in plasma and tissue endothelin 
levels have been observed following subarachnoid haemorrhage and ischaemic stroke 
in experimental models and humans [Ziv et al., 1992; Suzuki et al., 1992; Duverger et 
al., 1992, Barone et al., 1994; Bian et al., 1994]. The recent development of endothelin 
receptor selective antagonists has seen these compounds investigated in a variety of 
cerebrovascular pathologies [Clozel and Watanabe, 1992; Clozel et al., 1993; Nirei et 
al., 1993; McAuley et al., 1994; Ohlstein et al., 1994; Zuccarello et al., 1994], The 
stimulation of endothelin ETb receptors, either by receptor agonism or selective 
antagonism of endothelin ETa  receptors, would be expected to increase cerebral blood 
flow. The availability of brain penetrating endothelin ETa  receptor antagonists would 
be of considerable value in manipulating the vasoconstrictor action of endothelins in 
ischaemic injury [Feuerstein et al., 1994; Ohlstein et al., 1994].
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Critical appraisal of in vitro and in situ techniques used for investigating responses 
o f cerebral vessels
An understanding of the responses of cerebral vessels to vasodilator and 
vasoconstrictor agents is a fundamental part of cerebrovascular research. There have 
been descriptions of the existence of perivascular nerves containing a range o f 
neurotransmitters and neuropeptides [see section 1.1.3]. A role for the vascular 
endothelium in the regulation of cerebrovascular tone has also been described [see 
section 1.1.3]. A complex interaction between the transmitters and peptides may exist 
under physiologic or pathophysiologic conditions. The use of in situ and in vivo 
techniques is essential for the identification of the role of the substances in the 
regulation of cerebrovascular tone under normal and pathophysiologic conditions.
The vessels o f the cerebral circulation differ in their m orphologic 
characteristics from the vessels in the peripheral circulation. The inflow arteries such 
as the basilar artery contain approximately 8-10 smooth muscle cell layers. The 
posterior cerebral artery, middle cerebral artery and the anterior cerebral artery contain 
5-6 smooth muscle cells on the circumference. The pial arteries and arterioles on the 
cortical surface contain 2-3 vascular smooth muscle layers on the circumference while 
the penetrating arterioles contain 1-2 vascular smooth muscle cell layers. The vascular 
endothelium in the cerebral circulation comprises the blood-brain barrier [see section
1.1.2 for description].
The differences in the morphology of the cerebral vessels has led to the 
development of two main techniques for cerebrovascular investigations. In vitro 
techniques utilise isolated cerebral blood vessels. The in situ techniques are used to 
examine the cerebral blood vessels in their normal physiologic milieu.
In vitro techniques
The in vitro techniques used to examine the vasomotor responses o f cerebral 
vessels to the endothelins have used ring segments of cerebral vessels, helical strips 
and cannulation of cerebral vessels [e.g. Saito et al., 1989; Saito et al., 1991; Feger et
128
al., 1994; Salom et al., 1995; Schilling et al., 1995]. The ring segments are the most 
commonly used preparation. The cerebral vessels are divided into rings and metal 
probes are inserted through the lumen of the segment. One of the probes is secured to 
the organ bath while the other probe is attached to a tension transducer to measure 
isometric force. Investigations have been performed using helical strips of the cerebral 
vessels and the responses of the strips are measured using tension transducers. The use 
of helical strips for examining the vasomotor responses has a disadvantage because the 
width and pitch of the strip will affect the responsiveness. More recent developments 
have seen the use of cannulations of cerebral vessels to measure vasomotor responses 
[Saito et al., 1991]. The two ends of the dissected vessel are cannulated with glass 
cannulae and the vessel perfused at a constant pressure.
There are a number of advantages of the use of in vitro techniques for 
investigating vasomotor responses of cerebral vessels. The use of in vivo techniques 
invariably involves the use of anaesthetic agents, such as the barbiturates and 
halothane, and these agents have been shown to affect vasomotor reactivity [Fitch et 
al., 1983; Bonvento et al., 1994]. The examination of cerebral vessels in vitro allows 
the examination of vasomotor responses in the absence of anaesthetic effects. The use 
o f organ baths permits a greater control of the surrounding milieu than would be 
achieved in the in vivo situation. The effect of hypoxia, hypocapnia, hypercapnia and 
pH on the vasomotor responses of cerebral vessels has been well documented [see 
Edvinsson et al., 1993 for details; Kuschinsky et al., 1972; McCulloch et al., 1982]. 
The in vitro techniques also allow the examination of the vasomotor effects of cerebral 
vessels isolated from a number of species. The use of cerebral vessels such as the 
middle cerebral artery or basilar artery from different species facilitates the 
comparisons between the species for that vessel. Additionally there is evidence to 
indicate the existence of multiple receptors and receptor subtypes on cerebral vessels 
[Edvinsson & Owman, 1974; Feger et al., 1994]. The use of receptor antagonists can 
aid the isolation of receptor subtype under investigation, e.g. 13-adrenoceptor 
antagonists for examining the effects of a-adrenoceptor activation. The interactions
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between the neurotransmitters and their receptors present in cerebral vessels can be 
effectively examined using in vifro techniques.
There is considerable evidence indicating the inability of peptide molecules to 
gain access to the cerebrovasculature following their systemic administration [Ermisch 
et al., 1993]. The blood-brain barrier prevents access of intravascularly administered 
endothelin to the cerebrovascular smooth muscle [Willette & Sauermelch, 1990a & 
1990b; Kobari et al., 1994a]. The use of isolated vascular segments in vitro has 
facilitated the identification of the role of the endothelins in the mediation of the 
vasomotor responses. The administration of peptide molecules like endothelin to the 
organ bath facilitates the access of the peptide molecule to the cerebrovascular smooth 
muscle and constrict the cerebral vessel [See Table 12]. The significance of the 
vascular endothelium in the regulation of vascular responses has added another 
dimension to the understanding of the responses of cerebral vessels. The use of in vitro 
techniques have facilitated the examination of the effect of neurotransmitters and 
neuropeptides in the presence and absence of the vascular endothelium. The vascular 
endothelium releases dilator substances (nitric oxide, prostacyclin) and transmitters 
such as acetylcholine release nitric oxide from the vascular endothelium and facilitate 
vasodilatation [see section 1.1.3]. However, the examination of vasorelaxation in vitro 
requires the preconstriction of the vessels and there is a risk of interaction between the 
pharmacological agents used for constricting the vessel and the use of the transmitter 
for the examination of vasodilatation.
The use of in vitro techniques for the examination of the vasomotor responses 
of cerebral vessels is limited by the size of vessel that can be examined. The size of the 
vessel can also determine the in vitro technique used. The larger cerebral vessels such 
as the middle cerebral artery and the basilar artery can be examined using ring 
segments or helical strips, although the species (rat, feline, canine, bovine, primate or 
human) from which the artery was dissected will affect the decision since the size of 
the major cerebral arteries will vary. The development of wire and pressure myographs 
for the measurement of vascular responses has facilitated the examination of the 
vascular responses of cerebral arteries and resistance arterioles (diameter 200-500 (im)
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[Kauser et al., 1990]. The wire myograph measures the isometric force developed by 
the vascular segm ent. In the pressure myograph a length of the vessel is perfused at a 
pressure that is representative of the perfusion pressure in vivo [Kauser et al., 1990]. 
The pressure myograph allows the examination of the vascular responses following the 
intraluminal or extraluminal administration of the neurotransmitter or neuropeptide 
e.g. endothelin [Saito et al., 1991].
A major issue in cerebrovascular research is the contribution of the resistance 
arterioles in the regulation of cerebral blood flow compared to the contribution of the 
major cerebral arteries [Stromberg & Fox, 1972]. The development o f in vitro 
methodology for the measurement of vasomotor responses has enhanced the 
understanding of the role of the resistance arterioles and the major cerebral arteries in 
the regulation of cerebral blood flow.
In situ techniques
The in situ techniques developed have concentrated on the measurement of the 
vascular responses of the cerebral resistance arterioles overlying the cortical surface 
(pial arterioles). The morphology of the pial arterioles compared to the major cerebral 
arteries and intraparenchymal arterioles has been discussed at the beginning o f this 
section. The pial arterioles are innervated by sympathetic and parasympathetic nerves 
and the neurotransmitters and neuropeptides released can regulate the vasomotor 
responses of the arterioles [see section 1.1.3]. There is evidence that the cortical pial 
arterioles may be a transitional zone for the blood-brain barrier as indicated by the 
permeability to small neutral amino acids [Blasberg et al., 1983], The permeability 
characteristics of the pial arterioles indicate that they are less permeable than the 
peripheral arterioles but more permeable than the intracerebral arterioles. The pial 
arterioles in vivo demonstrate vasomotor responses to hypercapnia (dilatation), 
hypoxia (dilatation), hypertension (constriction) and hypotension (dilatation) that are 
characteristic of the cerebral circulation [Rosenblum & Kontos, 1974; Paulson et al.,
1990]. The responsiveness of pial arterioles to physiologic alterations have formed the
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basis of the justification of the use of these vessels for the examination of vasomotor 
responses in situ.
The in situ techniques for the measurement of cerebrovascular responses have 
a number of advantages compared to the in vitro techniques. The in vitro techniques 
are limited by the size of vessel and the level of the arterial tree that can be examined. 
The in situ techniques facilitate the measurement of the vascular responses of cerebral 
resistance arterioles with a wider range of diameters (<30 Jim) than permitted by the in 
vitro techniques [Wahl et al., 1972; data from present investigations]. The 
vasodilatation of pial arterioles can be elicited in the absence of preconstriction and the 
inherent pharmacological interactions that may exist. The pial arterioles examined in 
situ are in their normal physiologic milieu and neurogenic control [Wahl et al., 1972]. 
The techniques used in situ permits the rapid multiple measurement of the diameter o f 
the resistance arteriole (approximately 2 sec) and facilitates the understanding of a 
time course of the development of the response especially for long acting peptides 
such as endothelins [Robinson & McCulloch, 1990]. The use of single concentrations 
of transmitters or peptides facilitates the understanding of the t \/2 of the agent in vivo. 
In in vitro investigations the potential absence of uptake and degradation mechanisms 
as a result of the dissection process may prevent an accurate estimation of the half life.
There are essentially two in situ techniques that have been developed for the 
examination of the vasomotor responses of cerebral arterioles. The open skull 
preparation was developed by Wahl and colleagues in Munich (1970). A craniectomy 
is performed and the underlying dura is resected to expose the cortical surface [Wahl 
et al., 1970], The cerebral microenvironment is protected by a pool of mineral oil and 
the agents are applied by a subarachnoid microinjection into the perivascular space. 
Microlitre quantities of the substances are administered locally around the arteriole 
and the vessel calibre is measured using an image splitting technique [see material and 
methods]. In the closed skull preparation, a craniectomy is performed and the dura 
resected and a sealed transparent window placed over the craniectomy site. The 
technique was developed by Raper and colleagues in Virginia (1971). The cerebral 
microenvironment underlying the cranial window is superfused with artificial CSF and
132
the pH and oxygenation of the CSF is controlled. The substances added to the CSF and 
superfused over the cortical surface and the vascular diameter measured using image 
splitting techniques. The closed skull technique has been modified to include laser 
doppler probes to permit the monitoring of cerebral blood velocity in the underlying 
cortex.
There has been some controversy over the relative merits of the use of open 
and closed skull preparations. There have been suggestions that there is marked 
alkalosis in the underlying cortex in the open skull preparation [Navari et al., 1978], 
However, the investigations of Kuschinsky and Wahl (1979) have demonstrated that 
the pH of the underlying cortex is maintained by the mineral oil (the open skull 
preparation used in the present thesis is as described by Wahl et al., 1970). The action 
o f the mineral oil as a concave lens has been suggested and has been refuted. The 
responses of cerebral arterioles to hypercapnia and hypotension are similar in the open 
and closed skull preparations [Raper et al., 1971; Kontos et al., 1978; MacKenzie et 
al., 1979; Gregory et al., 1980]. The exposure of the cortical brain surface may lead to 
herniation through the craniectomy in the open skull preparation. The open skull 
preparation, as described by Wahl and colleagues (1970), has frequently been used to 
examine feline cortical cerebral arterioles. There is no evidence for herniation of the 
feline brain but the use o f the open skull preparation in smaller species such as the rat 
may lead to herniation of the brain over a prolonged experimental period. In species 
such as the rat it may be beneficial to use the closed skull preparation where a positive 
intracranial pressure can be maintained.
The differences in the vasomotor responses of the cerebral arterioles in the 
open and closed skull preparations has been attributed to a number of differences in 
the methodology rather than the intrinsic differences in the responses of the cerebral 
arterioles to the agents [Navari et al., 1978; Kontos et al., 1980; Kuschinsky & Wahl, 
1980]. An important difference in the in situ and in vitro techniques is the use of 
anaesthetic agents. The common anaesthetic agents used in in vivo experimental 
studies are halothane and the barbiturates. There have been a number of investigations 
that have demonstrated that the barbiturates and halothane alter cerebral blood flow
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and the resting vasomotor tone (by inducing a vasodilatation) [Fitch et al., 1983; 
Bonvento et al., 1994]. The observed differences in the actions of vasoactive agents 
such as potassium can be attributed to the anaesthetic regimen used. The investigations 
of Fitch et al. (1983) have demonstrated the marked differences in the vasomotor 
response of cerebral arterioles to potassium in barbiturate and chloralose anaesthetised 
cats. In the present thesis, the examination of vasomotor responses of cerebral 
arterioles were carried out under chloralose anaesthesia.
Cerebral blood flow and the calibre of cerebral resistance arterioles is affected 
by alterations in the local metabolic balance [MacKenzie et al., 1976; Harper & 
M acKenzie, 1977; Paulson et al., 1990; ]. In investigations using superfusion, 
alterations in cerebral arteriolar calibre have been attributed to the agents. 
Noradrenaline, 5-Hydroxytryptamine, vasoactive intestinal polypeptide and NMD A 
have demonstrated increases in cerebral arteriolar calibre [MacKenzie et al., 1976; 
Harper & MacKenzie, 1977]. These observations have been attributed to the activation 
of the respective receptor subtypes on the cerebral arterioles. However, the superfusion 
of the agents does not permit the isolation of the vascular responses that can be 
attributed to receptors on the arterioles and effects that are the result of the metabolic 
alterations. The agents administered by superfusion can act on receptors that are 
present on neurones in the underlying cortex and the alterations in vasomotor 
responses may be due to the alterations in cerebral metabolic rate.
In the open skull preparation, substances are applied by subarachnoid 
microinjection into the perivascular space. The microlitre quantities are applied locally 
in the vicinity of the arteriole. The concentration of the vasoactive agents is maximum 
at the site of injection and can be attributed to the effects on the cerebral arterioles. 
The agent is diluted in the perivascular space and thus minimal amount of the agents 
will act on the cortical surface. The existence of the perivascular space means that the 
concentrations o f drugs described are those in the micropipette and the exact 
concentration at the receptor is unclear.
The in situ techniques have been important in the identification o f the 
vasomotor effects of vasoactive peptides such as CGRP, Vasoactive Intestinal
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Polypeptide and endothelins [see section 1.1.3 and 1.3]. The closed and open skull 
preparations have been used for examining the effect of Vasoactive Intestinal 
Polypeptide on cerebral arterioles. The investigations demonstrated that vasoactive 
intestinal polypeptide was approximately 10 fold more sensitive in the open skull 
preparation that the closed skull preparation in the cat [McCulloch & Edvinsson, 
1980]. A comparison of responses of cerebral arterioles in the cat to the superfusion 
and microapplication of endothelin-1 has not been carried out. Observations in the rat 
indicate that higher concentrations of endothelin-1 are required to constrict cerebral 
arterioles using the superfusion method rather than the microapplication method 
[Salom et al., 1995]. The differences in responses of peptides in the closed and open 
skull preparation could be explained by the arachnoid membrane limiting access to the 
cerebrovascular smooth muscle when the peptide molecules are superfused over the 
cortical surface. In the open skull preparation the peptides are delivered by 
perivascular microapplication directly to their site of action.
A fundamental difference between the in situ and in vitro techniques is the size 
of cerebral vessels that can be examined. The in vitro techniques have been used for 
examining the vasomotor responses of the larger cerebral arteries. However, the pial 
arterioles are the major contributors to cerebrovascular resistance and the regulation of 
cerebral blood flow. The use of in situ techniques has provided evidence for the 
dependence of arteriolar response on the size of arteriole examined [Wahl et al., 1972; 
Harper & MacKenzie , 1977; McCulloch & Edvinsson, 1980]. The smaller pial 
arterioles (<100 |im) demonstrated greater reactivity to vasodilatation induced by 
Vasoactive Intestinal Polypeptide, 5-HT and the endothelin ETb receptor agonist BQ- 
3020 [Harper & MacKenzie , 1977; McCulloch & Edvinsson, 1980; present thesis]. 
The larger pial arterioles demonstrated greater reactivity to vasoconstriction elicited by 
5-HT and noradrenaline. The size limitations of the in vitro techniques would not have 
facilitated the identification of the altered reactivities of cerebral arterioles.
The in vitro techniques allow the isolation of single receptor subtype and the 
examination of the vasomotor responses of cerebral arterioles following the exposure 
to the drug. The in vitro techniques allow detailed pharmacological analysis to be
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carried out and multiple dose response curves to be performed on the same segment of 
cerebral artery. The pharmacology of receptor antagonists such as the endothelin ETa 
receptors can be characterised in vitro preparations. The in situ techniques do not 
permit detailed pharmacological analysis on the cerebral arterioles.
Species differences in the responses of cerebral vessels is an important issue in 
research. The in situ techniques permit the examination of the same vessel from a 
variety of species. In endothelin research, in situ investigations have been performed 
on cerebral vessels from a variety of species (see Table 14 for references). There are 
no significant differences in the EC50 values for endothelin-1 in the major cerebral 
arteries (see Table 12). The species that can be used in in vitro investigations are 
limited by the size of vessel. However, the majority of in in situ investigations have 
been carried out in the cat and the pial arterioles are commonly examined from the 
territory of the middle cerebral artery. The most commonly used species in endothelin 
research are the cat and the rat. The vasomotor responses of cerebral arterioles to 
endothelin-1 and endothelin receptor agonists have been characterised, however, there 
are few investigations examining the vasomotor responses of cerebral arterioles form 
the rat.
Following the identification of the pharmacological characteristics of potential 
therapeutic agents, the next stage is the evaluation of the pharmacological effects of 
the therapeutic agents on the cerebrovasculature. The existence of the blood-brain 
barrier and the ability of a drug to penetrate the blood-brain barrier has important 
implications for drug development. The in situ techniques do not perm it the 
assessment of such properties. The in situ techniques, especially the open skull 
preparations, facilitate the examination of the effects of therapeutic agents when they 
administered systemically. In the present thesis we have examined the ability of the 
endothelin receptor antagonists to attenuate the vasoconstrictor actions of exogenous 
endothelin-1. We have used the in situ open skull preparation to examine the 
vasomotor effects of endothelin receptor antagonist following middle cerebral artery 
occlusion. The ischaemic conditions cannot be modelled in situ preparations, although 
investigators have exposed arteries to hypoxia. The combination of in vitro and in situ
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techniques permits the characterisation of the endothelin receptors and the impact of 
endothelin receptor activation on cerebral blood flow under normal and pathological 
conditions.
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4.1.2 Endothelin  Receptor Antagonists
The development of endothelin receptor antagonists was important for 
understanding the role of endothelins in vascular pathophysiology. The first 
antagonists described were natural by-products of the fermentation of Streptomyces 
misakiensis (BE-18257B) [Ihara et al., 1991]. This compound demonstrated low 
potency at endothelin receptors in binding and functional bioassays (IC50 endothelin 
E T a  1-4 fiM; endothelin ET b >100 p.M) [Ihara et al., 1991]. Structure activity 
relationship studies have led to modifications of the peptide structures of the 
endothelins and to the development of a series of peptide endothelin ET a , endothelin 
E T b and combined endothelin ETa /ET b endothelin receptor antagonists [Ishikawa et 
al., 1994, Ihara et al., 1991; Ihara et al., 1992; Cody et al., 1993; Itoh et al., 1993]. 
BQ-123 is the most potent of this series and selective for the endothelin E T a  receptor 
[Ihara et al., 1992]. The ICso's in binding studies of some of the compounds used in 
cerebrovascular investigations are described in Table 2.
The distinguishing feature of the cerebral circulation is the blood-brain barrier. 
The blood-brain barrier is formed of tight junctions between endothelial cells and 
prevents paracellular transport of large and charged molecules [Edvinsson et al.,
1993]. The absence of pinocytotic vesicles prevents transcellular transport of 
molecules across the blood-brain barrier [Ermisch et al., 1993]. The presence of the 
blood-brain barrier means that therapeutic agents, such as the endothelin receptor 
antagonists, that are targeted at the brain must penetrate this barrier to gain access to 
the cerebrovascular smooth muscle and neurones. There are a num ber of 
disadvantages in the use of peptide endothelin receptor antagonists as therapeutic 
agents for cerebrovascular diseases. The peptide antagonists would undergo rapid 
hydrolysis by peptidases present in the systemic circulation or in the gastro-intestinal 
tract if  administered intravenously or orally. More importantly, bioactive amounts of 
peptide endothelin antagonists do not gain access to the adventitial surface of cerebral 
arterioles when administered systemically [Patel et al., 1995; Clozel & Watanabe,
1993]. The importance of blood-brain barrier permeability for endothelin antagonists
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was demonstrated by the failure of intravenous administration of peptide endothelin 
receptor antagonist (BQ-123) to attenuate cerebral vasospasm or vasoconstrictor 
action of exogenous endothelin-1 applied to cerebral arterioles [Clozel & Watanabe,
1993].
Recently there has been the development of non-peptide endothelin receptor 
antagonists (see Table 2). The first non-peptide endothelin receptor antagonist 
described was Ro46-2005 and its therapeutic potential was demonstrated in 
experimental subarachnoid haemorrhage [Clozel et al., 1993]. A number o f other 
potent non-peptide endothelin receptor antagonists selective for the endothelin ETa  
and combined endothelin ETa/ETb receptors have been developed (see Table 2). We 
have examined the ability of non-peptide endothelin receptor antagonists to gain 
access to the cerebrovascular smooth muscle and attenuate the vasoconstriction 
induced by the adventitial application of endothelin-1 and demonstrated the potential 
of these antagonists as therapeutic agents [present thesis]. However, the non-peptide 
structure of an endothelin receptor antagonist does not necessarily confer blood-brain 
barrier permeability (e.g. SB209670) [Ohlstein et al., 1994].
The attenuation of the effects of endogenous endothelins in cerebrovascular 
disease may also be achieved by endothelin converting enzyme inhibitors. The 
cDNA's encoding endothelin converting enzyme(s) (ECE) have recently been cloned 
and will facilitate the development of enzyme inhibitors selective for ECE [Schmidt et 
al., 1995; Deschepper et al., 1995]. In contrast to the rapid development of endothelin 
receptor antagonists, only a few ECE inhibitors have been developed e.g. 
Phosphoramidon, CGS26303, CGS26393 [Kukami et al., 1994; De Lombaert et al., 
1995]. The utility of the ECE inhibitors has been examined in preliminary studies in 
focal cerebral ischaemia [Duverger et al., 1993].
The efficacy of peptide and non-peptide endothelin receptor antagonists in 
attenuating the responses of exogenous endothelin-1 and in pathophysiologic 
conditions has been demonstrated. In the cerebrovasculature, the endothelin receptor 
antagonists have attenuated vasospasm following subarachnoid haemorrhage but the 
antagonists were administered directly into the cistema magna thus circumventing the
139
blood-brain barrier [Clozel & Watanabe, 1993; Cosentino et al., 1993; Nirei et al., 
1993; Itoh et al., 1993; Itoh et al., 1994; Hirose et al., 1995]. The intravenous 
administration of the peptide antagonist BQ-123 had no effect on post subarachnoid 
haemorrhage induced cerebral hypoperfusion [Clozel & Watanabe, 1993]. In the 
cerebrovasculature the ability of the endothelin receptor antagonist to penetrate the 
blood-brain barrier is essential for their therapeutic utility.
The permeability of the blood-brain barrier alters as the arterial tree progresses 
[Yamashita et al., 1985]. The main inflow vessels, the carotid arteries and the basilar 
artery, have been demonstrated to possess an endothelial barrier that is permeable to 
horseradish peroxidase [Yamashita et al., 1985]. In conditions of subarachnoid 
haemorrhage the integrity of the blood-brain barrier may be compromised as a result 
of the rupture of the cerebral vessel or damage to endothelium caused by blood borne 
substances such as thrombin. At the level of the pial resistance arterioles on the 
cortical surface the evidence suggests that the blood-brain barrier may be in a 
transitional zone and permeable to small neutral amino acids [Blasberg et al., 1983]. 
The investigations in the thesis compared the ability of a hexapeptide endothelin 
receptor antagonist, PD 145065 and a non-peptide endothelin receptor antagonist 
P D 155080 to attenuate the vasoconstrictor actions of endothelin-1 following the 
intravenous administration of the agents.
In our investigations the intravenous administration of the non-peptide 
endothelin receptor antagonist PD 155080 effected a dose dependent attenuation of 
exogenous ET-1 induced vasoconstriction. In contrast, the intravenous administration 
o f the hexapeptide endothelin receptor antagonist PD 145065, did not alter the 
vasoconstriction elicited by exogenous ET-1. These observations indicated the 
inability of the hexapeptide endothelin receptor antagonist to gain access to the 
cerebrovascular smooth muscle to exert its effects. The access to the abluminal surface 
of the cerebral resistance arterioles critical for the endothelin receptor antagonists to 
exert their effects. However, access of the non-peptide antagonist to the parenchyma 
may be more important in pathophysiologic conditions. We have demonstrated that 
following intravenous administration approximately 10-12% of the plasm a
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concentration of an analogue, PD 156707, can be detected in the CSF aspirated from 
the cistema magna [T. R. Patel, unpublished observations].
The intravenous administration of the hexapeptide antagonist PD 145065 could 
have resulted in its inactivation by circulating peptidases or by peptidases present in 
the vascular endothelium [Rubanyi & Polokoff, 1994]. In our investigations we 
administered ET-1 as an intravenous bolus injection 120 min. following the 
intravenous administration of PD 145065. The transient reduction in the MABP elicited 
by ET-1 and the ET-1 induced increase in MABP was attenuated by the dose of 
PD 145065 used in the present investigations. These observations indicated that 
hexapeptide PD 145065 was able to attenuate the haemodynamic responses of 
exogenous ET-1 in the periphery and the inability of PD 145065 to attenuate the ET-1 
induced vasoconstriction of pial resistance arterioles was not the result o f the 
inactivation of the hexapeptide antagonist or the inadequacy of the dose of PD 145065 
used.
The intravenous doses of the non-peptide receptor antagonist PD 155080 and 
the hexapeptide antagonist PD 145065 were selected from the in vivo and in vitro 
pharmacology of the compounds previously described [Cody et al., 1993; Doherty et 
al., 1995]. The dose of PD 145065 selected in the present investigations (30 |imol/kg) 
was 3 fold greater than IC50 concentration required for the attenuation of the 
haemodynamic responses of exogenous ET-1 in the rat [Cody et al., 1993]. The 
intravenous dose of PD155080 used in the present investigations (19.2 jimol/kg) was 
the IC50 dose for the attenuation of the vasoconstrictor response of ET-1 (1 nmol/kg) 
in the rat [Doherty et al., 1995]. The transient alterations in blood pressure observed 
during the intravenous injection of choline salt of PD155080 were also observed 
during the intravenous injection of choline chloride. The mechanism underlying these 
transient alterations in blood pressure are unclear, but, it has been suggested that 
choline may act by increasing central cholinergic neurotransmission and activate 
central mechanisms involved in the regulation of blood pressure [Ulus et al., 1995].
The pharmacology of Bosentan (Ro 47-0203) has recently been characterised 
in detail [Clozel et al., 1994] and it shares many similarities with the structurally
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related agent Ro 46-2005 [Clozel et al., 1993], Bosentan is a competitive antagonist at 
endothelin ETa and endothelin ETb receptors. In isolated tissues, Clozel and 
colleagues (1994) have shown that Bosentan inhibits the action of endothelin at 
endothelin ETa receptors (rat aorta), ETb l receptors (receptor m ediating 
vasodilatation in the rabbit superior mesenteric arteries) and the ETb 2 receptors 
(receptor mediating vasoconstriction in rat tracheal rings) with pA2 values o f 7.28, 
6.72 and 5.94 respectively. In that study the in vitro demonstration of the competitive 
antagonism of the ET-1 induced vasoconstriction in the rat aorta by Bosentan at doses 
of 0.3 - 3 |iM, is in accordance with the antagonists dose range utilised perivascularly 
in the present study. With systemic dosing, similar to that employed in the current 
study, Bosentan per se did not alter blood pressure in the pithed rat [Clozel et al., 
1994]. However these authors did demonstrate that intravenously administered 
Bosentan (3-30 mg/kg) dose-dependently attenuated the initial vasodepressor and 
subsequent vasopressor effects of intravenous ET-1 (0.03 -1 nmol/kg).
The present studies investigated 3 distinct issues. First, co-application of 
Bosentan, PD155080 and PD145065 onto the adventitial surface has been shown to 
attenuate the vasoconstriction induced by exogenous ET-1 and that the concentrations 
required in the present study are in accord with those in peripheral vascular tissues in 
vitro [Cody et al., 1992; Clozel et al., 1994; Doherty et al., 1995]. Second, the 
microapplication of Bosentan, PD155080 and PD145065 per se (at concentrations 
which prevent ET-1 induced vasoconstriction) had no effect on pial arteriolar calibre. 
Such data are consistent with the view that, at least at the level of the adventitial 
surface, there is minimal tone due to endogenous endothelins under normoxic, 
normocapnic, normotensive, non-pathologic conditions. The available evidence from 
the present study suggests that exogenous endothelins can act at the level of the 
adventitial surface in cerebral vessels. Third, the present data provide evidence that 
sufficient Bosentan and PD 155080 gains access after intravenous administration to the 
vicinity of pial arterioles to attenuate the constrictions induced by topical application 
of ET-1 (10 nM). The ability to manipulate cerebrovascular endothelin receptors with
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systemic drug administration will facilitate the elucidation of the role of endothelins in 
cerebrovascular pathology.
The endothelin receptor subtype (s) which mediate the constriction of cerebral 
blood vessels to endothelin has been the subject of limited investigation. The available 
evidence suggests that endothelin constricts the major cerebral arteries o f the guinea 
pig and goat via an endothelin ETa receptor [Adner et al., 1993; Salom et al., 1993]. 
Our investigations point to the endothelin ETa receptor subtype mediating ET-1- 
induced cerebral vasoconstriction in feline pial arterioles in situ. Irrespective of the 
roles of different endothelin receptor subtypes, the present studies suggested that 
Bosentan and PD155080 (applied topically or systemically) would be valuable tools 
in the elucidation of the functional significance of endothelins in the cerebral 
circulation in vivo [Figure 44].
Concluding Remarks
The therapeutic utility of the endothelin receptor antagonist depends on their 
blood-brain barrier permeability. The demonstration in these investigations that the 
non-peptide endothelin receptor antagonist attenuate the vasoconstriction elicited by 
exogenous endothelin-1 provides evidence that the non-peptide antagonists penetrate 
the blood brain barrier [Figure 44], However, we must be cautious when interpreting 
these investigations because there is evidence that the cortical surface arterioles are 
more permeable to small neutral amino acids than the intraparenchymal arterioles (but 
less permeable than peripheral blood vessels. The critical observation in such 
investigations would be the detection of drug concentrations in the CSF following 
their systemic administration. Recent investigations have indicated that in the cat 10- 
12% of the systemic dose of PD 156707 was detected in the CSF while in the rat 
approximately 1% of the systemic dose of Bosentan was detectable in the CSF [Patel 
& McCulloch, unpublished observations; M. A. McAuley, unpublished observations]. 
These observations have strengthened arguments for using these compounds for 
examining the role of the endogenous endothelins in pathophysiology.
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Figure 44 Schematic representation of the cerebral circulation. The gap junctions 
present at the level of the major cerebral arteries may permit access of peptide 
endothelin receptor antagonists to the cerebrovasculature. However, the peptide 
endothelin receptor antagonists fail to gain access to the cerebrovascular smooth 
muscle of pial and intracerebral arterioles.

4.2 Pathophysiological role o f endothelin and endothelin receptor antagonists
The potent constrictor actions of endothelins have implicated them in a variety 
of vascular and non vascular pathologies [Rubanyi & Polokoff, 1994]. There is 
evidence for a role of the endothelins in cardiac ischaemia, renal ischaemia and 
hypertension [Rubanyi & Polokoff, 1994; Gandhi et ah, 1994; Gellai et al., 1994; 
Brunner et al., 1992]. However, the discussion of pathophysiological roles of the 
endothelins in the periphery is outside the scope of the present article [Rubanyi & 
Polokoff, 1994; Gandhi et al., 1994],
The application of exogenous endothelin-1 to neuronal cell cultures failed to 
demonstrate a neurotoxic effect [Lustig et al., 1992; Nikolov et al., 1993]. The 
administration of exogenous endothelin-1 into the cerebral ventricles following focal 
cerebral ischaemia appeared to exacerbate the ischaemic damage in the mouse 
[Nikolov et al., 1993]. Topical application of exogenous endothelin-1 on to the middle 
cerebral artery in the rat is associated with a marked reduction in cerebral blood flow 
and ischaemic neuronal damage within the cortex and striatum [Fuxe et al., 1992, 
Robinson et al., 1990; Macrae et al., 1993; Sharkey et al., 1993]. These effects 
demonstrate the ability of endothelin-1 to overwhelm the protective homeostatic 
mechanisms that exist in the brain to maintain blood flow and induce neuronal 
damage.
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4.2.1 Experimental Cerebrovascular Diseases 
Global Ischaemia
Transient global cerebral ischaemia is characterised by a marked reduction in 
cerebral blood flow followed by transient hyperaemia and delayed hypoperfusion 
[Hossmann et al., 1973; Miller et al., 1980; Pulsinelli et al., 1982; Kagstrom et al., 
1983]. The onset o f post ischaemic hypoperfusion is rapid after the transient 
hyperaemic response, and the mechanisms mediating post ischaemic hypoperfusion, 
despite much speculation, remain unclear [ Miller et al., 1980; Frerichs et al., 1992]. 
An increase in vascular tone, obstruction of the cerebral microvasculature, as a result 
of blood aggregation or constriction of cerebral vessels as result o f tissue oedema or 
glial swelling, are but some of the mechanisms proposed [Grogaard et al., 1989; 
Moskowitz et al., 1990; Wahl & Schilling, 1993; del Zoppo, 1994; Dimagl et al., 
1994].
The phenomenon of post-ischaemic hypoperfusion has been investigated 
following transient focal and global ischaemia in the rat and the cat [Hossmann et al., 
1973; Miller et al., 1980; Pulsinelli et al., 1982; Kagstrom et al., 1983]. There are a 
number of factors that can be involved in the maintenance of hypoperfusion such as 
increased vascular tone or microvascular plugging [Wade et al., 1975; Grogaard et al., 
1989; Moskowitz et al., 1990; Wahl & Schilling, 1993; Dimagl et al., 1994 ]. This 
investigation failed to demonstrate any increases in the endothelin mediated vascular 
tone during post-ischaemic hypoperfusion. The vascular mechanisms involved in post- 
ischaemic hypoperfusion have been investigated using the calcium channel antagonist 
nimodipine [Kazda et al., 1982; Steen et al., 1984]. The ability of nimodipine to 
alleviate hypoperfusion indicates an increase in vascular tone of cerebral vessels 
during the post-ischaemic period [Kazda et al., 1982]. This attenuation o f post- 
ischaemic hypoperfusion has been associated with increases in neuronal survival and 
neurologic outcome in experimental models of global ischaemia [Steen et al., 1984].
The endothelins have been implicated in cerebrovascular pathology [Rubanyi 
& Polokoff, 1994]. Increases in tissue endothelin immunoreactivity have been 
measured following global and focal ischaemia [Duverger et al., 1992; Viossat et al.,
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1993; Barone et al., 1994]. Increases in plasma and CSF endothelin levels have been 
reported in subarachnoid haemorrhage, stroke and global ischaemia at shorter time 
points [Suzuki et al., 1992; Ziv et al., 1992; Barone et al., 1994; Giuffrida et al., 
1990; Giuffrida et al., 1992; Willette et al., 1992].
The endothelin E T a  receptor antagonists BQ-123 and SB209670 have 
demonstrated a decrease in neuronal damage in hippocampal CA1 neurones in a gerbil 
model of global ischaemia [Feuerstein et al., 1994; Ohlstein et al., 1994] (see Table 
15). The mechanism underlying this process is unclear but an increase in cerebral 
blood flow and direct neuronal effects of the endothelin receptor antagonists are 
possibilities. This investigation did not attempt to investigate the effect of Bosentan on 
neuronal damage following transient global ischaemia in the acute phase. Recently 
Yamashita and colleagues (1994) have demonstrated an increase in endothelin E T b 
receptors in CA1 pyramidal neurones following transient forebrain ischaemia. The 
increase in endothelin receptors is associated with microglia and the role of 
endothelins in the progression of neuronal cell death following forebrain ischaemia is 
unclear. The investigations in the present thesis were designed to examine if delayed 
hypoperfusion associated with transient forebrain ischaemia could be modified by the 
combined endothelin ETa/ETb receptor antagonist Bosentan.
The vasoconstrictor actions of endothelins are mediated prim arily via 
endothelin ET a  receptors although constrictor endothelin ET b receptors have been 
reported [Seo et al., 1994; Rubanyi and Polokoff, 1994]. Recent data has indicated the 
presence of endothelin ET b receptors in the cerebral resistance arterioles that mediate 
vasodilatation [Kobari et al., 1994; present thesis]. Bosentan is a combined endothelin 
E T a /E T b receptor antagonist and the absence of any increases in cerebral blood flow 
during post-ischaemic hypoperfusion could be the result of the inhibition of the dilator 
endothelin E T b receptor and the constrictor endothelin E T a  receptor [Clozel et al.,
1994]. The increases in endothelin mediated tone in cerebral resistance arterioles 
following focal cerebral ischaemia in the cat indicates a regulatory role for the 
endothelin peptides during the post-ischaemic phase [present thesis]. However, 
Bosentan failed to increase cerebral blood flow or reduce the volume of damaged
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Table 15
T able 15
Effect of endothelin receptor antagonists in animal models of global and focal cerebral 
ischaemia
Model/species Compound 
(dosage)
Global Cerebral Ischaemia
Administration 
schedule (route)
Outcome Reference
Gerbil BQ-123
(lOpg)
SB209670
(50pg)
Rat Bosentan (17 
pmol/kg)
5 min pre & 60 min 21% Decrease Feuerstein et
post induction of CA1 neurones al., 1994
global; ischaemia; (61% decrease
neuronal counts at 7 inC A l
days post-ischaemia neurones in
(i.c.v.) vehicle treated 
animals)
Administered 5 min 6% Decrease Ohlstein et
pre & 60 min post CA1 neurones al., 1994
ischaemia; neuronal (55% decrease
counts 7 days post- in CA1
ischaemia (i.c.v.) neurones in 
vehicle treated 
animals)
15 min prior to No effect on Present
induction of post-ischaemic Thesis
ischaemia; CBF hypoperfusion
measured pre & post­
occlusion using 
autoradiography and 
hydrogen clearance) 
(i-v.)
Focal Cerebral Ischaemia
Rat
Rat (SHR)
Bosentan 15 min prior to marginal
(25.5 MCAO; infarct decrease in
fimol/kg) measured 4 hours post volume of
MCAO) (i.v.) infarct (17%)
BQ123 30 min pre-ischaemia; no effect
(23 infarct measured 24
pmol/kg/hr) hours post MCAO 
(i-v.)
Phosphoramidon 15 min & 5 hours 30% decrease
(3 mg/kg)a following MCAO; in volume of
infarct measured 48 hemispheric
hours post occlusion 
(i-v.)
infarct
SB217242 7 days prior to decrease in
(15 mg/kg) MCAO; Infarct volume o f
measured 24 hours 
post-MCAO) (p.o.)
infarct (30%)
BQ123 30 min pre-ischaemia; decrease in
(23 infarct measured 24 volume of
pmol/kg/hr) hours post MCAO 
(i-v.)
infarct (25%)
McAuley et 
al., 1994
Checkley et 
al., 1995
Duverger et 
al., 1993
Barone et al., 
1995
Patel et al., 
1995
T able 15
Bosentan Around individual 29% increase Present
(30|iM) arterioles 30-210 min 
following MCAO 
(Topical)
in post­
occlusion 
arteriolar 
diameter
Thesis
PD155080 Around individual 21% increase Present
(30pM) arterioles 30-210 min 
following MCAO 
(Topical)
in post­
occlusion 
arteriolar 
diameter
Thesis
PD156707 (3 Administered 30 min decrease in Present
jimol/kg following MCAO; volume of Thesis
bolus + 5 infarct measured 6 infarct (45%)
jimo 1/kg/hr hours post MCAO Increase in
infusion) (i-v.) penumbral 
CBF 
(to pre­
occlusion 
baseline levels)
a Endothelin-converting enzyme inhibitor
Abbreviations: CBF (cerebral blood flow); MCAO (middle cerebral artery occlusion); 
i.v. (intravenous); i.e. (intracistemal); i.c.v. (intracerebroventricular); p.o. (oral)
tissue in focal ischaemia in the rat [McAuley et al., 1994]. Similarly, the inability of 
Bosentan to increase cerebral blood flow following transient global ischaemia 
indicates that the contribution of endothelins in mediating post-ischaemic vascular 
tone may be less pronounced in the rat. The reasons for such differences are not 
immediately clear but differences in distribution or density of endothelin receptor 
subtypes in the rat and cat are possibilities [Kobari et al., 1994; Feger et al., 1994]. 
There is no clear evidence to suggest that differences in endothelin receptors may 
exist between these two species. Other possible explanations include the differences 
in the cerebrovascular anatomy of the rat and cat [Coyle & Jokelainen, 1982; 
Mchedlishvili & Kuridze, 1984]. The lower density of connections between collateral 
vessels in the cerebral cortex of the rat is one possible explanation for the failure of 
Bosentan to increase cerebral blood flow following transient global ischaemia [Coyle 
& Jokelainen, 1982; Mchedlishvili & Kuridze, 1984],
The source of endothelins following cerebral ischaemia is unclear [see section
4.2.2]. Endothelin receptor binding sites and mRNA have been described on neuronal 
and glial cells [MacCumber et al., 1990; Ehrenreich et al., 1991]. There are a number 
o f possible triggers for the synthesis of endothelin peptides, e.g. tissue hypoxia and 
thrombin [Kurihara et al., 1989]. Tissue hypoxia during the period of global 
ischaemia and the pooling of blood in the microvasculature could be possible 
triggers for the release or synthesis of endothelins. The role of vascular elements such 
as leucocytes and neutrophils in microvascular obstruction has been investigated 
[Wahl & Schilling, 1993; Dimagl et al., 1994]. The haemorrhage and the subsequent 
re-infusion of blood could cause trauma to the cellular contents and increase the 
ability o f platelets to aggregate and increase leucocyte adhesion to vascular 
endothelium [Grogaard et al., 1989; Dimagl et al., 1994]. The increased trauma to 
blood cells such as the platelets can result in the release of vasoconstrictor factors or 
an increase in endothelin-1 mRNA and thus increase vascular tone [Kurihara et al., 
1989]. The haemorrhagic hypotension employed to reduce cerebral blood flow could 
by itself result in the increase in systemic endothelin release [Zimmermann et al.,
1994]. An increase in the shear stress on endothelial cells has been shown to stimulate
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increases in endothelin release [Malek & Izumo, 1992]. The transient hyperaemic 
response immediately following the restoration of cerebral blood flow may be one of 
the triggers for increased endothelin release or production. The transition from 
transient hyperaemia to delayed hypoperfusion is a rapid event (approximately over 5 
minutes). The mechanism mediating the rapid transition is unclear but Moskowitz and 
colleagues (1990) have suggested that there is a loss of dilator vascular tone. Pial 
cerebral arterioles have perivascular nerves containing dilator peptides such as CGRP 
and sudden loss of tone leads to the constriction of vessels and reduction in cerebral 
blood flow. We have demonstrated an increase in endothelin mediated vascular tone in 
vessels following middle cerebral artery occlusion in the cat [present thesis]. 
However, the inability of Bosentan to alleviate the hypoperfusion following transient 
global ischaemia indicates that the endothelins may not play a major role in the 
maintenance of hypoperfusion.
In a pharmacological investigation which fails to reveal a significant effect, the 
issue o f adequacy of experimental design is crucial to the interpretation of the results. 
The dose of Bosentan (17 pmol/kg) utilised in the present investigation has been 
demonstrated to significantly reduce the pressor effect of exogenous ET-1 in the rat by 
approximately 40 mmHg (ED50 dose) [Clozel et al., 1994]. Our own investigations in 
feline pial arterioles have demonstrated that this dose of Bosentan completely inhibits 
the vasoconstrictor response following the perivascular application of ET-1 (10 nM) 
[Patel et al., 1994]. However, differences in the reactivity of feline pial arterioles and 
rat intracerebral microvessels to endothelins or endothelin receptor antagonists cannot 
be excluded absolutely [Robinson & McCulloch, 1990; Feger et al., 1994; Sagher et 
al., 1994]. The plasma half-life of Bosentan is approximately 3 hrs [Clozel et al.,
1994], thus, the absence of an effect may not be due to rapid clearance of the drug 
from the circulation. The issue of the adequacy of experimental design was addressed 
by post hoc statistical power analysis. In the Iodoantipyrine autoradiography 
investigations, the present studies would permit the significant detection of a 40% 
increase in CBF following treatment with Bosentan. In the hydrogen clearance studies 
a 30% increase in CBF would be detected significantly with the current experimental
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design. The studies were carried out using two different techniques for measuring 
cerebral blood flow, one with excellent spatial resolution ([14C]-Iodoantipyrine 
autoradiography) and the other with good temporal resolution (hydrogen clearance), 
and employing two different models of ischaemia, one severe that is associated with 
marked hypoperfusion (carotid artery occlusion with hypotension) and the other with 
moderate severity with minimal hypoperfusion (common carotid artery occlusion). 
The failure of Bosentan to alter acutely the post-ischaemic hypoperfusion does not 
rule out the possibility of the endothelins playing a role in global cerebral ischaemia.
Subdural Haematoma
Head injury is often associated with ischaemic neuronal damage, the 
pathophysiologic processes that ensue following the head injury are varied but despite 
the use of drugs and surgical intervention the prognosis for these patients is poor 
[Jamieson & Yelland, 1972; Seelig et al., 1981; Stone et al., 1983; Bullock & 
Fujisawa, 1992]. Neurosurgical intervention involving the removal of a subdural 
haematoma is often associated with a high risk of mortality (-50% ) and neurological 
disabilities (-20-30%) in those patients that survive [Jamieson & Yelland, 1972; 
Seelig et al., 1981; Stone et al., 1983; Bullock & Fujisawa, 1992].
Ischaemic neuronal damage following head injury is often the result o f 
cerebral contusions, diffuse axonal injury or hypoxic damage [Graham et al., 1989; 
Meldrum et al., 1990; Bullock & Fujisawa, 1992]. Reductions in cerebral blood flow 
have been observed in patients with acute subdural haematomas [Wyper et al., 1991]. 
The experimental model of subdural haematoma in the rat used in the present thesis 
displays marked ischaemic neuronal damage (-60 mm3) confined to the cerebral 
cortex immediately underlying the haematoma [Miller et al., 1990; Chen et al., 1991b]. 
The measurement of CBF in the underlying cortex demonstrated a reduction in the 
blood flow to below 20 ml/lOOg/min. in -130  mm3 of the ipsilateral cerebral 
hemisphere [Kuroda & Bullock, 1992a; Kuroda & Bullock, 1992b].
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Glutamate is the major excitatory amino acid in the brain and elevated levels 
of glutamate are associated with neuronal damage [Choi, 1990; Benveniste, 1991]. 
Elevations in extracellular glutamate concentrations have been measured following 
focal and global cerebral ischaemia [Benveniste, 1991]. The subdural haematoma in 
the rat is associated with an increase in extracellular glutamate with the peak of the 
glutamate concentration measured at 45 min. following the haematoma [Bullock et al., 
1991]. The elevations in extracellular glutamate concentrations were observed in the 
cerebral cortex immediately underlying the haematoma and a 3 fold increase in 
extracellular glutamate was measured in the underlying hippocampus [Bullock et a l,
1991]. The elevations in glutamate concentrations were associated with elevations in 
cerebral glucose utilisation in the molecular layer of the hippocampus and limbic 
system [Kuroda & Bullock, 1992a; Inglis et al., 1992]. In contrast the cerebral cortex 
displayed a marked reduction in glucose utilisation [Inglis et al., 1992]. The 
hippocampus and cerebral cortex subsequently demonstrated ischaemic neuronal 
damage [Chen et al., 1991b]. The reductions in glucose use in the cerebral cortex were 
reversed by the intravenous administration of the excitatory amino acid antagonist D- 
CPP-ene and the hypermetabolism hippocampus was attenuated by D-CPP-ene [Inglis 
et al., 1992].
The primary insult leading to ischaemic neuronal damage following subdural 
haematoma is the reduction in CBF in the cerebral cortical areas underlying the 
haematoma [Miller et al., 1990; Kuroda & Bullock, 1992b]. Autoradiographic studies 
have demonstrated that the cerebral cortical regions below the haematoma are perfused 
by CBF at levels that will result in ischaemic damage (-20 ml/100g/min.; see section
1.1.3) [Kuroda & Bullock, 1992b]. The induction of the subdural haematoma is 
associated with an increase in the intracranial pressure (ICP) but the ICP returns to 
baseline level 1 hr following the induction of the haematoma [Kuroda et al., 1994], 
However, the reductions in CBF are maintained for the duration of the experimental 
period (typically 2-3 hr) [Kuroda & Bullock, 1992b]. The subdural haematoma is also 
associated with a marked increase in brain swelling [Kuroda & Bullock, 1992b]. The 
absence of any alteration in the CBF in the ischaemic territory over the course of the
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experimental period suggests that the cerebral oedema is cytotoxic rather than 
vasogenic in origin [Kuroda & Bullock, 1992b].
The reductions in CBF associated with experimental subdural haematomas are 
only observed in the presence of subdural blood [Kuroda & Bullock, 1992b]. The use 
of inert materials , e.g. silicone, to occupy the subdural space have been associated 
with minimal alterations in the levels of CBF and only a small volume of neuronal 
damage compared to the animals treated with blood [Miller et al., 1990; Kuroda & 
Bullock, 1992b], These observations suggests that the decreases in CBF and associated 
neuronal damage is com bination o f the space occupying lesion and 
vasoactive/cytotoxic mediators released form the blood clot.
The therapeutic interventions in patients with head injury have been confined 
to the use of excitatory amino acid antagonist or agents to control the elevations in ICP 
following the haematoma [Kuroda et al., 1994]. In the rat model of subdural 
haematoma, NMDA receptor antagonists, glycine site receptor antagonists and flow 
enhancing strategies have been examined with varying degrees o f success [Chen et al., 
1991b; Kuroda et al., 1994; Tsuchida & Bullock, 1995]. In the rat, pre-treatment with 
the competitive NMDA receptor antagonist D-CPP-ene reduced the volume of 
ischaemic neuronal damage associated with the subdural haematoma [Kuroda & 
Bullock, 1992b]. Similar volume of neuroprotection were afforded by the non­
competitive NMDA antagonist MK-801 and NMDA glycine-site antagonist, ACEA- 
1021 [Kuroda et al., 1994; Tsuchida & Bullock, 1995].
However, the primary trigger for the ischaemic cascade is the reduction in 
CBF and we examined the efficacy of the combined endothelin E T a /E T b receptor 
antagonist Bosentan. The efficacy of endothelin receptor antagonists in reducing 
neuronal damage following global and focal cerebral ischaemia has indicated a role for 
the endogenous endothelins in the progression of neuronal damage [Barone et al., 
1995; Feuerstein et al., 1994; Ohlstein et al., 1994; Patel et al., in press]. Vasoactive 
substances present in the blood, e.g. oxyhaemoglobin, thrombin and platelet derived 
growth factor, stimulate the synthesis or release of endothelin-1 (see section 4.2.2 ). 
Preliminary evidence has also demonstrated an increase in endothelin converting
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enzyme mRNA following experimental head injury [Tayag et al., 1995]. The 
investigations in the thesis were designed to examine the effect of Bosentan on 
cerebral blood flow following subdural haematoma. Bosentan failed to alter CBF in 
the cerebral hemisphere ipsilateral to the haematoma. There was no significant 
difference in the degree of brain swelling in the Bosentan and vehicle treated animals. 
The failure of Bosentan to have any significant effect on cerebral blood flow could be 
the result of several possibilities. The severity of the ischaemia following the 
haematoma resulted in a relatively large volume of tissue perfused by CBF <20 
ml/lOOg/min. (25% of total ipsilateral hemispheric volume). The volume o f tissue 
available for salvage by Bosentan , i.e. tissue which is perfused by CBF for moderate 
ischaem ia (20-50 ml/100g/min.), is markedly less (15% o f total ipsilateral 
hemispheric volume). These volumes of tissues are in contrast to the volume of 
penumbral tissue available following focal cerebral ischaemia in the rat (CBF <20 
ml/100g/min.: 18% of ipsilateral hemispheric volume; CBF 20-50 ml/100g/min.: 22% 
of ipsilateral hemispheric volume) [Mackay et al., 1993b]. The smaller volume of 
tissue available for salvage is further compromised by the extensive brain swelling in 
the ipsilateral hemisphere that is observed at an early time point (2.5 hr). The 
increased cerebral oedema would be expected to elevate ICP and result in an decrease 
in the cerebral perfusion pressure [Seelig et al., 1981; Kuroda et al ., 1994]. Tissue 
oedema in the cerebral cortex would also constrict the intraparenchymal arterioles and 
the ischaemic lesion may be exacerbated as result of a reduction in the amount of 
blood flowing through the collateral channels. The ability o f endothelin receptor 
antagonist to reduce ischaemic neuronal damage in focal cerebral ischaemia has been 
attribute to the ability of these agents to increase cerebral blood flow. The use of flow 
enhancing strategies like the endothelin receptor antagonist may serve to exacerbate 
the cerebral oedema associated with subdural haematoma.
The endothelin receptor antagonist used in the present experiment is a 
combined antagonist for both endothelin ETa  and endothelin ETg receptors. The 
receptor distribution of the endothelin receptors in the cerebrovasculature of the rat has 
indicated the presence of constrictor endothelin ETa receptors on the vascular smooth
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muscle and vasodilator endothelin ET b receptors on the vascular endothelium 
[Rubanyi & Polokoff, 1994]. The pharmacology of Bosentan indicates that any 
beneficial effects resulting from increases in cerebral blood flow by endothelin ET b 
receptor activation will be antagonised by Bosentan [Clozel et al., 1994]. There have 
been reports concerning the accessibility of Bosentan to the adventitial surface of 
cerebral resistance arterioles following its systemic administration in the rat. We have 
evaluated the efficacy of systemic administration o f Bosentan to antagonist the 
contractile effects of exogenous ET-1 on cerebral cortical arterioles in the cat [present 
thesis]. However, there are morphologic differences in the structure of the blood-brain 
barrier at the level of the surface arterioles and the intraparenchymal arterioles that 
may account for the ability of bioactive amounts of Bosentan to gain access to the 
cerebrovasculature (see section 4.1.1). Preliminary investigations examining the 
blood-brain barrier permeability of Bosentan in the rat indicates that approximately 
1% of a intravenous bolus dose is detectable in the cisternal CSF [M. A. McAuley, 
unpublished observations].
Two important issues that arise from a negative drug study are the adequacy of 
the drug dosing regimen and the optimisation o f the study design. The dose of 
Bosentan used in the subdural haematoma studies was the ED50 dose for the inhibition 
of the vasoconstrictor actions of intravenous ET-1 (1 nmol/kg) [Clozel et al., 1994]. 
We have previously demonstrated that bioactive amounts of the dose of Bosentan used 
in the studies gains access to the cerebrovasculature of the cat. The small sample size 
in the study and the timing of the measurement of the blood flow measurements would 
have contributed to the failure to detect an increase in the cerebral blood flow by 
Bosentan.
Subarachnoid Haemorrhage
The significance of the endothelins in subarachnoid haemorrhage is in its 
purported role as a mediator of delayed cerebral vasospasm (which normally occurs 3- 
7 days following the subarachnoid haemorrhage) [Suzuki et al., 1992; Kraus et al., 
1991; Fujimori et al., 1990; Yamaura et al., 1992]. The measurement o f elevated
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levels o f endothelin-1 in the plasma and CSF and increases in endothelin 
immunoreactivity in cerebral vessels following experimental and clinical subarachnoid 
haemorrhage has implicated endothelin-1 in the development of vasospasm [Suzuki et 
al., 1992; Kraus et al., 1991; Fujimori et al., 1990; Yamaura et al., 1992; Roux et al.,
1995]. The pathological significance of elevated plasma endothelin-1 levels in 
subarachnoid haemorrhage is unclear since the available evidence indicates that the 
actions of the endothelins are exerted locally at the site of synthesis or release 
[Yoshimoto et al., 1990; Wagner et al., 1992] (see Table 16). There is no clear 
correlation of increases in plasma and CSF endothelin immunoreactivity and the 
severity of vasospasm.
Increased sensitivity of rat cerebral arteries in vitro to endothelin-1 following 
subarachnoid haemorrhage has been reported [Alafaci et al., 1989]. The mechanism 
underlying this effect is unclear but is indicative of the role the endothelin peptides 
may play in the development of vasospasm. Experimental data demonstrating the 
efficacy of endothelin receptor antagonists in subarachnoid haemorrhage have been 
described in a variety o f species (see Table 16). The peptide endothelin receptor 
antagonists administered into the cerebral ventricles (BQ-123, BQ-485, FR139317) 
have demonstrated the efficacy of these compounds in attenuating vasospasm 
following subarachnoid haemorrhage [Itoh et al., 1993; Clozel et al., 1993; Nirei et al., 
1993; Itoh et al., 1994]. The non-peptide endothelin receptor antagonists Ro46-2005 
and Bosentan administered orally or intravenously attenuate vasospasm following with 
subarachnoid haemorrhage [Clozel et al., 1993; Roux et al., 1995; Zimmermann et al., 
1995; Shigeno et al., 1995]. In the experimental studies, endothelin ET a receptor 
selective and combined endothelin ETa/ETb receptor antagonists attenuate vasospasm 
and there are no demonstrable differences in the efficacy of these sub-groups o f 
receptor antagonists. In the rabbit double haemorrhage model the combined endothelin 
ETa/ETb antagonist PD 145065 attenuates vasospasm to a greater degree than the 
endothelin E T a  antagonist BQ-610 indicating that vasoconstriction in the rabbit 
basilar artery is mediated by endothelin E T a  and endothelin E T b receptors. The 
administration of L-arginine (substrate for the production of nitric oxide) had a
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T able 16
Table 16
Effect of endothelin receptor antagonists in animal models of subarachnoid
haemorrhage
Model/species Compound 
(dosage)
Subarachnoid Haemorrhage
Administration 
schedule (route)
Outcome Reference
Rat BQ123 10 min prior to SAH; CBF restored
(Single (lOpM ) CBF measured using to baseline
Haemorrhage) microspheres (i.e.) levels at 60, 
120 min
BQ123 (4.5 10 min prior to SAH; No alteration in
Jimol/kg) CBF measured using 
microspheres (i.v.)
CBF following 
SAH
Ro46-2005 (3 10 min prior to SAH; 10% decrease
mg/kg) CBF measured using 
microspheres (i.v.)
in CBF at 60 
and 120 min 
(30% decrease 
in CBF in 
vehicle treated 
animals)
Rabbit PD145065 Superfusion on basilar 87% increase
(Double (lpM) artery ; 4 days after in diameter of
Haemorrhage) 2nd haemorrhage; 
vessel diameter 
measured in situ
vasospastic
artery
Clozel & Watanabe, 
1993
Clozel & Watanabe, 
1993
Clozel et al., 1993
Zuccarello et al., 
1993
BQ610 Superfusion on basilar 45% increase
(l|lM ) artery ; 4 days after in diameter of
2nd haemorrhage; vasospastic
vessel diameter artery
measured in situ
Zuccarello et al., 
1993
BQ123 (40 
nM)
Superfusion on basilar 
artery ; 2 days after 
2nd haemorrhage 
vessel; diameter 
measured in situ
71% increase 
in diameter of 
vasospastic 
artery
Foley et al., 1994
Rabbit Bosentan (51 2 days following
(Single |imol/kg) induction of SAH
haemorrhage) (i.v.)
36% increase 
in diameter of 
basilar artery at 
day 7
Roux etal., 1995
Dog FR139317 0, 2 ,4  days after
(double (0.1 mg) induction of SAH
haemorrhage) (i.c.v.)
14% increase Nirei et al., 1993
in basilar artery
diameter
BQ123 
(5 jiM/ day)
2 days prior to 
induction of SAH; 
vessel diameter 
measured using 
angiography at day 7 
(i.e.)
Restoration o f  
basilar artery 
diameter to 
baseline levels 
at day 7)
Itoh et al., 1994
Tafrlg K
BQ485 (120 
mg/day)
2 days prior to 
induction of SAH; 
vessel diameter 
measured using 
angiography (i.c.v.)
25% reduction 
in diameter of 
basilar artery at 
7 days (41% 
reduction in 
vehicle treated 
animals)
Itoh et al., 1993
BQ123
(100}iM/day)
BQ123 
(1 |imol/kg)
Phosphoramidon 
(200 nM/day) a
Bosentan (51 
jimol/kg/day)
Bosentan (51 
jimol/kg)
30 min prior to 
induction of SAH; 
vessel diameter 
measured using 
angiography (i.e.)
Administered on day 
4 & 5 following 
induction of SAH; 
vessel diameter 
measured using 
angiography (i.e.)
30 min prior to 
induction o f SAH; 
vessel diameter 
measured using 
angiography (i.e.)
1 day prior to 
induction of SAH 
(p.o.)
Day 7 prior to 
measurement o f  
basilar artery diameter 
(i-v.)
No significant 
effect on 
basilar artery 
diameter on 
day 7
basilar artery 
diameter 22% 
of pre SAH 
baseline at day 
5 (37% of pre 
SAH baseline 
in vehicle 
treated 
animals)
No significant 
effect on 
basilar artery 
diameter on 
day 7
13% reduction 
in diameter of 
basilar artery at 
day 8(31%  
reduction in 
vehicle treated 
animals)
10% increase 
in diameter of 
basilar artery at 
day 8
Cosentino et al., 1993
Hirose et al., 1995
Hirose et al., 1995
Zimmermann et al. 
1995
Roux et al., 1995
Bosentan (17 Immediately 21% decrease
pmol/kg, bid) following induction of in basilar artery
SAH; vessel diameter diameter at day
measured using 7 (49%
angiography at day 7 decrease in
(i-v) diameter in 
vehicle treated 
animals)
SB209670 Administered 1 day basilar artery
(360 p.g/day) prior to induction of diameter 68%
SAH; vessel diameter of pre SAH
measured using baseline at day
angiography (i.e.) 7 (27% of pre 
SAH baseline 
in vehicle 
treated animals
Shigeno et al., 1995
Willette et al., 1994
aEndothelin-converting enzyme inhibitor
Abbreviations: CBF (cerebral blood flow); MCAO (middle cerebral artery occlusion); SAH 
(subarachnoid haemorrhage); i.v. (intravenous); i.e. (intracistemal); i.c.v. (intracerebroventricular); p.o. 
(oral); bid (twice daily)
transient effect on the diameter of the vasospastic basilar artery compared to the 
sustained increases in diameter effected by the endothelin receptor antagonists [Hirose 
et al., 1995], These observations indicate the inactivation of vasodilator nitric 
oxide/EDRF, e.g. by haemoglobin present in the subarachnoid clot, while the 
vasoconstrictor actions of the endothelins are unaffected. The m ajority of 
investigations have demonstrated the efficacy of endothelin receptor antagonists in 
experimental subarachnoid haemorrhage, although, the observations of Cosentino et 
al. (1993), in a canine model of subarachnoid haemorrhage, where BQ-123 and 
Phosphoramidon failed to alter basilar artery diameter, are in marked contrast to the 
results obtained in other investigations using a similar model [Itoh et al., 1994; 
Cosentino et al., 1993; Hirose et al., 1995].
Focal Ischaemia
A persuasive case is developing for the involvement of endothelins in the 
pathophysiology of focal cerebral ischaemia and for the therapeutic potential of 
endothelin antagonists [Ziv et al., 1992; Rubanyi & Polokoff, 1994]. The ability of 
exogenous ET-1 to overwhelm homeostatic mechanisms that maintain cerebral blood 
flow, even in the normal CNS, has attracted interest in its role in regulating post- 
ischaemic cerebral blood flow [Robinson et al., 1990; Fuxe et al., 1992; Macrae et al., 
1993; Sharkey et al., 1993]. Endothelin receptor antagonists have no significant effect 
on cerebral arterial or pial arteriolar calibre under non-pathologic conditions in vivo 
nor do they alter cerebral blood flow in normal animals [Foley et al., 1994; McAuley 
et al., 1994; present thesis]. However, topical application of endothelin antagonists 
increases the calibre of cortical arterioles in vivo in the ischaemic penumbra following 
a focal cerebral ischaemic challenge [present thesis].
The potent vasoconstrictor effects of the endothelins has attracted much 
speculation for their involvement in almost every vascular pathology although the 
precise definition o f their pathophysiologic role has proven elusive [Brunner et al., 
1992; Ziv et al., 1992; Gellai et al., 1994; Rubanyi & Polokoff, 1994]. The
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perivascular microapplication of Bosentan or PD155080 on non-ischaemic feline pial 
arterioles had minimal effect on arteriolar calibre [Patel et al., 1994, 1995b]. These 
observations indicate that under normal physiologic conditions there is minimal 
endothelin mediated vascular tone. The present data suggest that following focal 
cerebral ischaemia, endogenous endothelins constrict and restrict the dilatation of 
cortical arterioles in the ischaemic penumbra. The constrictor effects of endogenous 
endothelins (defined by reversal with the endothelin antagonists, Bosentan and 
PD 155080) are demonstrable early in the evolution of ischaemic injury, at times when 
neuroprotective drugs, such as NMDA receptor antagonists, can still salvage tissue 
from irreversible damage [Ozyurt et al., 1988]. The perivascular microapplication of 
the endothelin receptor antagonist, PD155080 and Bosentan provided an insight not 
only to a possible pathophysiologic role for endothelins in cerebral ischaemia but also 
provides a basis for the use of endothelin antagonists in the treatment of occlusive 
stroke.
A marked reduction in cerebrovascular resistance and the dilatation o f the 
cerebral vasculature occur at the onset of cerebral ischaemia in an attempt to maintain 
tissue oxygenation. The mechanism for this event has long been attributed to the 
release of ’’chemical products of cerebral metabolism” with hydrogen ions, potassium 
ions and adenosine among the most favoured candidates. In contrast, there is evidence 
that endogenous constrictor mechanisms evolve, which effectively limit tissue 
perfusion to ischaemic and peri-ischaemic brain regions [Teasdale et al., 1981]. In 
focal ischaemia, vasodilator agents (calcium entry blockers, papaverine etc.) have been 
utilised to produce further decreases in vascular resistance, increase calibre of 
arterioles and, if systemic hypotension is avoided, increases in tissue blood flow to the 
ischaemic penumbra [Brandt et al., 1983; Date & Hossmann, 1984; Mohammed et al.,
1985].
Several mechanisms have been proposed (and disputed) to restrict tissue 
perfusion in cerebral ischaemia, including intraluminal obstruction, mechanical 
compression o f the intraparenchymal vessels (consequent to astrocytic swelling and 
ultimately tissue oedema] and active vasoconstriction [Teasdale et al., 1981; Hatashita
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& Hoff, 1986; Wahl & Schilling, 1993). The demonstration that arteriolar calibre in 
the ischaemic penumbra is increased after microapplication of the endothelin receptor 
antagonists Bosentan and PD 155080, indicates that endogenous endothelins may be 
involved in limiting blood flow to this zone. While this report clearly demonstrates 
that there is an endothelin mediated component to alterations in vessel calibre 
following a focal ischaemic insult, endothelin antagonists (including Bosentan) have 
been shown to markedly reverse the vasospasm of arteries associated with 
subarachnoid haemorrhage in several species [Rubanyi & Polokoff, 1994]. In this 
instance, the stimulus for the increased levels of ET’s is likely to be blood products 
and agents present at the site of injury [Yanagisawa et al., 1988; Kurihara et al., 1989; 
Ohlstein & Storer, 1992].
The interpretation of the present study depends upon the selectivity of action of 
Bosentan and PD 155080 on endothelin receptors. Bosentan inhibits the binding of 
radiolabelled ET-1 to endothelin ET a  and endothelin E T b  receptors with K i values of 
5 nM and 95 nM respectively [Clozel et al., 1994]. Bosentan has no demonstrable 
effects on the binding of other peptides with the exception of Neurokinin A, the 
binding of which was reduced at very high Bosentan concentrations (10 |iM) [Clozel 
et al., 1994]. In contrast PD155080 inhibits binding of radiolabelled ET-1 to 
endothelin E T a  and endothelin E T b  receptors with ICso's of 7.8 nM and 3.5 jiM 
respectively [Doherty et al., 1995]. In feline pial arterioles in situ , perivascular 
micro application of Bosentan or PD155080 have no effect on arteriolar calibre under 
norm oxic, normocapnic and normotensive conditions [present thesis]. Co- 
administration of Bosentan or PD 155080 with ET-1 (10 nM) inhibits the ET-1- 
induced constriction of pial arterioles (but not that produced by other vasoconstrictors) 
with an IC50 of 1 p.M (for both antagonists) and complete blockade was achieved with 
co-application of higher concentrations of the antagonists (micropipette concentration 
= 30 |iM ) [present thesis]. Despite the slow dissociation of endothelin from their 
receptors [Marsault et al., 1993; Wu Wong, 1994 & 1995], the present data in 
normal cats indicates that partial reversal of ET-1-induced cerebral vasoconstriction 
can be achieved by delayed treatment with either Bosentan or PD 155080.
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We examined the effects of a combined endothelin E T a /E T b  receptor 
antagonist (Bosentan) and an endothelin E T a  selective receptor antagonist 
(PD155080) on ischaemic arterioles. Bosentan and PD155080 elicited similar 
magnitude of effects on ischaemic dilated and constricted arterioles. Activation of 
endothelin ET a  and endothelin ET b  can each mediate vascular contractions depending 
on the vessel examined. In feline pial arterioles, however, the ET-1-induced 
vasoconstriction appears to be mediated via endothelin ETa receptors whereas 
endothelin E T b  activation produces vasodilatation [Kobari et al., 1994; present thesis]. 
Receptor characterisation of ET-1 cerebrovascular actions in other species generally 
supports such a view of the function of ET receptor subtypes [Kitazono et al., 1993; 
Feger et al., 1994]. The use of a mixed antagonist such as Bosentan does not allow 
elucidation of the endothelin receptor subtype which mediates the observed 
cerebrovascular constriction. However, the ability of the endothelin E T a  receptor 
selective antagonist PD155080 to increase the calibre of both post-occlusion dilated 
and constricted arterioles indicates that endothelin E T a  receptor activation is probably 
the dominant mediator of the cerebrovascular effects of endogenous ET-1 following 
focal ischaemia. The ability of an endothelin ETa receptor antagonist to increase 
cerebral blood flow to the ischaemic penumbra and reduce ischaemic neuronal 
damage has been demonstrated [present thesis]. An important aspect o f the 
pharmacology of Bosentan and PD 155080 is their ability to gain access to the vascular 
smooth muscle of cerebral resistance vessels after intravenous administration [present 
thesis]. These observations and the demonstration that the calibre of vessels in the 
ischaemic penumbra can be increased by Bosentan and PD 155080 provided a basis for 
assessing the therapeutic utility of endothelin receptor antagonists in focal cerebral 
ischaemia.
Recent studies have examined the effects o f peptide and non-peptide 
endothelin receptor antagonists in focal cerebral ischaemia [McAuley et al., 1994; 
Barone et al., 1995; Checkley et al., 1995; Patel et al., 1995; Umemura et al., 1995] 
(see Table 15). In the normotensive rat, the combined endothelin E T a /E T b  receptor 
antagonist Bosentan and endothelin E T a  selective antagonist BQ-123 elicited
158
minimal alterations on the volume of ischaemic damage or cerebral blood flow 
following permanent focal ischaemia [McAuley et al., 1994; Checkley et al., 1995] 
(see Table 15). In the spontaneously hypertensive rat (SHR) SB217242 and BQ-123 
demonstrated 30% and 25% reductions in the volume of ischaemic damage 
respectively following permanent focal ischaemia [Barone et al., 1995; Patel et al., 
1995]. The inability of the Bosentan to significantly alter the volume o f ischaemic 
damage or cerebral blood flow in the rat is probably due to the selectivity o f the 
antagonist for both constrictor endothelin ET a  receptors and dilator endothelin E T b 
receptors and the loss of endothelin E T b  receptor mediated increases in cerebral blood 
flow [McAuley et al., 1994]. The inability of BQ-123 to alter the volume of ischaemic 
damage in the normotensive strain is probably due to the peptide antagonists not 
penetrating the blood-brain barrier. In the SHR strain, the ability of BQ-123 to reduce 
the volume of ischaemic damage is probably due to the damage to the blood-brain 
barrier n this strain and this allows the peptide antagonist to gain access to the 
cerebrovasculature [Horie et al., 1978]. The combined endothelin E T a /E T b  receptor 
antagonist SB217242 reduced the volume of ischaemic damage in a rat model of focal 
cerebral ischaemia [Barone et al., 1995]. However, the poor blood-brain barrier 
permeability of this compound required 1 week of pre-dosing. The combination of 
tissue Plasminogen activator (t-PA) and FR139317 did not the increase the protective 
effect of t-PA in a thrombo-embolic model in the rat [Umemura et al., 1995],
Reports of increased plasma endothelin levels in patients with acute ischaemic 
stroke has facilitated interest in the therapeutic potential of endothelin receptor 
antagonists in the treatment of stroke [Ziv et al., 1992; Estrada et al., 1994]. The 
elevations in plasma endothelin-1 levels ranged from 4 to 28 pg/ml in the first 72 
hours following an ischaemic stroke (control levels 2 pg/ml) [Ziv et al., 1992; Estrada 
et al., 1994], however, the pathological significance of elevations in plasma 
endothelin-1 levels in the progression of cerebral ischaemic damage is unclear since 
endothelin-1 does not cross the blood-brain barrier and the evidence indicates that the 
actions of the endothelins are paracrine in nature [Yoshimoto et al., 1990; Wagner et 
al., 1992; Mima et al., 1989]. Increases in tissue endothelin immunoreactivity have
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been demonstrated in experimental focal cerebral ischaemia (permanent and transient 
models) (magnitude 50-80% increases from controls) [Barone et al., 1994; Duverger et 
al., 1992; Viossat et al., 1993]. The increases in tissue endothelin immunoreactivities 
have been measured at 4 hours (50% increase compared to sham animals) and with 
marked elevations at 24 and 72 hours following focal cerebral ischaemia (400% 
increase compared to sham animals at 72 hours) [Barone et al., 1994; Duverger et al., 
1992; Viossat et al., 1993].
Endothelin receptor antagonists have no significant effect on cerebral arterial 
or pial arteriolar calibre under non-pathologic conditions in vivo nor do they alter 
cerebral blood flow in normal animals [Foley et al., 1994; McAuley et al., 1994; 
present thesis]. Following the demonstration that the topical application of endothelin 
antagonists increases the calibre of cortical arterioles in vivo in the ischaemic 
penumbra following a focal cerebral ischaemic challenge [Patel et al., in press], we 
proceeded to examine the effects of the endothelin E T a receptor antagonist PD 156707 
on peri-ischaemic cerebral blood flow (measured by laser doppler flowmetry) and on 
neuronal ischaemic damage.
Despite the existence of multiple homeostatic mechanisms to protect blood 
flow to the brain from compromise, constrictor mechanisms which limit tissue 
perfusion to the ischaemic penumbra following cerebral ischaemia are well recognised 
[Hossmann et al., 1973]. A variety of mechanisms for reductions in CBF following 
focal ischaemia have been proposed, these include vasoconstriction, increased tissue 
pressure and luminal obstruction [Teasdale et al., 1981; Hatashita & Hoff, 1986; Wahl 
& Schilling, 1993]. However, the precise mechanism for the maintenance of reduced 
post-ischaemic cerebral blood flow is unknown. The ability of the endothelin receptor 
antagonist PD 156707 to increase cerebral perfusion indicates a role for endothelin in 
the regulation of vascular tone and cerebral blood flow following MCA occlusion. The 
sources and mechanisms that underlie the increases in endothelin mediated vascular 
tone are presently unclear but increases in tissue and CSF endothelin 
immunoreactivities following focal cerebral ischaemia have been reported by a
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number of groups [Ziv et al., 1992; Viossat et al., 1993; Barone et al., 1994] [see 
following section].
PD 156707 per se failed to alter the calibre of non-ischaemic feline pial 
arterioles indicating that, under the experimental conditions used, there is minimal 
endothelin mediated tone in cerebral resistance vessels [Patel et al., in press]. The 
immediate response following MCA occlusion is a decrease in cerebrovascular 
resistance in order to compensate for the reduction in blood flow. A number of 
investigations have been performed where vasodilator substances, such as papaverine 
and nimodipine, increase cerebral blood flow provided systemic hypotension is 
avoided [Kazda et al., 1982; Brandt et al., 1983; Date & Hossmann, 1984; Mohammed 
et al., 1985]. The perivascular microapplication of the calcium channel antagonist 
nifedipine demonstrated an increase in calibre of post-ischaemic constricted arterioles 
indicating an active vasoconstriction of these blood vessels [Brandt et al., 1983]. The 
perivascular microapplication of endothelin receptor antagonists on ischaemic 
arterioles has demonstrated an increase in endothelin mediated vascular tone following 
focal ischaemia [present thesis].
Although the role of the endothelins as neurotransmitters or neuromodulators 
has been suggested, the effects of endothelin receptor antagonists per se on neuronal 
function has not been examined [Gross et al., 1993; Berrino et al., 1994], There are 
very few studies examining the efficacy of endothelin receptor antagonists acutely 
following focal cerebral ischaemia [McAuley et al., 1994; Patel et al., 1995; Patel et 
al., in press]. PD 156707 (at a single dose validated for efficacy) reduces the volume of 
focal ischaemic damage, however, the mechanism of action for this reduction in 
unclear [Figure 45]. It can be speculated that since PD156707 increases perfusion in 
the peri-ischaemic regions the effect mav be the result o f an enhancement o f peri- 
ischaemic cerebral perfusion [Figure 46].
The endothelin receptor antagonists targeted at cerebral resistance blood 
vessels must gain access to the adventitial surface of cerebral resistance arterioles 
[Edvinsson et al., 1993; present thesis]. The intravenous dose of PD156707 examined 
in this investigation attenuates exogenous ET-1 induced vasoconstriction o f non-
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Figure 46 Cerebral Perfusion (determined by laser doppler flowmetry) in 
vehicle and PD156707 treated animals. Data are mean ±  S.E.M  from 8-10  
probes overlying the ectosylvian and suprasylvian gyri in 10 cats ( 5 in each 
group).
The vehicle (saline) was administered 30 min. following M CA occlusion as 
an intravenous bolus injection follow ed by a continuous infusion (top 
panel).
PD 156707 (3 |im ol/kg) was administered as an intravenous bolus injection 
30 min. after MCA occlusion followed by a continuous intravenous infusion  
(5 |imol/kg/hr) (lower panel).
ischaemic arterioles demonstrating that bioactive amounts of PD 156707 gain access to 
the adventitial surface of cerebral resistance arterioles. Our unpublished observations 
have indicated that approximately 12% of the plasma drug level is detectable in the 
CSF [T. R. Patel, unpublished observations]. This validated dose of PD156707 was 
subsequently used in the focal ischaemia investigations and demonstrated its ability to 
increase cerebral perfusion and reduce ischaemic damage.
PD 156707 is a highly selective antagonist for endothelin receptors. PD 156707 
in concentrations up to 10 mM did not inhibit the binding of 25 ligands to various 
neurotransmitter systems including angiotensin II, neuropeptide Y and vasoactive 
intestinal peptide [Reynolds et al., 1995]. In vitro pharmacological data for 
PD 156707 indicates that this compound is selective for the endothelin ET a receptor 
subtype with an IC50 0.3 nM and 420 nM at endothelin E T a  and endothelin ET b  
receptors respectively [Doherty et al., 1995]. In in vitro functional studies PD 156707 
demonstrates a 100  fold selectivity for the endothelin E T a  receptor compared to the 
endothelin E T b  receptor [Reynolds et al., 1995]. The dose of PD156707 used in the 
present investigations markedly attenuates the vasoconstrictor response to ET-1 (1 
nmol/kg, intravenous bolus) and does not affect the vasodilator response (endothelin 
E T b  receptor mediated) elicited by this dose of ET-1 indicating the selectivity of 
PD156707 for the endothelin ETa  receptor [T. R. Patel, unpublished observations].
Previous investigations to characterise the endothelin receptor subtypes in 
feline cerebral arterioles has demonstrated that endothelin E T a  receptors mediate 
vasoconstriction and endothelin E T b  receptors mediate vasodilatation [Kobari et al., 
1994; present thesis]. The increase in cerebral perfusion in peri-ischaemic areas 
induced by PD 156707 is probably due to antagonism of endothelin E T a  receptor 
mediated vasoconstrictions and, perhaps, the unmasking of endothelin E T b  receptor 
mediated vasodilatation [Kobari et al., 1994; present thesis]. The contribution of 
endothelin E T b  receptors to the regulation of perfusion in cerebral ischaemia could be 
assessed by the selective endothelin ET b  receptor antagonists and agonists. The ability 
of the endothelin receptor antagonists to increase the calibre of cerebral resistance 
arterioles, increase cerebral perfusion in peri-ischaemic areas and reduces hemispheric
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ischaemic damage after experimental focal cerebral ischaemia, indicates the 
importance of endogenous endothelins in the regulation of cerebrovascular tone in the 
post-ischaemic phase and the therapeutic potential of endothelin receptor antagonists 
in the amelioration of ischaemic damage.
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Critical appraisal o f techniques used for measuring cerebral blood flow
The principles for the measurement of cerebral blood flow were first described 
by Kety and Schmidt in the 1940's. The techniques were based upon the exchange of 
inert gases, such as nitrous oxide, between the blood and the brain tissue. The original 
techniques were modified to measure the cerebral blood flow using radioactive tracers 
by Sokoloff and colleagues and the developments of polarographic techniques to 
measure cerebral blood flow using inert gases such as hydrogen.
Hydrogen Clearance
The hydrogen clearance technique for the measurement of cerebral blood flow 
was devised by Aukland and colleagues in the 1960's. However, prior to this Misrahy 
and Clark (1956) had demonstrated that electrical potentials measured using platinum 
electrodes implanted the cerebral cortex were altered when the inspired gases 
contained hydrogen. The electrical potentials increased in magnitude when C 02  was 
inhaled and decreased when barbiturates were administered [Misrahy & Clark, 1956]. 
The original techniques described were selective for hydrogen but there was no 
correlation between the hydrogen concentration and the electrical potential generated 
when using platinum electrodes. The studies of Hyman (1961) and Aukland et al. 
(1964) correlated the hydrogen concentration in the tissue with the electrical potential 
generated.
There are a number of properties of hydrogen that led to the use of the gas as 
tracer for the measurement of cerebral blood flow. Molecular hydrogen is not 
normally found in tissues and it is freely diffusible across lipid membranes in 
biological tissues, additionally, hydrogen possess a low water/gas partition coefficient 
and thus when the gases are turned off it is readily removed from the circulation via 
the lungs.
The hydrogen clearance technique used in the present thesis was a 
polarographic technique where an electrode is implanted into the tissue of interest. In 
the present studies platinum electrodes were used (See section 2.3 for methods). The 
polarographic technique is based on the principle that the molecular hydrogen is
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converted to hydrogen ions at the polarised platinum electrodes implanted into the 
brain. The resultant electrical signal generated is recorded on to a chart recorder and 
the cerebral blood flow is calculated by the fitting of the data to an exponential 
function and from the equation given in section 2.3. In brain tissues the process of 
ionisation of the hydrogen is limited by the rate of diffusion of the hydrogen to the 
electrode and since the diffusion coefficient of hydrogen is one, the ionisation is 
limited by the cerebral blood flow to the area where the platinum electrode is 
implanted [Doyle et al., 1975; Young, 1980].
The hydrogen clearance technique has number o f advantages for the 
measurement of blood flow. Cerebral blood flow can be measured from any site in the 
brain where an electrode can be placed. The placement of multiple electrodes in 
various brain regions would permit the examination of cerebral blood flow across the 
brain. The electrodes are normally positioned at a particular site for the duration of the 
experimental period and this allows the multiple determination of cerebral blood flow 
and a temporal profile of the cerebral blood flow can be examined in the brain region 
of interest. The hydrogen is normally introduced by inhalation and the alteration of the 
inspired gas mixture and so is relatively easy to execute the procedure. The hydrogen 
clearance technique has been used for the measurement of cerebral blood flow in a 
range of species under normal and ischaemic conditions [Fieschi et al., 1969; Gotoh et 
al., 1966; von Kummer & Herold, 1986, von Kummer et al., 1986; Symon et al., 1970; 
Symon et al., 1976; Haining et al., 1968; Mackay et al., 1996; Young, 1980].
There are a number of limitations to the use of hydrogen clearance to measure 
cerebral blood flow. The electrodes used for the measurement o f CBF are normally 
implanted into the brain regions of interest. Local tissue injury resulting from the 
placement o f the electrodes may alter the cerebral blood flow in the vicinity o f the 
electrode [Young et al., 1980]. The clearance of hydrogen from the brain tissue is 
polyexponential in nature and the calculation of cerebral blood flow from the 
monoexponential curves normally used will give rise to erroneous CBF measurements 
[Doyle et al., 1975; Young, 1980; von Kummer & Herold, 1986]. A major assumption 
of the hydrogen clearance technique is that the arterial concentration of the gas falls to
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zero once the gas has been turned off [Young, 1980]. There is evidence that in the first 
minute following the turning off of the gas, there is a recirculation of hydrogen 
through the small arteries and arterioles [Stosseck, 1970]. Fieschi et al. (1969) 
demonstrated that in the major arteries 95% of the hydrogen is removed from the 
circulation in the first minute. However, in the smaller arteries and arterioles the 
clearance of hydrogen lags behind by a few minutes due to the recirculation into the 
microvasculature from the tissue [Stosseck et al., 1970]. The electrodes used for the 
measurement of hydrogen are polarised to a set voltage (+700 mV). The electrodes 
used can also be sensitive to the oxidation of oxygen at the electrodes.
The limitations of the hydrogen clearance techniques are overcome by a 
variety of methods. The original studies of Aukland and colleagues used electrodes of 
approximately 1 mm diameter but the electrodes used in more recent studies are of 
much smaller diameter, typically <250 (im. The smaller electrode diameters result in 
less localised tissue damage although due to the invasive nature o f the implantation 
tissue damage cannot be completely avoided. The recirculation artefacts that occur 
following the removal of the hydrogen are counteracted by the discarding of the first 
minute of the clearance curve. At the end of the clearance period a shift in the baseline 
of the curve is normally observed. The reasons for the shift are unclear but its has been 
suggested that the baseline shift may be the result of the oxidation of substances such 
as ascorbate following the induction of cerebral ischaemia (oxidation occurs at levels 
close to +600 mV). The baseline shift was carefully monitored during the course of 
the experiment and at the end of each flow determination the baselines were reset to 
the pre-occlusion baselines. The oxidation of oxygen at the electrode site resulting in a 
contamination of the hydrogen signal is counteracted by the polarising the platinum 
electrode to greater than + 600 mV and the contribution of oxygen to the signal is 
negligible at this voltage [Kissinger et al, 1973; Young, 1980]. It has been observed 
that the signal at electrodes polarised to +200 mV is contaminated by the oxidation of 
catecholamines, haemoglobin and oxygen in addition to the oxidation of hydrogen 
[Kissinger et al, 1973; Young, 1980]. The hydrogen clearance technique has been used 
in investigations in cerebral ischaemia. During the measurement of cerebral blood
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flow the diffusion of the hydrogen is assumed to be constant. Under ischaemic 
conditions, the development of cerebral oedema will alter the diffusion of hydrogen in 
the tissue and thus have an adverse effect on the measurement of cerebral blood flow. 
The evidence indicates that there is no significant cerebral oedema at time points less 
than approximately 6 hours. The use hydrogen clearance in cerebral ischaemia 
investigations with chronically implanted electrodes may have results to the contrary.
A persistent problem associated with the hydrogen clearance technique for the 
measurement of cerebral blood flow is the localisation of the site o f blood flow and 
the volume of tissue involved in there cording of the cerebral blood flow. The 
investigation performed to investigate this have indicated that tissue involved in the 
estim ation o f cerebral blood flow is between 2-5 mm from the site o f the 
electrode[von Kummer & Herold, 1986]. Additionally, the disruption of the blood- 
brain barrier by the hydrogen electrodes increases permeability of drugs that may not 
normally penetrate the blood-brain barrier. The ability of Bosentan to increase in 
cerebral blood flow following transient occlusion of the common carotid arteries may 
be the result o f increased concentrations of Bosentan penetrating the blood-brain 
barrier.
[14C]-Iodoantipyrine autoradiography
The original autoradiographic techniques were designed for the use with radioactive 
tracers such as trifluoroiodoethane ([131I] CF3I) and [l4C]-Antipyrine [Landau et al., 
1955]. The use of radio labelled gases was developed because of the unrestricted 
diffusion of the gases across the lipid membranes from the blood stream. However, 
[131I] CF3I had a relatively short half-life and the problem of storage. The technique 
was modified by Reivich and colleagues (1969) to allow the use o f [ 14C] labelled 
Antipyrine. The use of [14C] labelled Antipyrine had the added the benefit of the long 
half life compared to the iodinated ligands but the measurements of cerebral blood 
flow were underestimated when [14C]-Antipyrine was used. [14 C]- Antipyrine 
affected the measurements of cerebral blood flow because of its ability to diffuse 
across the blood-brain barrier. The use of [14C]-Antipyrine was superseeded by the
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use of [ 14C]-Iodoantipyrine which had a higher partition coefficient (lipid/water) and 
the measurements of cerebral blood flow were similar to the values obtained by CF3I 
[Sakurada etal., 1978],
The use of Iodoantipyrine autoradiographic has a number of advantages. The 
radiolabelled tracer is a freely diffusible tracer and hence the measurements of cerebral 
blood flow in the region of interest is limited by the level of blood flow. The 
autoradiography technique has excellent spatial resolution and perm its the 
measurement of CBF in multiple brain regions. Additionally, the brain areas with 
alterations in patterns of blood flow can be visualised on the autoradiograms and 
determined. In comparison, the hydrogen clearance relies on the pre-selection of the 
brain region of interest and a limited number of sites can be examined at any one 
point. The autoradiographic technique also has the added advantage that since 
extensive studies have been carried out on the neuronal pathways in the brain we can 
determine the patterns of cerebral blood flow in the areas following interventions. An 
important advantage of the Iodoantipyrine autoradiography technique is that it is non- 
invasive. Unlike the hydrogen clearance technique where the platinum electrodes are 
implanted in the brain tissue, the radiolabelled tracer is administered intravenously. 
The implantation of the hydrogen electrodes can lead to localised tissue damage and 
may lead to aberrant readings in the values of cerebral blood flow.
One of the main disadvantages of autoradiographic techniques for measuring 
cerebral blood flow is that in order to gain temporal insight into the alterations in 
cerebral blood flow multiple groups would be required for each individual time point 
to be investigated. The methodology for the Iodoantipyrine technique is complex and 
requires the accurate measurement of parameters such as the time of the blood sample, 
and the duration of the experiment [Sakurada et al., 1978; Patlak et al., 1984]. The 
inaccurate measurement of any of these parameters can result in marked errors in the 
value of cerebral blood flow obtained [Patlak et al., 1984]. The use o f radioactive 
tracers, such as Iodoantipyrine, also have the additional problems of the back flux of 
the tracer from the tissue into the blood [Patlak et al., 1984]. The errors arising from 
the potential back flux of the Iodoantipyrine are reduced by using a short experimental
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schedule (30 s) infusion and the use of a ramped infusion schedule, with the arterial 
concentration of the Iodoantipyrine tracer increasing with time [Patlak et a l, 1984],
The benefits of Iodoantipyrine autoradiography are the most marked when 
used to examine the alteration in cerebral blood flow following focal and cerebral 
ischaemia. The technique is commonly used in conjunction with potential 
neuroprotective drugs and to gain insight into their mechanism of action. The 
complexity and the cost of conducting investigations using Iodoantipyrine has seen the 
increased use of laser doppler flowmetry in cerebral blood flow investigations. 
However, laser doppler flowmetry measures the velocity of the erythrocytes in 
cerebral tissue rather than the flow of plasma and the erythrocytes and thus cerebral 
perfusion is measured in arbitrary units. Laser doppler flowmetry has excellent on-line 
and temporal monitoring of the alterations in cerebral perfusion but poor spatial 
resolution (similar to hydrogen clearance) [Fabricius & Lauritsen, 1994]. The laser 
doppler probes are normally placed on the surface of an intact dura and used to 
monitor the alterations in cortical perfusion. Preliminary evidence has compared the 
values of CBF obtained by using Iodoantipyrine autoradiography and laser doppler 
flowmetry [Fabricius & Lauritsen, 1995], The results indicated that laser doppler 
flowmetry overestimated the alterations in cerebral perfusion when compared to CBF 
obtained by Iodoantipyrine autoradiography. The measurement of erythrocyte flow by 
the laser doppler technique and total CBF by the autoradiography technique is one 
possible explanation for the discrepancies in the two techniques.
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4.2.2 Sources and Triggers for endothelin synthesis following cerebrovascular 
injury
The sources of endothelin release following cerebrovascular injuries are 
unclear. A number of triggers for the synthesis of endothelin peptides from astrocytes, 
neurones or endothelial cells have been suggested [MacCumber et al., 1990; 
Ehrenreich et al., 1991] and these include tissue hypoxia, thrombin, transforming 
growth factor-B (TGF-B), oxyhaemoglobin and mechanical shear stress [Yanagisawa 
et al., 1988; Kurihara et al., 1989; Malek & Izumo, 1992; Ohlstein & Storer, 1992; 
Tippler et al., 1994; Kourembanas et al., 1993; Elton et al., 1992; Kuchan & Frangos, 
1993; Mac Arthur et al., 1994; Morita et al., 1993; Ehrenreich et al., 1990] (Table 17).
Thrombin is an important component of the coagulation cascade. Thrombin 
has been shown to induce an increase in ET-1 mRNA levels and ET-1 release 
[Kurihara et al., 1989; Fukunaga et al., 1991; Zoja et al., 1991]. However, exposure of 
renal mesangial cells to thrombin results in decrease in endothelin receptor numbers 
[Albrightson et al., 1995]. The endothelins have been implicated in the pathogenesis of 
vasospasm following subarachnoid haemorrhage. Subarachnoid haemorrhage is often 
associated with the rupture of cerebral blood vessels and the presence of thrombin in 
the subarachnoid space may increase the synthesis and release of endothelin in the 
vicinity of the haemorrhage.
Oxyhaemoglobin has been implicated as a pathogen for development o f 
vasospasm following subarachnoid haemorrhage. Oxyhaemoglobin stimulates the 
release of ET-1 from endothelial cell cultures [Ohlstein & Storer, 1992]. Lysed 
erythrocytes (from human and rat) facilitate the production of ET-1 from the 
precursor, pre pro- ET-1 [Tippler et al., 1994]. Platelets have been demonstrated to 
increase ET-1 mRNA [Ohlstein et al., 1991] and potentiate the release of ET-1 from 
endothelial cell cultures [Ohlstein & Storer, 1992; Umekawa et al., 1994]. Platelet 
derived growth factor (PDGF) also facilitates the release of ET-1 from endothelial 
cells [Janat et al., 1992; Kohno et al., 1993]. In cerebral ischaemia an increased
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Table 17
Local triggers for the release o f  endothelins
T rig g ers
Platelet derived growth 
factor (PDGF)
Lysed erythrocytes
Platelets
Tissue hypoxia
Thrombin
T ran s fo rm in g  grow th  
factor-13 (TGF-13) 
Oxyhaemoglobin
R eferences
Bakris et al., 1991; Janat & Liaw, 1992; Kohno et 
al., 1993
Tippler et al., 1994
Ohlstein et al., 1991; Ohlstein & Storer, 1992; 
Umekawa et al., 1994
Ehrenreich et al., 1990; Morita et al., 1993; 
Kourembanas et al., 1993;
Yanagisawa et al., 1988; Kurihara et al., 1989
Yanagisawa et al., 1988; Kurihara et al., 1989
Ohlstein & Storer, 1992; Tippler et al., 1994
Mechanical shear stress Elton et al., 1992; Malek & Izumo, 1992; Kuchan
& Frangos et al., 1993
expression of PDGF has been observed [Iihara et al., 1994] and there is the potential of 
interactions between PDGF and ET-1 in the development is ischaemic damage.
Aggregated platelets release the platelet derived polypeptide TGF-13 and 
TGF-13 can be synthesised in vascular endothelial cells. TGF-13 has been shown to 
increase ET-1 mRNA levels in endothelial cells [Kurihara et al., 1989; Murata et al., 
1995]. Increased release of TGF-13 has been observed in myocardial infarction and the 
TGF-13 may be produced from the platelets, vascular endothelial cells or vascular 
smooth muscle cells. The role of TGF-13 in the development of vascular injury may be 
enhanced by its ability to increase the synthesis and release of ET-1 [Casscells et al., 
1990; Brown et al., 1991].
Thus the implication is that blood per se may not result in the vasoconstrictive 
response but constituents contained in blood, such as the platelets, may cause the 
generation of endothelins through the induction of endothelin mRNA and may 
indirectly result in the production of ET-1 and the manifestation of delayed 
vasospasm.
There are a number of possible triggers for the release and synthesis of 
endothelins including tissue hypoxia [Elton et al., 1992]. The reduction in cerebral 
blood flow and the possibility of blood pooling within the ischaemic region could 
trigger the release or synthesis of endothelins [Kurihara et al., 1989; Ohlstein & Storer,
1992]. Products from platelets such as TGF-13 and PDGF are known inducers of 
endothelin synthesis and may also provide a trigger for the release/synthesis of 
endothelins following an ischaemic insult [Kurihara et al., 1989]. Hypoxia, following 
an occlusive insult, is the most likely candidate as the trigger which elicits an increase 
in endothelins to vasoactive concentrations. Several studies in cell culture would 
support this idea [Elton et al., 1992]. However, evidence in the present studies indicate 
that rheologic factors (or reactive alterations in vessel calibre) per se are insufficient to 
elicit vasoactive amounts of endothelins, since there was an absence of a vasomotor 
response to Bosentan or PD 155080 in the post-occlusion dilated vessels overlying the 
parasagittal gyrus (blood flow derived from the anterior cerebral artery) following 
MCA occlusion in the cat.
171
Among the many features associated with cerebrovascular disease is damage to 
the vascular endothelium either due to mechanical damage by clots, increased 
mechanical or fluid shear stress or disruption of the endothelial cell membranes by free 
radicals produced during cerebral ischaemia [Siesjo et al., 1992a; Phillis, 1994]. An 
increase in fluid shear stress on endothelial cells, e.g. experienced in recanalisation of 
occluded vessels, has been shown to stimulate increases in endothelin mRNA and 
endothelin release [Kuchan & Frangos, 1993]. Blood in the intracranial space or 
damage to the vascular endothelium can increase the ability of platelets to aggregate 
and increases leucocyte adhesion to endothelial cells [Grogaard et al., 1989; Dimagl et 
al., 1994]. Following subarachnoid haemorrhage constituents of blood such as platelets 
can induce the release of vasoconstrictor factors such as TGF-13 and increase the 
production of ET-1 [Kurihara et al., 1989]. The increased expression of ET-1 mRNA 
or the release of ET-1 may be involved in the development of delayed vasospasm 
following subarachnoid haemorrhage. In astrocytic cell cultures, ET-1 has been 
demonstrated to evoke the release of arachidonic acid [Tence et al., 1992]. The role of 
arachidonic acid metabolites in the generation of free radicals has been a mechanistic 
basis for the progression of neuronal damage following cerebral ischaemia [Phillis, 
1994]. In cerebral ischaemia, hypoxia within the ischaemic territory may stimulate the 
production of ET-1 and have a role in the progression of ischaemic neuronal damage.
Evidence from cell culture studies indicate that shear stress may induce an 
increase in ET-1 mRNA or ET-1 release [Kuchan & Frangos et al., 1993; Morita et al., 
1993; MacArthur et al., 1994]. Differences in the source and target of ET's may occur 
depending on the brain injury [Kurihara et al., 1989; Barone et al., 1994].
Apart from the proposed cerebrovascular role o f the endothelin peptides, 
evidence from binding assays has shown the presence of binding sites for endothelins 
in both rodent and human brain [Ambar et al., 1989; Jones et al., 1989; Koseki et al., 
1989] and spinal cord [Niwa et al., 1992] and glia [Koseki et al., 1989; MacCumber et 
al., 1990; Ehrenreich et al., 1991]. Glial cells may be an important source of 
endothelins within the CNS [MacCumber et al., 1990; M arsault et al., 1990; 
Ehrenreich et al., 1991]. However, these are not the only sources of production or
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binding sites within the brain. Endothelial cells and vascular smooth muscle cells of 
cerebral vessels have also shown the ability to generate endothelins and the existence 
of binding sites has been demonstrated in these cells [Yoshimoto et al., 1990; Resink 
et al., 1990; Hirata et al., 1993; Takenaka et al., 1993]. The endothelin receptor 
subtype(s) mediating endothelin actions within the CNS are unclear. The mixed action 
of Bosentan at endothelin ETa and endothelin ETb receptors could be harnessed to 
investigate other roles of endothelin within the CNS. The trigger for and sources of the 
putative increased perivascular endothelins in focal ischaemia are presently unclear. 
Intracellular concentrations of ET-1, as determined by radioimmunoassay, are 
increased 24 hours after a focal (MCA occlusion) or global (two vessel occlusion plus 
hypotension) ischaemic insult [Duverger et al., 1992; Barone et al., 1994]. Endothelial 
ceils and neurones from the brain and spinal cord express ET mRNA and ET- 
immunoreactivity, implicating these cells as potential sources of endothelins following 
an ischaemic insult [Giaid et al., 1989; Lee et al., 1990; MacCumber et al., 1990]. 
Although secretory granules are not generally found in endothelial cells, in contrast to 
neurones, it is known that endothelial cells do contain some ET-like peptide which 
may be released immediately under certain conditions [MacArthur et al., 1994]. This 
supports evidence that de novo synthesis of this peptide (which may take hours) is not 
always necessary and may explain the ability of Bosentan and PD 155080 in the 
present study, to alter or reverse ischaemically-induced perturbations in pial vessel 
calibre relatively acutely after the insult.
The cellular source of endothelins following a cerebrovascular insult is 
unclear. The presence of endothelin mRNA and release of ET-1 from cerebrovascular 
endothelial cells have been demonstrated [Yoshimoto et al., 1990; Saito et al., 1991]. 
In brain tissue, both astrocytes and neurones have been reported to possess endothelin 
mRNA [MacCumber et al., 1990; Ehrenreich et al., 1991]. The release of endothelin 
from endothelial cells or from neurones and astrocytes may account for the rapid 
perturbations in blood vessel calibre following MCA occlusion [MacArthur et al., 
1994]. The presence of stores of endothelins in some cells indicates that de novo 
synthesis of endothelins may not be necessary for the development of the acute effects.
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4.2 .3  P h arm acoth erap y  o f cerebral ischaem ia: com parisons w ith  en d oth elin
receptor antagonists
Pharmacotherapy of cerebral ischaemia has two general approaches. Firstly, 
pharmacological interventions are directed at various points in the cascade of 
neurochemical events which lead to neuronal damage, for example, NMDA and 
AMPA receptor antagonists, glutamate release inhibitors, nitric oxide synthase 
inhibitors, free radical scavengers and the inhibition of the effects of the cytokines 
[Rothwell & Relton, 1993; Gill, 1994; Muir & Lees, 1994; Phillis, 1994]. Secondly, 
pharmacological interventions that are directed at removing the primary intraluminal 
obstruction (e.g. Tissue Plasminogen Activator) or by reducing the vasoconstrictor 
influences on collateral vessels to the tissue at risk (e.g. L-type calcium channel 
antagonists) [Kazda et al., 1982; Fisher & Grotta, 1993; Overgaard, 1994]. The 
demonstration o f elevated endothelin levels following subarachnoid haemorrhage, 
focal and global cerebral ischaemia has led to the investigation of endothelin receptor 
antagonists as potential therapeutic agents.
The ability o f endothelin receptor antagonists to reduce ischaemic neuronal 
damage following focal and global cerebral ischaemia has been demonstrated in a 
number of recent investigations. However, the precise mechanism of action o f the 
endothelin receptor antagonist is at present unclear. One can speculate that since the 
endothelin receptor antagonist increases cerebral perfusion and reduce ischaemic 
neuronal damage following focal cerebral ischaemia, the neuroprotective effects of the 
antagonist may be the result of increasing cerebral blood flow to the ischaemic 
penumbra [Patel et al., in press].
Focal Cerebral Ischaemia
The ability o f L-type calcium channel antagonists, primarily nimodipine, to 
reduce ischaemic neuronal damage following focal cerebral ischaemia has been 
investigated extensively in a variety of species. The results obtained with nimodipine 
are diverse with some authors demonstrating significant neuroprotection while others
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have demonstrated the absence of any significant effects. Previous investigations have 
demonstrated that the L-type calcium channel antagonist nifedipine increased the 
calibre of cortical surface arterioles following MCA occlusion. The actions of the 
endothelin receptor antagonist to similarly increase the calibre of cortical surface 
arterioles indicated the existence of endothelin mediated vasoconstrictor tone on these 
vessels. The ability of nimodipine to reduce ischaemic neuronal damage has been 
attributed to a combination of reduction in neuronal influx of calcium and an increase 
in cerebral blood flow. In the rat, pre-treatment with nimodipine reduced ischaemic 
neuronal damage (20 - 30% reduction in hemispheric infarct) following focal cerebral 
ischaemia [Mohammed et al., 1985; Jacewicz et al., 1990a] while post-treatment failed 
to demonstrate a reduction in the volume of ischaemic neuronal damage [Gotoh et al.,
1986]. The administration of nimodipine offset vasoconstriction observed in the 
cerebral arterioles following focal cerebral ischaemia and reduced the volume of tissue 
perfused by cerebral blood flow the ischaemic threshold [Jacewicz et al., 1990b]. 
Although post-treatment with nimodipine failed to reduce the volume of ischaemic 
neuronal damage, there was evidence that nimodipine increased the cerebral blood 
flow in the brain regions on the margins of the territory of the middle cerebral artery. 
Bosentan and BQ-123 failed to reduce the volume of ischaemic damage following 
focal cerebral ischaemia in the normotensive rat (see Table 15) [McAuley et al., 1994; 
Checkley et al., 1995]. Unlike nimodipine, Bosentan failed to demonstrate any 
significant increases in cerebral blood flow following focal cerebral ischaemia in the 
rat [McAuley et al., 1994]. In the spontaneously hypertensive rat, BQ-123 and 
SB217242 reduced the volume of ischaemic neuronal damage following focal cerebral 
ischaemia [Barone et al., 1995; Patel et al., 1995].
The effects of nimodipine have also been examined following focal cerebral 
ischaemia in the cat. The intracarotid infusion of nimodipine prior to the ischaemic 
insult failed to alter the volume of infarct following focal cerebral ischaemia [Barnett 
et al., 1986] while intravenous pre-treatment reduced the volume o f ischaemic 
neuronal damage and increased the calibre of cortical surface arterioles in the territory 
of the middle cerebral artery [Mokry et al., 1987; Mokry et al., 1989]. The
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administration of nimodipine post-MCAO failed to demonstrate any significant 
reduction in the volume of ischaemic damage [Mokry et al., 1987]. These observations 
are in stark contrast to our observations in the cat where the post-treatment with an 
endothelin receptor antagonist increased the cerebral perfusion and reduced the 
volume of ischaemic neuronal damage [Patel et al., in press].
The absence of any significant effect observed by either the endothelin 
receptor antagonist or nimodipine can be attributed to a variety of factors. The 
differences in the doses of nimodipine and administration schedules of nimodipine 
could account for the absence of any significant effect in focal cerebral ischaemia. 
Similar issues regarding the adequacy of drug dosing may account for the absence of 
any significant effects with endothelin receptor antagonists. However, the selectivity 
o f the endothelin receptor antagonists for dilator endothelin ETb receptors or 
constrictor endothelin ETa receptors is one possible explanation for the absence of 
any effects (particularly Bosentan). The inability of the peptide endothelin receptor 
antagonist (BQ-123) to permeate the blood-brain barrier explains the absence of any 
effect. Other possible explanations include the differences in the cerebrovascular 
anatomy of the rat and cat [Coyle & Jokelainen, 1982; Mchedlishvili & Kuridze, 
1984]. The lower density of connections between collateral vessels in the cerebral 
cortex of the rat is one possible explanation for the failure of Bosentan to increase 
cerebral blood flow following focal cerebral ischaemia [Coyle & Jokelainen, 1982; 
Mchedlishvili & Kuridze, 1984],
The elevations of extracellular glutamate concentrations associated with focal 
cerebral ischaemia have formed the basis of anti-ischaemic drug development. For the 
last decade, NMDA and non-NMDA receptor antagonists have been at the forefront 
o f anti-ischaemic drug development. The antagonists that have been developed have 
been targeted at the NMDA receptor complex and at the AMPA receptors (see section
1 .2 .2  for pathophysiology of cerebral ischaemia).
The neuroprotective effects of a variety o f AMPA and NMDA receptor 
antagonists have been examined in a range of species. NBQX and LY293558, which 
are potent AMPA receptor antagonists, have been demonstrated to reduce the volume
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of ischaemic neuronal damage following focal cerebral ischaemia in the rat and cat 
[Bullock et al., 1994; Gill, 1995] The NMDA receptor antagonist are targeted at 
multiple sites on the NMDA receptor complex including the neurotransmitter 
recognition site, glycine site, ion channel and the polyamine site (see section 1 .2 .2  for 
functional significance of receptor sites). The non-competitive NMDA ion channel 
blockers (MK-801; CNS 1102) have demonstrated marked efficacy in experimental 
focal cerebral ischaemia. In the feline model of permanent focal cerebral ischaemia, 
MK-801 reduced the hemispheric volume of ischaemic damage by 50% when 
administered pre or post-MCAO [Ozyurt et al., 1988; Kurumaji et al., 1989]. The 
neurotransmitter recognition site antagonist, CGS19755 and D-CPP-ene, also reduce 
the volume of ischaemic damage following focal cerebral ischaemia in the cat 
[McCulloch et al., unpublished observations; Chen et al., 1991a]. The pre-treatment 
with glutamate release inhibitors (CI-977) and low affinity NMDA ion channel 
blockers (Remacemide) have demonstrated the ability to reduce ischaemic neuronal 
damage [Mackay et al., 1993; Bannan et al., 1995; Mackay et al., in press]. In the rat, 
the magnitude of reduction of ischaemic damage is greater with the competitive and 
non-com petitive NMDA receptor antagonists than with the AMPA receptor 
antagonist. The increased prevalence of NMDA receptors compared to AMPA 
receptors in the brain may account for the differences in the efficacy of the two 
classes of compounds. The neuronal damage that is associated with cerebral ischaemia 
is normally the result of elevated levels of intracellular calcium. The calcium can enter 
the cell through the ion channels associated with either the AMPA receptors or the 
NMDA receptors. Since there are more NMDA receptors, the antagonism of the 
AMPA receptors may have a limited effect on preventing neuronal damage. Despite 
the possible differences in the mechanism of action, the efficacy of the endothelin 
receptor antagonist PD 156707 is comparable to the efficacy of the NMDA receptor 
antagonists (Figure 47).
The marked neuroprotective effects of the endothelin receptor antagonist could 
be attributed to the increase in cerebral blood flow in the penumbral areas of the focal 
ischaemic lesion. Recent evidence has suggested the interaction between NMDA
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Figure 47 Effect of neuroprotective agents upon the hemispheric volume of 
ischaemic damage after permanent MCA occlusion in the cat. The data are 
expressed as the mean ± S.E.M. of volume of tissue salvaged. *P<0.05 
compared to vehicle treated animals in each study (one tailed Student's t-test). 
The drugs were administered as intravenous bolus doses plus continous 
infusion for 6 hours post-MCAO unless where indicated below. The data are 
derived from the investigations of:
Ozyurt et al., 1988 MK-801 a non-competitive NM DA antagonist (administered 30 min
pre-MCAO)
Bullock et al., 1990 D-CPP-ene a competitive NM DA antagonist (administered 30 min 
pre-MCAO)
Bannan et al., 1995 Remacemide a non-competitive NMDA antagonist (administered 90 min pre 
MCAO and discontinuedat MCAO)
Patel et al., in press PD 156707 an endothelin ETA receptor antagonist (administered 30 min 
post-MCAO)
Park et al., 1988 MK-801 a non-competitive NMDA antagonist (administered 2 hours 
post-MCAO)
Mackay et al., 1994 CI-977 a k-opioid receptor agonist (administered 15 min pre-MCAO)
McCulloch & Bullock, unpublished CGS-19755 a competitive NMDA antagonist (administered 30 
min pre-MCAO)
Bullock et al., 1994 LY293558 an AMPA receptor antagonist (administered 30 min pre-MCAO)
Chen et al., 1991 D-CPP-ene a competitive NMDA antagonist (administered 60 min 
post-MCAO)
receptor activation and endothelin mediated regulation of cardiovascular tone. 
However, these interactions were observed in the cardiovascular control centres in the 
brain stem. The failure of endothelin receptor antagonists to alter cerebral blood flow 
in the normotensive rat suggests that the endothelins have minimal role in normal 
brain function. The neuroprotective effects of the endothelin receptor antagonists 
could be attributed to their ability to reduce elevations of intracellular calcium. The 
endothelin ETb receptor subtype has been identified on neurones and glia but the 
significance of these receptors in normal brain function are as yet undetermined.
Global Cerebral Ischaemia
The patterns of neuronal damage associated with global cerebral ischaemia are 
distinct from the neuronal damage associated with focal cerebral ischaemia (see 
section 1.2. 3) [Kirino et al., 1982; Kirino et al., 1984]. The main features of global 
cerebral ischaemia are post-ischaemic hypoperfusion that is observed for the first six 
hours following ischaemia [Pulsinelli et al., 1982b] and the delayed neuronal damage 
that is typically observed 24-72 hours following ischaemia. The efficacy o f 
pharm acological agents have been examined in their ability to alleviate the 
hypoperfusion and reduce the extent of neuronal damage.
The aetiology of the post-ischaemic hypoperfusion is unclear but the L-type 
calcium channel antagonist nimodipine has been demonstrated to alleviate post- 
ischaemic hypoperfusion. In a canine model of global cerebral ischaemia, post- 
ischaemically administered nimodipine alleviated the hypoperfusion despite a 
reduction in mean arterial blood pressure [Steen et al., 1984]. Investigations in the rat 
model o f global cerebral ischaemia demonstrated a heterogeneous alterations in 
cerebral blood flow [Kazda et al., 1982; Smith et al., 1984]. Microvascular plugging 
and constriction of the cerebral arterioles may explain the heterogeneity o f the 
responses [Wade et al., 1975; Grogaard et al., 1989; Moskowitz et al., 1990; Wahl & 
Schilling, 1993; del Zoppo, 1994; Dimagl et al., 1994 ]. No significant link has been 
observed between the improvement in post-ischaemic hypoperfusion and the 
improved neurologic function [Smith et al., 1984; Steen et al., 1984].
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Delayed neuronal damage associated with global cerebral ischaemia has been 
reduced by the administration of AMPA receptor antagonists and endothelin receptor 
antagonist [Gill, 1994; Feuerstein et al., 1994; Ohlstein et al., 1994]. The endothelin 
receptor antagonist SB209670 and BQ-123 have been demonstrated to reduce the 
damage of hippocampal CA1 neurones [Feuerstein et al., 1994; Ohlstein et al., 1994]. 
The delayed administration of AMPA receptor antagonists (between 12-24 hours post 
global ischaemia) reduces the damage of hippocampal neurones [Li & Buchan, 1993; 
Xue et al., 1994]. The efficacy of endothelin receptor antagonists when administered 
immediately post-ischaemia or 12-24 hours following the ischaemic insult has not 
been examined. NMDA antagonists (MK801) demonstrate reduced efficacy in global 
cerebral ischaemia when compared to the AMPA receptor antagonists [Buchan et al., 
1991; Nellgard et al., 1991; Gill, 1994]. The efficacy of the AMPA receptor 
antagonists could be the result of their reducing the influx of calcium into the 
hippocampal neurones. AMPA receptor antagonists depress cerebral glucose use while 
the NMDA antagonists such as MK-801 elicit hypermetabolic responses in the 
hippocampal pathway [Kurumaji et al., 1989; Suzdak & Sheardown, 1993; Brown & 
McCulloch, 1994]. The increases in cerebral metabolism may be associated with the 
absence of effect of the NMDA receptor antagonists.
The absence of any link between the neurologic function and increases in 
cerebral blood flow suggests that the two mechanisms play different roles in the 
development of neuronal damage following global cerebral ischaemia [Steen et al., 
1984]. The endothelin receptor antagonist Bosentan failed to alter post-ischaemic 
hypoperfusion suggesting that the role of the endothelins in the mediation of this 
phenomenon may be minor. However , the efficacy of the endothelin receptor 
antagonist in reducing hippocampal neuronal damage is comparable to the effects of 
the AMPA receptor antagonists [Feuerstein et al., 1994; Ohlstein et al., 1994]. The 
mechanism of action of the endothelin receptor antagonists may be related to presence 
of endothelin ETb receptors on neurones and glia.
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4.3 Endothelins: from gene to therapeutic agents
A feature of endothelin research has been the role o f molecular biological 
techniques. The identification of the peptide from porcine endothelial cells was rapidly 
followed by the identification of the gene codes for the endothelin isopeptides and the 
endothelin receptors [Arai et al., 1990; Inoue et al., 1989; Sakurai et al., 1990]. The 
advances in the molecular biology of the endothelins have led to the breeding of 
transgenic animals with the endothelin genes knocked out. The identification of 
altered endothelin gene expression has provided circumstantial evidence for the role of 
the endothelins in the development of a number of disease states (cardiac ischaemia, 
congestive heart failure, subarachnoid haemorrhage, stroke). The progression from the 
initial description of the peptide structure to the use o f endothelin receptor antagonists 
as therapeutic agents has been rapid has been rapid (see Table 18).
The role of the endothelins in cardiovascular diseases such as hypertension, 
congestive heart failure and myocardial ischaemia have been areas of active research. 
The role of the endothelins in hypertension has been controversial. The use of 
spontaneously hypertensive strains of rat has demonstrated the increase in plasma 
endothelin concentrations and the ability of endothelin receptor antagonists to reduce 
mean arterial blood pressure [Bazil et al., 1992; Hughes et al., 1992; Nishikibe et al., 
1993]. In clinical investigations, there is no clear evidence implicating an elevation in 
plasma endothelin concentrations in the development of hypertension [Battistini et al.,
1993].
Plasma concentrations of endothelins increased following experimental cardiac 
ischaemia (Watanabe et al., 1990; Brunner et al., 1992; Grover et al., 1993; Ray et al., 
1992; Brunner, 1995]. In clinical studies similar increases in plasma endothelin-1 
levels have reported [Stewart et al., 1991; Lechleitner et al., 1992; Ray et al., 1992]. 
The efficacy of endothelin receptor antagonists, such as BQ-123 , Bosentan, 
FR139317, have been examined in experimental cardiac ischaemia and found to 
reduce the extent of cardiac ischaemic damage [Grover et al., 1993; McMurdo et al., 
1994; Wang et al., 1995a; Wang et al., 1995b; Watanabe et al., 1995]. The ability of
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Table 18
1988
1989
1990
1991
1992
1993
Table 18
Progression in endothelin research
Yanagisawa et al. report the isolation of the endothelin peptide.
The isolation o f the genes encoding the endothelin isopeptides 
described.
Structure of the sarafotoxins (venom from the Israeli burrowing asp) 
described by Sokolovsky and colleagues.
The mRNA for endothelin ETa and endothelin ETb receptors described 
( Arai et al.; Sakurai et al.).
Efficacy of endothelin antibodies in experimental myocardial infarction 
described (Watanabe et al.).
The first description of a peptide endothelin receptor antagonist (BE- 
18257E) isolated from Streptomyces misakiensis (Ihara et al.)
Preliminary evidence indicating a role for endothelins in SAH and 
elevated CSF endothelin levels in patients following SAH (Kobayashi 
et al.; Kraus et al.)
The pharmacology of the endothelin ETa  receptor antagonist BQ-123 
and endothelin ETb agonist BQ-3020 described (Ihara et al.; Ihara et 
al.).
Hexapeptide combined endothelin ETa/ETb endothelin receptor 
antagonists PD142893 and PD145065 described (Cody et al.).
Clinical evidence demonstrating elevated plasma endothelin levels 
following subarachnoid haemorrhage (Suzuki et al.).
Elevated plasma endothelin levels in patients following acute stroke 
(Ziv et al.).
Elevations in endothelin immunoreactivity in brain tissue following 
focal cerebral ischaemia (Duverger et al.)
Structure and pharmacology of the first non-peptide com bined 
endothelin ETa /ETb endothelin receptor antagonist, Ro46-2005, 
described (Clozel et al.).
Bosentan (analogue of Ro46-2005) made available and examined in 
feline pial arterioles.
Table 18
1994
1995
Endothelin ETb receptor mediated vasoconstriction described in some 
tissues (Shetty et al.; Warner et al.).
Efficacy of peptide and non-peptide endothelin receptor antagonist in 
experimental SAH described (Clozel et al.; Clozel & Watanabe; Nirei 
et al.).
Efficacy of phosphoramidon in reducing focal ischaemic damage 
described (Duverger et al.).
Subdivision of endothelin ETb receptors into ETbi (dilator) and ETb2 
(constrictor) (Masaki et al.).
Structure and pharmacology of Bosentan published (Clozel et al.).
Effects of Bosentan in feline cerebral arterioles described (Patel et al.).
Pharmacology of non-peptide endothelin receptor antagonists 
B M S182874 (ETa  antagonist) SB209670 (ETa/ETb antagonist) 
described (Webb et al.; Ohlstein et al.).
Elevated levels of endothelins in global and focal cerebral ischaemia 
described.
BQ-123 and SB209670 reduced hippocampal neuronal damage 
following global cerebral ischaemia (Feuerstein et al.; Ohlstein et al.).
Structure and pharmacology of non-peptide endothelin receptor 
antagonists disclosed (PD 156707; PD 155080) (Doherty et al.).
PD 156707 in reduces neuronal damage and increases cerebral perfusion 
following focal cerebral ischaemia in the cat.
Clinical efficacy of bosentan in patients suffering from congestive heart 
failure (Kiowski et al.).
Clinical trials of Bosentan in subarachnoid haemorrhage started.
the endothelin receptor antagonist to reduce the myocardial ischaemic damage 
indicates that these compounds may useful in the clinical context.
Congestive heart failure is usually accompanied by an increase in vascular tone 
and evidence has indicated that there is an increase in plasma endothelin levels [Cody 
et al., 1992; Murray et al., 1992; Lerman et al., 1992; Cacoub et al., 1993]. The 
peptide antagonist FR 139317 reduced the systemic blood pressure and peripheral 
resistance in a canine model of congestive heart failure [Clavell et al., 1995]. The non­
peptide antagonist Bosentan has been in clinical trials in patients with congestive heart 
failure and has been found to reduce the mean arterial blood pressure and vascular 
resistance in the patients [Kiowski et al., 1995].
The development of the non-peptide endothelin receptor antagonists has 
facilitated the investigations into the role of the endothelins in cerebrovascular disease. 
The majority of experimental investigations have focused on the role of endothelin-1 
as a mediator of delayed vasospasm following subarachnoid haemorrhage. The basis 
o f these investigations was the detection of elevated plasma and CSF endothelin-1 
immunoreactivities and the endothelin receptor antagonists attenuate vasospasm 
following experimental subarachnoid haemorrhage (see Table 19). The mechanism of 
action of the endothelins are unclear but increases in endothelin-1 mRNA and 
alterations in endothelin receptor numbers and subtypes have been observed following 
subarachnoid haemorrhage [Roux et al., 1995; Shigeno et al., 1995]. The efficacy of 
the endothelin receptor antagonists in preventing delayed vasospasm associated 
subarachnoid haemorrhage has been extensively studied (see Table 16). The 
experimental investigations have demonstrated that the administration o f  the 
endothelin receptor antagonists reduces the vasospasm following subarachnoid 
haemorrhage. As a result of the extensive studies the combined endothelin ETa /ETb 
receptor antagonist Bosentan is currently undergoing clinical trials in subarachnoid 
haemorrhage.
The endothelin receptor subtypes present in the cerebral circulation in 
experimental species and the clinical target, man, is an important issue for the 
development of therapeutic strategies. The available evidence indicates that the
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T able 19
Human plasma and CSF endothelin-1 levels measured by radioimmunoassay 7 days 
following subarachnoid haemorrhage (SAH)
Plasma
CSF
Control (pg/ml) SAH (pg/ml) Reference
13.2 ± 0 .4  18.1 ±1.3*** Seifert et al., 1995
12.4 ± 0.4 18.7 ±1.6** Shirakami et al., 1994
2.6 ±1.1 ~ 5 Ehrenreich et al., 1992
1.1 ±0.1 7.8 ±0.9** Suzuki etal., 1992
Control (pg/ml) SAH (pg/ml)
7.4 ± 1.4 10.1 ± 1.6 Gaetani et al., 1994
9.1 ±0 .2  18.4 ± 2.4** Shirakami et al., 1994
20.2 ± 1.8 28.3 ± 12.1*** Kraus et al., 1991
27.9 ± 1.3 Hirata etal., 1990 
27.9 ± 2.0 42.1 ± 4.5 Suzuki et al., 1992
Control samples were collected from subjects without any neurological disorders. ** 
indicates a statistically significant difference from control values (p<0.01); *** 
indicates a statistically significant difference from control values (p<0.001)
endothelin ETa receptor is the predominant constrictor receptor. The receptor 
subtypes present in human cerebral vessels is less clear but in the peripheral blood 
vessels the existence of constrictor endothelin E T a  and endothelin E T b  receptors have 
been demonstrated [Rubanyi & Polokoff et al., 1994; Seo et al., 1994]. The 
identification of the receptor subtypes in man has important implications for the use 
of combined endothelin ETa /E T b  receptor antagonists or antagonists selective for the 
endothelin E T a  receptor. In experimental subarachnoid haemorrhage there does not 
appear to be any difference in the efficacy of the combined endothelin E T a /E T b  
receptor antagonists compared to the endothelin E T a  receptor selective receptor 
antagonists. The endothelin ET a  receptor selective antagonists may be beneficial in 
attenuating the vasoconstrictor (endothelin E T a ) actions and facilitate endothelin E T b  
receptor mediated vasodilatation and a possible increase in cerebral blood flow. In 
contrast the presence of a mixed population of receptors may require the use of the 
combined endothelin ET a /E T b  receptor antagonists. The existence of the blood-brain 
barrier means that the endothelin receptor antagonists targeted at the cerebral 
circulation must penetrate the blood brain barrier. The demonstration that the non­
peptide endothelin receptor antagonists (Bosentan, PD155080, PD 156707), following 
their intravenous administration, gain access to the cerebrovascular smooth muscle in 
cerebral cortical arterioles [present thesis] and attenuate vasospasm and ischaemic 
neuronal damage [Clozel et al., 1993; Roux et al., 1995; Shigeno et al., 1995; Patel et 
al., in press] demonstrates the utility of these compounds as therapeutic agents.
The endothelin receptor antagonists have been the main focus o f drug 
development but the targeting of endothelin converting enzyme (ECE) may provide 
another site for the regulation of endothelin synthesis. The efficacy of endothelin 
receptor antagonists in attenuating cerebral vasospasm and focal ischaemic damage 
provide a novel therapeutic for the treatment of cerebrovascular diseases. The absence 
o f any significant hypotensive effect in experimental studies indicate that the 
endothelin receptor antagonists may be of greater therapeutic utility than the agents 
that induce hypotension on administration, e.g., the L-type calcium channel 
antagonists (nimodipine). Recent meta-analysis data has indicated that the absence of
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any significant effect of nimodipine in stroke patients may have been the result of the 
delay in the treatment (longer than 12 hours) [Mohr et al., 1994]. The analysis showed 
that the outcome was improved in patients who were treated within 12 hours of the 
stroke. The endothelin receptor antagonist PD 156707 is effective in experimental 
studies when administered 30 min post -MCA occlusion and may have a role in the 
treatment of acute stroke.
The glutamate receptor antagonists have been associated with adverse effects, 
e.g. hallucinations, in clinical trials and this has precluded their use in the treatment of 
stroke and head injury [Muir & Lees, 1995]. The effect of endothelin receptor 
antagonists on cerebral function are unclear but the absence of alterations in cerebral 
blood flow in experimental investigations suggests that they may not alter cerebral 
function. The use o f neuroprotective agents targeted at the glutamate receptors or 
inhibitors of glutamate release combined with the endothelin receptor antagonists may 
provide novel strategies in the treatment of cerebrovascular diseases.
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